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SHORT ABSTRACT 
Lung cancer is deadly, killing more people than breast, colon and prostate cancer combined. 
Surgeons evaluating patients for lung cancer face a dilemma: to operate and subject the individual 
to operation associated mortality and morbidity or not operate and possibly miss early diagnosis 
and treatment.  No models designed for surgeons evaluating lung lesions.  We successfully 
estimated the TREAT model. A model designed for surgeons with an internally validated AUC of 
0.87 and Brier score of 13.  
 
If the TREAT model is applied to a national population, its accuracy may decrease due to local 
conditions.  To determine the possible extent of such variation, benign disease prevalence after 
lung surgery was estimated using 2009 Medicare hospital discharge data.  Significant variation in 
benign disease prevalence between states was observed with a low of 1.3% in Vermont and a 
high of 25% in Hawaii. The causes for this observed variation are unknown. Residence in a 
county with high fungal lung disease prevalence was not associated with increased likelihood of 
benign disease. 
 
FDG-PET scan variance was observed in the national ACOGOS Z4031 trial.  FDG-PET 
sensitivity (82%) and specificity (31%) were significantly lower than in previous published 
studies.  Granuloma occurred in 68% of the false positive FDG-PET scans and sensitivity varied 
significantly between sites.  Scan accuracy increased with increasing lung lesion size. Whether 
the observed variation is caused by practice variation, referral patterns, fungal lung disease, or 
other factors is unknown.   
 
A meta-analysis examined FDG-PET accuracy to diagnose lung lesions sought to determine if 
other researchers had observed variance in FDG-PET accuracy. Seven studies reported false 
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positive scans arising from granulomas caused by infectious lung disease. Specificity of those 
studies was 59%, significantly lower than the specificity (77%) observed in the remaining 53 
studies.  Studies whose mean lesion size was less than or equal to 20 mm had significantly lower 
sensitivity than studies conducted in larger lesions. 
 
The TREAT model shows clinical promise and should be externally validated. The causes of 
observed variation in benign disease prevalence and FDG-PET accuracy should be investigated 
with particular attention made to measuring infectious disease exposures that cause granulomas. 
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ABSTRACT 
 
More people die in the United States (US) from lung cancer than from breast, colon, and prostate 
cancer combined with over 160,000 deaths occurring annually.  Early detection, diagnosis and 
treatment improve cancer survival. Screening for early detection of disease with low dose 
computed tomography (LDCT) reduced lung cancer related mortality by 20% in a recently 
concluded national trial; however, screening resulted in many false positive results requiring 
further evaluation. Surgeons evaluating patients for lung cancer face a dilemma: to operate and 
potentially subject the individual to significant operation associated mortality and morbidity or 
not operate and possibly miss early diagnosis and opportunities for treatment. F18-
fluorodeoxyglucose positron emission tomography (FDG-PET) is one of the most accurate, non-
invasive tests available for diagnosing lung nodules. However, lung granulomas with an 
infectious disease etiology appear physiologically and metabolically similar to cancer and 
generate false positive CT and FDG-PET scans. If an association exists between imaging detected 
granulomas and the infectious lung diseases that created them, then populations may exist that 
will not benefit from FDG-PET scans for diagnosis of lung cancer. If the prevalence of benign 
diagnosis after lung surgery varies across the US, then the benefit from a national screening 
program will likely be less in areas with higher benign disease prevalence. Exploration of 
possible causes of regional variation in benign disease prevalence and creation of a predictive 
model for surgeons to diagnose lung cancer has the potential to reduce the morbidity and 
mortality arising from unnecessary surgery for patients with benign disease.  
 
Current models estimating lung cancer risk were not developed in populations being evaluated by 
surgeons. Using the diagnostic information available to surgeons at the point of decision to 
operate that includes the diagnostic work-up of all previous specialists combined, the TREAT 
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Lung Cancer model was estimated. Clinical and radiographic imaging information was 
retrospectively collected from a population being evaluated for known or suspected lung cancer 
by surgeons at Vanderbilt University Medical Center. The predictors for lung cancer included: 
age, sex, smoking history, pre-operative symptoms, previous history of cancer, body mass index, 
predicted forced expiratory volume in one second, lesion characteristics, and FDG-PET avidity. 
The TREAT model better discriminated lung cancer (AUC=0.89, 95%CI: 0.86-0.92) in the 
surgical evaluation population than the previously validated Mayo model (AUC=0.80, 95%CI: 
0.76-0.85). The TREAT model was better calibrated using the Brier score metric (0.12) when 
compared to the Mayo model (0.17). When the variables from the Mayo model were re-estimated 
using the Vanderbilt population (AUC 0.83, 95% CI: 0.79-0.87), the more comprehensive 
TREAT model continued to better discriminate cancer from benign disease (p<0.001). Lesion 
size, age, avidity on a FDG-PET scan, and observed growth on serial CT scans were the strongest 
predictors for lung cancer. The model had little reduction in AUC (0.87) or Brier score (0.12) on 
internal validation with bootstrap methodology. 
 
The TREAT model to predict lung cancer was more accurate than previously published models. 
Its 89% AUC is the highest among all published models. However, to be clinically useful in a 
surgical evaluation population with its high prevalence of lung cancer, all variables that might 
indicate benign disease or influence the primary predictive variables of growth or FDG-PET 
avidity must be explored. Granulomas arising from infectious lung diseases including 
histoplasmosis, coccidiomycosis, blastomycosis and tuberculosis have been reported in the 
literature and generate false positive imaging scans for lung cancer. Granulomas were the most 
common benign diagnosis after surgery for suspected lung cancer in this research, and they were 
60% to 70% of the etiologies observed with false positive FDG-PET scans. Also, individuals with 
clinical early stage disease, a population similar to that likely found in the successful national CT 
screening program, have smaller lung nodules. Published literature and clinical data from a 
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national trial showed that FDG-PET scans failed to differentiate cancer from benign disease in 
populations with smaller lesions or with endemic infectious lung disease. This research calls into 
question the use of FDG-PET scans for diagnosis in populations with lesions under 2cm or 
having a high prevalence of infectious lung disease.  
  
To investigate the possible range of variability in benign disease, benign disease point prevalence 
after surgical operation was investigated by state in the 2009 Medicare population. Each 
individual was matched to a probability of fungal lung disease prevalence as measured in a 
national surveillance program from the 1960s. Benign disease prevalence variation was observed 
between states, from a low of 1.3% in Vermont to a high of 25% in Hawaii. The median point 
prevalence by state was 8.9% (IQR: 7.8 – 10.9; chi2<0.001). Historic fungal lung disease 
prevalence by county of residence at the time of surgery was not associated with benign disease at 
the individual level (p=0.9).   
 
In a secondary analysis examining the variation of FDG-PET scan diagnostic accuracy in 682 
individuals from a completed national trial, lower sensitivity and specificity was observed (82% 
and 31% respectively) compared to previously published studies. Wide variation in sensitivity 
across enrolling sites was observed (68% to 91%; p=0.03). Variation in the specificity of FDG-
PET scans was also observed (15% to 44%; p=0.72); however, the small number of benign 
disease cases at each individual site resulted in little power to draw conclusions regarding the 
specificity of FDG-PET scan variation by enrolling site. Scan accuracy increased with increasing 
lung lesion size. Of the 80 false positive scans, 69% were granulomas. All positive FDG-PET 
scans were examined separately and false positive FDG-PET scans were not found to be 
associated with historic fungal lung disease exposure after adjusting for age and size of the lung 
lesion (p=0.12). The causes of the observed variation in FDG-PET scan results are unknown. 
Possible causes of observed variation include verification bias which results in higher sensitivity 
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and lower specificity, practice variation, infectious lung diseases which generate granulomas that 
mimic cancer, or other unknown causes.  
 
A systematic review of the literature was conducted to examine whether other researchers had 
found similar poor performance of FDG-PET scans in the diagnosis of lung cancer and to update 
a meta-analysis conducted in 2001.  A systematic review of the literature found 60 studies 
reporting FDG-PET scan accuracy to diagnose lung cancer. The studies showed that FDG-PET 
scan sensitivity to diagnose lung cancer declines as lesion size decreases and the specificity 
increases slightly. The advent of fusion PET and CT scanners slightly increased sensitivity (88.4, 
95% CI: 84.2-91.7 to 90.0, 95% CI: 86.5-92.6) and significantly increased the specificity (69.4, 
95% CI: 63.0-75.2 to 77.9, 95% CI: 70.7-83.8) for diagnosis in 29 studies when compared to 24 
studies that reported using PET only scanners. In seven studies reporting endemic infectious lung 
disease, the sensitivity of FDG-PET was higher (91%, 95% CI: 90%-94%) to the 53 studies 
(90%, 95% CI: 82%-93%) that did not report infectious lung disease in the underlying study 
population. However, the specificity was lower in areas of endemic infectious lung diseases that 
cause granulomas (59%, 95% CI: 46%-70%) when compared to those studies that did not report 
underlying infectious disease (77%, 95%CI: 69%-86%) 
 
No direct association was observed between fungal lung disease exposures and higher benign 
disease prevalence or false positive FDG-PET scans. No direct measurement of fungal lung 
disease exposure was possible in this analysis. The prevalence of benign disease after lung 
surgery varied by state and the cause of this observation, whether practice variation, verification 
bias, infectious lung disease or other unknown causes, is not known at this time. Investigating 
possible causes of the observed variation in FDG-PET scan accuracy and in benign disease 
prevalence after lung surgery is needed in future research. Such information will inform policy 
makers and health researchers as they examine the efficacy of a national lung cancer screening 
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program. Furthermore, the influence of local practice and locally endemic benign lung disease on 
the diagnosis of lung cancer must be better understood and incorporated into any lung cancer 
predictive models for surgeons before such a model can be clinically implemented nationally.   
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Chapter 1 
 
 
1.0 An introduction to lung cancer, its epidemiology, evaluation and diagnosis 
 with a focus on variables for predictive modeling   
 
 1.1 Epidemiology of lung cancer 
 
Lung cancer is the most common cause of cancer-related death in the United States (US) and kills 
more people than breast, prostate, and colorectal cancers combined (Figure 1). An estimated 
226,160 new cases and 160,340 deaths from lung cancer occurred in the US in 2012, accounting 
for approximately 17% of annual incident cancers and 28% of all cancer deaths.1,2 One in 
fourteen individuals born today will be diagnosed with lung cancer at some time during their 
lifetime based upon incidence rates from 2007-2009. Lung cancer diagnosis and treatment exerts 
a significant economic burden as well. The US spends an estimated $10.3 billion on direct lung 
cancer care, which comprises 10% of all cancer related healthcare expenditures.3 These direct 
costs are dwarfed by the estimated $83 billion lost in productivity from caregiving to those with 
the disease and lost wages from early mortality.4 
 
Lung cancer, like most cancers, is a complex and diverse disease. It is caused primarily by 
environmental factors. Known risk factors for lung cancer include smoking tobacco, radon 
exposure, air pollutants, second-hand smoke, occupational exposures and individual genetic 
susceptibility. The primary risk factor for both small cell (SCLC), which comprises 14% of all 
lung cancers, and non-small cell lung cancer (NSCLC), which comprises the remaining 86%, is 
tobacco smoking. Approximately 85 to 90% of the population attributable risk for lung cancer is 
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due to tobacco smoking.5 Among non-smokers lung cancer is a relatively rare disease, less than 
15 per 100,000 person-years.6   
 
Lung cancer incidence has declined as smoking prevalence has declined in the US. The age-
adjusted incidence rates for lung cancer in the US, according to Surveillance Epidemiology and 
End Results (SEER) data, peaked in 1992 at 69.4 cases per 100,000 person-years. The trend in 
incidence has fallen with 58.8 per 100,000 person-years in 2009, the most recently available 
data.7 Among women, age-adjusted incidence has decreased to 51.2 per 100,000 since reaching 
its peak of 53.5 in 2005 (Figure 2). The incidence rate of lung cancer in men has steadily declined 
from its peak of 102.1 per 100,000 person-years in 1984 to 69.2 in 2009. Age-adjusted mortality 
rates in the US have seen slight declines in recent years for women (38.6 per 100,000) from their 
peak in 2002 of 41.6 per 100,000 person-years. A more dramatic decline in mortality among men 
has been observed from an age-adjusted high in 1990 of 90.6 to 62 per 100,000 person-years in 
2009.8 
 
The overall 5-year survival rate for lung cancer is 15.2%. This poor prognosis is largely due to 
the cancer’s typically advanced stage at the time of diagnosis.9 In comparison, using the more 
granular American Joint Committee on Cancer staging schema, populations with localized, 
pathological stage 1A lung cancer have a 73% 5-year survival rate, while metastatic stage IV 
disease has a 1.8% survival rate.10,11 To date, only surgical removal of cancerous tissue can cure 
lung cancer. Surgery for lung cancer is only indicated in those who can withstand the physical 
rigors of major surgery and have localized stage 1 or stage 2 disease.12 To reduce the mortality 
burden from lung cancer, detection of disease in its earlier stages when surgical treatment is a 
possibility is necessary. Early diagnosis and treatment that reduces lung cancer related mortality 
has been the subject of much research in the lung cancer field; however, none of the methods for 
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early detection had reduced mortality from lung cancer prior to the advent of low dose computed 
tomography (LDCT) scans.13-17 
 
1.2 The National Lung Screening Trial and the possibility of screening for lung 
cancer  
 
The recently concluded National Lung Screening Trial (NLST) was a two-arm randomized 
controlled trial that screened 53,454 asymptomatic individuals at high risk for lung cancer with 
either LDCT or chest x-ray. A 20% decrease in lung cancer related mortality in the LDCT arm 
was observed compared to those randomized to the chest x-ray arm (Figure 3). All-cause 
mortality was 7% less in the LDCT arm as well. However, the false positive rate for LDCT was 
96.4% and 39% of all participants had at least one positive scan between the three annual scans 
conducted during the trial. The success of LDCT in reducing mortality compared to chest 
radiograph in the NLST has caused physician and patient advocate groups to propose screening 
guidelines for lung cancer. The American College of Chest Physicians (ACCP), American 
Society of Clinical Oncology, National Comprehensive Cancer Network (NCCN), American 
Association of Thoracic Surgery, American Cancer Society, American Lung Association and 
American Thoracic Society all endorse using the NLST screening regimen as the basis for lung 
cancer screening.18 In addition, the NCCN expanded the pool of those to potentially be screened 
from ages 55 through 74 to 50 through 74, with more than a 20 pack-year history of smoking or 
who also have any secondary risk factors including: family history of lung cancer among first 
degree relatives, previous cancer, asbestos or radon exposure, chronic obstructive pulmonary 
disease, or occupational exposure to a known lung carcinogen (Table 1).19   
 
Cost effectiveness of LDCT screening has been estimated to be as low as $19,00020 to over 
$110,000 per quality adjusted life year using the NLST based risk criteria21 for screening 
inclusion and accepted screening guidelines described above. More accurate estimates of cost-
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effectiveness within the NLST are expected to be published shortly.22 The publication of results 
from the NLST, the promulgation of clinical guidelines, and endorsement of LDCT lung cancer 
screening by clinical and patient advocacy groups led the US Preventive Services Task Force to 
initiate a review of their 2007 recommendation against screening with LDCT. Public 
announcement of the Task Force’s draft review of their recommendation is expected in of 2013.23 
Should the Task Force find strong evidence of benefit from lung cancer screening with LDCT, 
then Medicare and other insurers would be required to cover the expense of screening with 
LDCT. Thus, screening for lung cancer would join that of breast, colon, cervical and prostate 
cancer. 
 
Using the proposed screening guidelines based upon the NLST definition of a high risk 
individual, an estimated 7.4 million current and former smokers would be eligible for lung 
screening.24,25 In the National Lung Screening Trial (NLST), a lung abnormality was identified in 
39% of patients during the screening protocol requiring additional diagnostic testing, but less than 
4% of those were malignant.26 If the false positive rate for national screening is similar to that 
found during the trial, an estimated 2.9 million abnormalities will be found on LDCT over the 
first three years of the screening program, each requiring additional surveillance and diagnostic 
testing.   
 
1.3 Conceptual framework for the surgical evaluation of lung nodules and the 
diagnosis of lung cancer 
 
 
An individual can present to a clinician for evaluation and diagnosis of a lung nodule suspicious 
for lung cancer three ways: symptomatically, incidental discovery of the nodule after imaging for 
another clinical indication, and from periodic screening. Irrespective of source, the diagnosis of 
lung cancer begins with radiographic imaging of the chest and detailed history and physical of the 
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individual. Previously, most lung cancer was diagnosed symptomatically (estimated 75%), but 
incidental discovery has increased recently with the proliferation of imaging modalities like CT 
scans.27 If a screening program is initiated in the US, then an explosion in asymptomatic lung 
nodules requiring diagnosis will occur. Since the lung is difficult to access outside the immediate 
proximity to an airway, clinicians rely heavily on available non-invasive diagnostic tools, like 
radiographic imaging, to diagnose lung cancer. 
 
Lung anomalies on radiograph are generally characterized as either lung nodules, opacities, 
lesions or masses. Abnormalities or lesions of the lung are generally classified according to size 
at maximum average diameter and morphological characteristics that are observable on 
radiograph. Lung nodules are larger than 3mm in maximum diameter and less than 30mm (Figure 
4A). Lung masses are 30mm and larger in size. Nodules and masses appear as generally solid 
collections of tissue on CT scan (Figure 4B). Ground glass opacities and ground glass nodules 
can vary widely in size and are characterized by their non-solid appearance or shadow 
consistency on imaging (Figure 4C).28 For the purpose of this dissertation, “nodule” and “lesion” 
are synonymous.   
 
Figure 5 illustrates the three-step progression of a lung lesion in an individual from the time at 
which the lesion is “Undetectable” (step 1) to “Detectable” (step 2) and finally to the surgical 
evaluation of a “Suspicious” lesion (step 3). This conceptual framework begins with the “at risk” 
patient prior to developing a detectable suspicious lung lesion and moves through time until a 
definitive diagnosis of cancer or benign disease occurs at the time of an operation or through 
prolonged radiographic surveillance. At each step of their evaluation, patients accumulate 
additional clinical and imaging diagnostic information until presenting to the surgeon who must 
decide to either operate or continue following the lesion radiographically over time. 
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In the first step, the patient has an “undetectable lung lesion”. Every person has genetic, 
demographic, environmental and behavioral risk factors for the development of lung cancer. 
While smoking and advanced age are the primary risk factors for developing lung cancer, clinical 
diagnoses of other lung diseases like chronic obstructive pulmonary disease (COPD), asbestosis, 
etc. may also increase or decrease the risk of lung cancer. Most individuals are asymptomatic at 
this point in the growth and detectability of a lung lesion. Models developed to estimate the 
likelihood of lung cancer in this population of undetectable lung lesions focus on common 
epidemiologic risk factors including age, sex, race, years smoked, number of cigarettes smoked 
per day, family history of cancer, occupational exposures to carcinogens, age at smoking 
initiation, or years since smoking cessation.29-33 This first group of epidemiologic models uses 
population characteristics to estimate the likelihood of developing cancer over a one-year, five-
year, or ten-year time frame. These population risk models categorize individuals into cancer risk 
strata, and those strata at highest risk are then likely candidates for LDCT screening or greater 
surveillance. The most widely used in the US is the Bach model.29,34 Other models including 
those by Spitz, Tammemagi, and Cassidy have been validated.30,35-38 One model by Hoggart and 
colleagues, though promising, has not been validated but performed similarly to the Bach 
model.39 Model accuracy as measured by C-statistic or area under the curve (AUC) is 65% to 
80% among the four models and 60% to 75% in external validation populations. The prevalence 
of disease in the populations from which these models were developed range from 0.01% to 1% 
(Table 2).33,40 In high risk cohorts like that included in the NLST, lung cancer incidence was 6.45 
per 1000 person years.22   
 
Once a lung lesion is present, the individual can be clinically evaluated, the nodule discovered 
and categorized, and likelihood of cancer assessed. Discovery and evaluation of a lung lesion is 
encapsulated in Step 2 of the conceptual model. In this step, the lesion is radiographically 
detectable by CT scan and clinical symptoms may or may not be present. LDCT scans are fairly 
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sensitive (90-95%) in the detection of lung lesions down to 3 to 5mm, and high dose, thin slice 
CT scans can detect lung anomalies smaller than 3mm.41 Common symptoms of possible lung 
cancer include unexplained weight loss, shortness of breath and hemoptysis. Discernible imaging 
characteristics of the lesion are now observable on CT scan and indicate the relative likelihood 
the lesion is cancerous. The prevalence of lung cancer in this population is much higher than that 
prior to lesion discovery.  Four percent of lung anomalies discovered on LDCT scan were 
cancerous in the NLST and a higher prevalence of disease (25-55%) was observed in the training 
datasets for the Mayo, Solitary Pulmonary Nodule (SPN) and Veterans Affairs models developed 
to diagnose lung cancer in indeterminate lung nodules.35,42,43  Clinical guidelines suggest an 
individual be evaluated by a primary care physician or pulmonologist who makes a clinical 
assessment of cancer risk.   
 
The correct diagnosis of a nodule suspicious for lung cancer is as much art as science. The 
clinician must individualize care by weighing the risks of increasingly invasive procedures and 
the patient’s physiological status with the need to treat in a timely fashion.  The diagnosis of lung 
cancer, as described hereafter, relies upon NCCN and ACCP as well as Fleischner Society 
guidelines, which both the NCCN and ACCP incorporate into their clinical guidelines.19,27,41,44-46 
The assessment of a lung lesions cancer risk should be based upon either clinical judgment or a 
validated prediction model at the time of evaluation (Figure 6).27,45   
 
The pre-operative diagnosis of lung cancer combines two classifications of clinical information.  
The first is primarily epidemiologic in nature and includes risk factors such as: age, smoking 
history, family history of cancer, occupational exposures to carcinogenic agents, environmental 
exposures and previous diagnostic history of other, non-cancerous lung diseases. These risk 
factors describe known population risks for developing lung cancer and are commonly obtained 
during initial clinical evaluation. Lesion or nodule specific information on lung cancer risk is 
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derived from imaging and various invasive procedures to obtain a tissue diagnosis. Data used to 
diagnose an individual can be placed on a continuum of increasingly invasive diagnostic tests. An 
examination starts with a history and physical, then progresses to an LDCT scan or chest x-ray, 
sputum cytology, a high dose CT scan with injected contrast or Positron Emission Tomography 
scan with injected radiotracer F18-fluorodeoxyglucose (FDG-PET). Each of these tests generates 
non-invasive diagnostic information. CT scans with contrast and FDG-PET scans are currently 
the most sensitive and specific non-invasive tests available. According to a meta-analysis, 
combination PET/CT scans have the highest overall accuracy with sensitivity of 92-96% and 
specificity of 78-84%.47,48 This combination of imaging modalities offers anatomic, morphologic 
and metabolic information on the lung lesion.45 Sputum cytology is a non-invasive test that can 
provide a pathological diagnosis, but has poor sensitivity and specificity.45 Increasingly invasive 
tests to obtain a tissue diagnosis include bronchoscopy, endobronchial ultrasound with biopsy, 
fine needle aspiration, thoracoscopic biopsy and finally thoracotomy. 
 
According to national guidelines, if the likelihood of cancer is less than 5% then continued 
surveillance with follow-up LDCT scans is recommended. When the likelihood of cancer is 
greater than 60% then surgical biopsy including bronchoscopy with biopsy, CT guided biopsy, 
mediastinoscopy or surgical resection is recommended. When the likelihood of malignancy is 
between 5% and 60%, then diagnostic CT scan with imaging contrast, FDG-PET scan or other 
non-invasive test is recommended (figure 6). Nodules greater than 8mm in maximum diameter 
are candidates for evaluation by injected radiotracer F18-fluorodeoxyglucose (FDG) followed by 
combined positron emission tomographic and computed tomographic scan (FDG-PET). A 
negative FDG-PET scan indicates a low likelihood of cancer. A scan is indicative of possible 
cancer when hypermetabolism, more commonly called avidity is observed. If the lesion is 
determined to be avid by FDG-PET scan, a biopsy or surgical excision should then be pursued to 
obtain pathological tissue diagnosis. If not avid, then continued surveillance by annual LDCT is 
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suggested. For any nodule that is stable or decreases in size on subsequent LDCT, continued 
surveillance with decreasingly frequent LDCT is warranted for an additional two years. 
Continued annual LDCT should be considered for those patients who are eligible for lung cancer 
screening until the individual is no longer eligible for definitive treatment of a lung cancer that 
could occur.19,41   
 
Three validated models are available to estimate the likelihood of lung cancer after detection of a 
lung lesion on radiographic imaging.35,36,42,43 Each model includes age, history of previous cancer, 
smoking history of the individual, the size of the lesion and one or more imaging characteristics 
from CT scans. Imaging characteristics associated with higher risk of cancer include a growth on 
serial CT scans; having a spiculated, diffuse coronal, spiky or pointed edge on the surface of the 
lesion compared to a lobulated or smooth lesion edge; and a lesion location in the upper lung. The 
SPN model developed by Gurney and colleagues also includes hemoptysis, lesion cavitation 
which indicates likely benign disease when cavitation is smaller than 16mm, calcification which 
also indicates benign disease, and FDG-PET avidity.49 The prevalence of lung cancer observed in 
the populations from which these models were developed ranged from 25% to 55%. The AUCs 
for these models were between 70% and 80%. Table 2 lists the models from Steps one and two of 
the conceptual model described in Figure 5 as well as the variables used in each model for 
comparison purposes.   
 
After a lesion has been detected, the clinician must estimate the likelihood of cancer using a 
predictive model or their clinical judgment. The evaluating clinician may also consider whether 
the likelihood for cancer is great enough to warrant referral to a surgeon for additional assessment 
and possible treatment. If so, the surgeon compiles all relevant diagnostic data acquired to date 
and may order additional testing to better estimate both the probability of cancer as well as 
whether the patient is a low enough operative risk to benefit from surgery. Additional testing may 
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include more invasive tests like endobronchial ultrasound, fine needle aspiration or navigational 
bronchoscopy. Assessment of operative risk includes pulmonary function tests and cardiac stress 
or diffusing capacity for carbon monoxide tests. At this point in the evaluation process, surgeons 
have access to all available data including patient risk factors, clinical and imaging 
characteristics, and the results of any additional procedural or operative evaluation tests. A final 
assessment of cancer risk occurs and a decision to operate or to continue surveillance through 
periodic radiographs is made. The surgeon weighs the likelihood of cancer with the possible 
benefits to the patient and possible harms from the procedure and plans a course of care which is 
personalized to the individual after conversation with the patient.46   
 
Epidemiologic risk models, such as those developed by Cassidy, Spitz, Tammemagi and Bach, 
assess a patient’s risk for developing cancer prior to imaging at step one in our conceptual model 
for evaluating lung lesions. These models assist in determining who benefits most from lung 
cancer screening by LDCT scan.29,31,33,40 Swensen’s Mayo model, Gould’s VA model and 
Gurney’s SPN calculator estimate the probability of cancer in patients with a known radiographic 
abnormality on CT scan or chest x-ray.42,43 These diagnostic models estimate the probability of 
malignancy to help the clinician decide in step two who needs watchful waiting, additional 
testing, or surgical referral. No published models are available for the surgeon evaluating 
individuals for possible surgical biopsy. Isbell and colleagues showed that Swensen’s Mayo 
model and Gurney’s SPN calculator model had similar accuracy to predict lung cancer as 
reported in the original studies (AUC of 78 and 80 respectively) but were poorly calibrated in the 
validation dataset from a single institution’s thoracic surgery practice. The prevalence of cancer 
in most surgical populations is between 50% and 80%. The three models available to evaluate 
lung nodules were developed or validated in populations with 25% to 55% cancer prevalence. 
Thus, all lung nodule risk models were developed in non-surgical populations with a lower 
prevalence of cancer compared to surgical populations. Currently available models to assess the 
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risk a lung nodule is cancerous tend to underestimate the likelihood of cancer in individuals with 
cancer and overestimate the probability of cancer in those with benign disease when applied to 
surgical populations.50  
 
Unlike the colon, breast or prostate, the lung is a difficult organ to access for some biopsies, and 
many individuals seeking diagnosis have poor lung function from their prolonged tobacco smoke 
exposure. Less invasive biopsies, like fine needle aspiration and transthoracic needle lung biopsy, 
are frequently complicated by pneumothorax or atrial fibrillation (15-25%) or by less frequent 
and more severe complications including internal bleeding or lung failure requiring mechanical 
ventilation.51-54 These biopsies are often not recommended for lesions occurring more centrally 
within the lung or near major vessels. Minimally invasive lung resection for biopsy of a lung 
nodule has a similar profile of complications but also has significant risk for mortality associated 
with it. In the NLST, which included primarily large academic cancer centers and procedures 
performed by thoracic specialists, surgeons experienced a 1.2% mortality rate within 60 days of 
their lung operation. Other researchers have found the mortality rate for thoracoscopic surgery to 
be even higher, between 2 and 5% within 30 days of the operation, depending upon the 
population and specialization of the surgeon.55,56 In comparison, breast lumpectomy with lymph 
node sampling has a 0% 30-day postoperative mortality rate.57 Thus, surgical lung biopsy has 
significant risk associated with the operation. The surgeon evaluating a lung nodule faces a 
significant dilemma: should he/she subject the patient to an operation with the possible range of 
complications associated with this major surgery, or miss catching the lung cancer and the only 
opportunity for a cure available if the cancer is early stage local disease. 
 
Prior to surgical evaluation, all prediction models, radiographic studies, and clinical evaluations 
are designed to rule in cancer and maximize sensitivity. Consequently, 20% to 40% of diagnostic 
lung operations result in a benign diagnosis.58-62 Thoracoscopic surgery in the NLST had a 24% 
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benign disease result prevalence at final pathology.22 Clearly, a model developed in a surgical 
population, with its larger available information set and higher prevalence of disease, is warranted 
to aid surgeons in the evaluation of lung nodules and avoid unnecessary surgeries.  Possible 
variables representing known risk factors or predictive variables will be discussed further below. 
 
1.4 Epidemiologic predictors of lung cancer  
 
Predictors of lung cancer in populations being evaluated for possible surgery can be categorized 
into two broad groups, epidemiologic and radiographic. Epidemiologic predictors, as discussed 
earlier, include age; sex; race; number of years of smoking; number of cigarettes smoked per day; 
family history of cancer; occupational exposures to carcinogens; age at smoking initiation; years 
of smoking cessation; presence of other lung diseases like emphysema or COPD; and presence of 
symptoms like hemoptysis, shortness of breath, unplanned weight loss, or fatigue. Factors unique 
to surgical populations that indicate relative tobacco exposure and the individual’s response to 
that exposure include body mass and relative lung function. Radiographic imaging variables 
associated with lung cancer include the location of the lesion in the lung, rate of growth, 
physiological shape, and metabolic activity relative to surrounding lung tissue. Each predictor and 
its association with lung cancer will be examined and use in other lung cancer prediction models 
discussed below. 
 
Host Factors and Lung Cancer Risk from Smoking 
Smoking has been a known cause of lung cancer for nearly six decades63,64. Doll and Hill’s 
seminal findings from their prospective cohort study confirmed previous retrospective studies that 
found tobacco smoking causes lung cancer.63 Approximately 80% of women and 90% of men 
diagnosed with lung cancer were smokers.  In the US smoking prevalence peaked among males in 
the 1940s and 50s at around 67%. Smoking prevalence peaked for US females in the late 1960s at 
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approximately 44%. Active tobacco smoking remains the greatest risk factor for lung cancer, 
although passive tobacco smoke exposure is a contributing risk factor especially among non-
smokers. Tobacco smoke and the carcinogenic chemicals in the smoke act on the lung to generate 
cancer through a number of biological processes. Polycyclic aromatic hydrocarbons (PAH), 
carcinogenic metals, and N-nitrosamines are all present in tobacco smoke and exert their effects 
on the lung and carcinogenesis through both gene mutations and the formation of DNA adducts 
(Figure 7). The subsequent cellular changes and mutation proliferation result in lung cancer.65,66   
 
There is an observed dose-response between smoking and lung cancer risk.32,43,67 The relative risk 
per year of contracting lung cancer increases between 8% and 17% per 10 cigarettes per day 
additionally smoked.68,69 The change in risk due to smoking is generally monotonic70,71 and 
Tammemagi found a non-linear relationship between the number of cigarettes smoked per day 
and lung cancer risk.33 The age at which smoking began, the number of cigarettes smoked per 
day, and the duration of smoking all influence the likelihood of developing lung cancer.29,72 
Current smokers have a 20-fold increase in lung cancer risk compared to never-smokers5. In one 
study, the cumulative risk of dying from lung cancer before age 85 was 22.1% for a male smoker 
and 11.9% for a female smoker of European descent, in the absence of competing causes of 
death. This compares to a 1.1% probability for a man and 0.8% probability for a woman non-
smoker dying from lung cancer before age 85.73 Smoking is often measured in pack-
years19,29,30,38,43, cigarettes per day33, years of smoking30,32 or as ever having smoked more than 
100 cigarettes30,35,42 when used in predictive modeling. 
 
Smoking cessation decreases all cause and lung cancer related mortality irrespective of the age at 
which one stops smoking.74,75 The benefits of quitting smoking for reducing lung cancer risk are 
also well documented.76,77 The benefits of smoking cessation to lung cancer risk reduction stop at 
around two times the risk for former smokers when compared to never smokers.78,79 Decreased 
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risk of lung cancer changes little after 15 years post-cessation, but risk remains elevated among 
smokers compared to non-smokers for at least 30 years after cessation.69  Years of smoking 
cessation or having quit smoking as a dichotomous outcome are included in screening 
models.19,29,30,33 Any model estimating lung cancer risk must include some measure of smoking 
exposure. 
 
Sex Differences in Lung Cancer Incidence 
Sex differences in lung cancer risk from smoking in the US have been observed in the past, and 
women have been considered more susceptible to developing lung cancer.80-82 More men are 
diagnosed with lung cancer than women but smoking prevalence among men has historically 
been higher compared to women. The gap in smoking rates between men and women has greatly 
narrowed and in 2009 23.5% of men and 17.9% of women were smokers.83 As the rates of 
smoking among both men and women have become more similar since the 1960s, their lung 
cancer incidences and age adjusted lung cancer death rates have converged (Figure 1).84,85 After 
controlling for smoking duration, age at initiation, and intensity, no sex specific differences in 
lung cancer risk have been found.29,70,85-87 However, death from lung cancer is lower in women 
compared to men, and this difference in cancer related death has been consistent over time.88,89 
 
Separating sex specific risk for lung cancer from that associated with smoking habits has been 
difficult. Some researchers investigating incident lung cancers found women smokers had higher 
risks for lung cancer when compared to male smokers, especially after age 70.81 Women have 
been found to have different distributions of lung cancer histology. Specifically, non-smoking 
women of all races are two to four times more likely to have bronchioloalveolar cancer compared 
to men.90-92 Among non-smokers, age and temporal biases within the cohorts studied may have 
influenced the relationship given that women live longer than men.93 A recent study examined sex 
specific risk for lung cancer by pooling non-smokers from 13 cohorts and 22 cancer registries 
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from around the world.73  Thun and colleagues found no differences in lung cancer age-
standardized incidence rates between men and women age 40 and higher.73 Sex is not included as 
an independent variable in any lung cancer prediction models of lung nodules; however, the Bach 
model includes sex as a covariate and the models developed by Spitz and Cassidy matched cases 
and controls on sex (Table 2).38,40  
 
Race 
A number of population studies have found that racial differences in response to smoking and 
lung cancer risk may occur due to intensity, types of cigarettes smoked or other environmental 
factors such as access to care or socio-economic status. Incidence rates of lung cancer among 
smokers are higher among African American men compared to Caucasian men67 Smoking 
prevalence among African American men is slightly higher than that observed among white men. 
However, the literature remains mixed as to whether race is an independent host factor for 
smoking related risk for lung cancer incidence. African Americans and Native Hawaiians appear 
to have higher risk of lung cancer at lower smoking exposure (<31 cigarettes a day). Lung cancer 
risks were similar among heavy smokers across races and sexes in one large multi-racial cohort94, 
and only African American heavy smokers had higher lung cancer risks in a case-control study.95  
 
One conjectured cause of the observed higher lung cancer risks among African Americans is their 
higher prevalence of mentholated cigarette smoking, 62% among African Americans compared to 
23% among Caucasian smokers.96 Menthol cigarettes are thought to be more difficult to quit 
compared to non-flavored cigarettes, thus contributing to the lung cancer burden from 
smoking.96,97 A recent study examined menthol cigarette use, lung cancer and smoking cessation 
in the Southern Community Cohort. The authors compared incidence and rates of smoking 
cessation between African American smokers and Caucasian smokers. They found lower 
incidence of lung cancer among menthol smokers irrespective of race and similar likelihood of 
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quitting smoking irrespective of the type of cigarette smoked.98 Other prospective studies also 
found no increased risk from mentholated cigarettes.99 Race is included only in the Tammemagi 
PLCO model for screening (Table 2).33 Years of education completed as a predictive variable was 
included in the Tammemagi PLCO model.  However, race in combination with education may be 
more indicative of socio-economic status or as an indirect measurement of occupational or other 
environmental exposures that are not fully captured by smoking. As such, race may be an 
important variable in epidemiologic models of lung cancer risk, but not in models assessing the 
risk from a discovered lung nodule.   
 
Second-hand Tobacco Smoke  
Exposure to second-hand or environmental tobacco smoke as a cause of cancer was first reported 
in 1981 in a study of non-smoking Asian women married to smokers100,101 More recent studies 
and meta-analyses found a dose-response relationship between lung cancer and environmental 
tobacco smoke exposure which strengthened the causal relationship found in earlier studies and 
reviews.102-104 In nonsmokers exposed to second hand smoke had seven percent of the cotinine 
and other tobacco specific metabolites compared to current smokers.105 Cotinine is a metabolite 
of nicotine and directly varies with the amount of nicotine inhaled. It is commonly used to 
estimate smoking exposure. Population exposure to second-hand smoke has been estimated to be 
around 40%, and an estimated one-fourth of lung cancer cases among non-smokers or 3,000 
deaths per year are attributable to environmental tobacco smoke in the US.103 Reduction of this 
exposure through recent workplace and public area restrictions of tobacco smoking has resulted 
in cotinine serum levels decreasing 2 to 3 fold compared to levels observed in the late 1980s.106,107 
Thus second hand smoke exposure, while a significant historical risk factor, will decrease in 
importance as a risk factor in the future with continued success of public health initiatives to 
reduce exposure to this carcinogen. 
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Second-hand smoke exposure has been included in some lung cancer risk models that estimated 
the likelihood of cancer among nonsmokers. The models were less accurate at estimating risk 
among nonsmokers when compared to former or current smokers as measured by AUC. Only 
Tammemagi and colleagues report evaluating second hand smoke exposure at a possible 
covariate.32 The NCCN guidelines for defining populations likely to benefit from screening 
specifically excluded environmental tobacco smoke exposure from the high risk group who 
should seek screening with LDCT. Second-hand smoking exposure is not a predictive variable in 
any models estimating lung cancer risk given a lung lesion found on radiograph (Table 2). No 
lung cancer prediction models that combine smoking and nonsmoking populations include 
second-hand smoking exposure. 
 
Non-smoking related exposures and risk factors for lung cancer 
Other environmental exposures associated with increased lung cancer risk include: naturally 
occurring radon (10-15% population attributable risk), asbestos, metal dusts and other 
occupational exposures (9-15%), and outdoor air pollutants (1-2%).5,107 Collectively, these 
environmental and occupational exposures represent much of the attributable risk in the 10% to 
15% of all lung cancers that occur among nonsmokers.107 Residential and occupational radon 
exposure is the second leading cause of lung cancer behind cigarettes.108 Asbestos, arsenic, 
chromium, nickel, beryllium and silica have been shown to increase risk for developing lung 
cancer among exposed, non-smoking workers. Other chemicals, including organic solvents, 
pesticides and non-ferrous metal dust or fumes have not consistently been shown to cause cancer 
in non-smokers.109-111 A number of studies have shown increased risk from radon and 
occupational carcinogen exposure concomitant with tobacco smoking.112 Wide variances in 
estimated occupational exposures are not uncommon in the literature, making risk estimation for 
individual chemicals problematic. Occupational exposure remains a significant burden for lung 
cancer in the US and across much of the developed world.111,113-115     
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Radon, asbestos, and occupational exposures are included in NCCN guidelines for defining 
possible high risk individuals eligible for screening. Outdoor air pollution has been reported as 
increasing lung cancer risk; however, the biases from residual confounding from occupational 
and smoking exposures does not allow for accurate estimates of risk.107,115 Radon and 
occupational exposure are significant risk factors for lung cancer at the population level, 
especially among nonsmokers.  Asbestos exposure is a risk factor in the Bach, Spitz and 
Liverpool models.  Occupationally occurring dust exposure is a risk factor in the Spitz model. No 
environmental risk factors are included in a lung cancer model that estimates risk after a lung 
nodule has been discovered (Table 2). 
 
Age and Lung Cancer 
Lung cancer is generally a disease of the elderly. Fewer than 1 in 100,000 individuals under age 
30 develop lung cancer.9 Lung cancer risk increases with age for both smokers and non-smokers. 
Lung cancer risk in non-smokers is 23 per 100,000 person years in individuals between the ages 
of 60 and 80.  The increased risk appears to be similar among never-smokers irrespective of race, 
except for Hispanics and African-American men about which there is too little data.73 Nearly two-
thirds of incident lung cancers occur in those over age 65. The median age at initial diagnosis is 
71 years.116  Age is included in all published lung cancer risk models.  The NCCN lung cancer 
screening recommendations consider those over age 55 years or over 50 years with additional risk 
factors as being in the high risk category (Table 2).   
 
Body Mass Index as a Risk Factor for Lung Cancer 
The evidence for body mass index (BMI) as a risk factor for lung cancer independent from 
smoking is generally weak and conflicting. A small case control study in non-smokers found 
those with a BMI over 30 had twice the odds of developing cancer when compared to those with 
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a BMI below 21.117 In a more recent study of the Women’s Health Initiative, BMI was found to 
be inversely related to lung cancer risk in smokers. In populations of non-smokers no association 
was found between BMI and lung cancer after adjusting for other lung cancer risk factors. BMI 
has been found to be inversely related to cancer incidence in populations with a history of tobacco 
use in a number of studies.98,118,119 BMI, independent of smoking, has not been found to be 
associated with lung cancer in a prospective cohort to date. Studies examining the relationship 
between BMI and lung cancer may suffer from residual confounding from smoking or from some 
other unknown biological mechanism occurring or associated with higher BMI as protective for 
lung cancer. Additional studies are needed to determine whether BMI is a lung cancer risk factor 
independent of smoking. As a possible predictive variable for lung cancer modeling, BMI is 
included only in Tammemagi’s PLCO model for screening (Table 2).33  BMI, like chronic 
obstructive pulmonary disease, may indicate the individual’s response to prolonged smoking 
exposure. It should be investigated as a predictor of lung cancer when evaluating lung nodules 
suspicious for lung cancer. 
  
Non-cancer lung disease 
Recent studies have shown a strong association between lung disease and lung cancer. An 
estimated 40 to 70% of those with lung cancer have co-morbid COPD.120 COPD has been found 
to be an independent risk factor for lung cancer in a number of studies.120-122 Individuals with 
COPD have a twofold higher risk for lung cancer  and are more likely to have squamous cell 
histology if diagnosed with lung cancer. Other lung diseases not directly caused by smoking have 
mixed results in their association with lung cancer risk. Asthma, for example, was associated with 
decreased risk of lung cancer in males in one study.122 On the other hand, pulmonary fibrosis and 
interstitial lung disease have been shown to exhibit an inflammatory response in airway 
epithelium leading to dysplasia. Subsequently, these two diseases have been found to be possible 
risk factors for lung cancer.123,124 Non-cancer lung diseases like COPD or pulmonary fibrosis are 
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an inclusion criteria for proposed NCCN lung cancer screening guidelines and may be an 
important risk factor for early detection.125 Tammemagi’s PLCO model, Spitz’s model, Cassidy’s 
Liverpool lung cancer screening model and the NCCN guidelines all include either COPD, 
emphysema, or COPD with other non-cancerous lung diseases in their risk estimation.  
 
Genetic Factors in Lung Cancer Risk 
An estimated 11% of smokers eventually develop lung cancer.126 The lack of lung cancer in the 
majority of those who smoke leads to the hypothesis that significant heritable risk factors exist 
and influence the tumorigenesis from tobacco exposure to lung cancer105 Studies showing an 
association between family history of cancer and increased lung cancer risk support this 
hypothesis.5,127 Aggregation of lung cancer within families has been shown in both case-control 
and cohort studies. One study examining the genetic evidence among twins and a second study in 
non-smokers and their first-degree relatives found higher risks for lung cancer within families. 
Furthermore, associations were stronger in lung cancers occurring at a younger ages.128,129 
Genetic mutations are grouped into two distinct categories: germline and somatic. Germline 
mutations are heritable and occur in a body’s reproductive cells. These mutations are incorporated 
into the DNA of every cell in the body of the offspring. For example, a germline mutation to the 
p53 region may make one more susceptible to the carcinogens in tobacco smoke or increase 
cancer risk independent of tobacco smoke exposure. Somatic mutations arise after conception. 
These mutations are not heritable and can arise from natural copy errors that are maintained 
through the DNA replication process or from environmental exposures that alter DNA. Biological 
pathways that regulate cells and mechanistically detoxify tobacco smoke can each be affected by 
either type of mutation (Figure 7).   
 
Cytochrome-p450 metabolizes the non-reactive compounds in tobacco smoke, primarily 
polycyclic aromatic hydrocarbons for example, into highly reactive intermediates. These reactive 
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compounds may bind to DNA and cause genetic injury (Figure 7). Glutathione s-transferase then 
transforms the intermediates created primarily by cytochrome-p450 into complexes that are more 
easily excreted. Germline mutations to genes which regulate either pathway may influence lung 
cancer risk.130,131  Similarly, mutations that influence enzymes from these pathways have been 
shown to increase lung cancer risk.132,133   
 
A second area of genetic interest is the tumor suppressor gene, p53. This gene influences multiple 
cellular response pathways relevant to carcinogenesis of various cancers and is not unique to lung 
cancer. The types of mutations in this gene in populations with lung cancer appear to be different 
between smokers and non-smokers. As such, the mutations in the p53 gene are likely somatic 
rather than germline. A third pathway for lung cancer susceptibility involves DNA repair and 
DNA repair capacity. Both germline and somatic mutations occur in the capacity of DNA repair 
enzymes to overcome miscoding or promote apoptosis. For example, DNA methylation, both 
hyper-methylation and hypo-methylation depending upon gene regions, increases risk.134 
Comprehensive review of genetic variations in the cause of lung cancer is beyond the scope of 
this chapter and other sources better serve this purpose.135-138   
 
Currently, no serum biomarker or other genetic test is recommended to assess risk for screening 
or diagnostic purposes.44 However, family history of lung cancer is a common risk factor among 
the risk models for screening populations. The Cassidy Liverpool model breaks family history of 
lung cancer into three categories: no history, early onset (<60 years), and late onset (≥60 years). 
Spitz defined family history as two or more relatives with history of any cancer. Tammemagi’s 
PLCO model defined family history of lung cancer as a dichotomous (yes or no) variable of lung 
cancer risk.   
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 1.5 Summary of epidemiological risk factors for lung cancer 
 
When assessing the variety of risk factors used to predict lung cancer, only age and some 
measurement of smoking exposure are common across all lung cancer risk models. These two 
variables are included in both screening models and in models assessing risk after the discovery 
of a lung lesion. Age is modeled linearly or as a categorical variable in the instance of NCCN 
guidelines or in Gurney’s Bayesian SPN model. Smoking exposure definition varies by model. 
The screening models, which rely solely on epidemiologic information, attempt to measure both 
the dose and duration of exposure by including cigarettes per day as well as years of smoking or 
the combination of the two as measured by pack-years. Length of smoking cessation is also 
considered in the Bach, Spitz and PLCO screening models as well as in the VA model for 
assessing lung lesions.  
 
Sex, COPD or emphysema, occupational exposures to dust or asbestos, and family history of 
cancer are each common predictive variables across three of the four screening models. COPD, 
occupational exposures and family history of lung cancer are additional risk factors that made 
individuals between ages 50 and 55 with between 20 and 30 pack years of smoking history 
eligible for LDCT screening in the NCCN screening guidelines (Table 1). Previous history of 
cancer is a risk factor in the PLCO and Liverpool screening models and in the Mayo and SPN 
lung nodule models. Race, education, and BMI are predictive variables only in the PLCO model.  
   
When examining the totality of the four validated lung cancer screening models (Bach, Spitz, 
Tammemagi PLCO 2012, and Cassidy Liverpool), the Tammemagi PLCO 2012 model, by 
Tammemagi et al.,  included the same broad factors of risk found in the other three models except 
for occupational exposure to asbestos. The Tammemagi PLCO model used modern statistical 
prediction techniques and best model development practices. It also had the highest apparent 
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AUC (80) and experienced only slight reduction in AUC in external validation sets. Estimated 
AUC in validation sets varied between 70 and 78 depending on the cancer risk cut-off used to 
include patients in the validation sets. The intent of these screening models, which rely 
exclusively on epidemiologic information, is to determine the characteristics of a population that 
would most benefit from screening. This screened population is a subset of those who will 
develop lung cancer.  Pinsky and Berg estimate that implementing a screening program based 
upon the NCCN guidelines or the more inclusive estimates of risk from the Tammemagi PLCO 
model will discover fewer than 10,000 of the 160,000 annual lung cancers.139 Many of the 
remaining 150,000 cancers will present to clinicians as either incidentally discovered lung lesions 
or symptomatically. Irrespective of the presentation to a surgeon, imaging will be available and 
the host of information that imaging provides can be used to estimate the likelihood of cancer. 
One study found that information from a CT scan was better at discriminating individuals with 
lung cancer than all the epidemiologic information combined.140   
 
1.6 Radiographic imaging and predicting lung cancer risk 
 
Once a lung lesion has been discovered, the breadth of information that imaging provides can be 
used to further characterize the lesion and it’s propensity to be cancerous. Imaging characteristics 
can be categorized broadly as either physical or metabolic. Physical characteristics include lesion 
shape, size and location in the lung. Lesions located in the upper lung are more likely to be of a 
smoking etiology and thus lung cancer, while lesions in the lower lung lobes are more commonly 
associated with infectious or granulomatous etiologies.35,42  Spiculation, coronal, or spikey edge 
characteristics (Figure 4A and 4B) indicate undifferentiated cells and thus cancer. Smooth lesion 
edges are common to calcified and benign tumors.27,141 Lung nodules smaller than 1 centimeter 
(cm), as measured by maximum diameter on a radiograph, are more often benign.27 Nodules over 
3 cm in diameter are 5 fold more likely to be cancerous than nodules about 1.5 cm in diameter.142  
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Lesion size as a predictive variable is common to all three models estimating lung cancer risk 
among patients with lung lesions.   
 
Metabolic characteristics include growth, doubling rate or volume change and radiotracer 
estimated avidity. Clinicians often consider lesion growth as the strongest indicator of cancer 
risk.143   Growth on serial radiographs is defined as an increase in mean diameter of 2 mm for 
nodules initially less than 15 mm in size and an increase of at least 15% compared to baseline 
scan for nodules more than 15 mm in size at baseline.19 However, a rapid increase in size should 
raise the suspicion of an inflammatory process or the possibility of small cell lung cancer. 
Volumetric measurement of lesions is a fairly recent development that shows some promise in 
screening populations with repeated scans to estimate the likelihood a lesion is cancerous.144 
Lesion volume is generated with 3 dimensional radiographic measurement and estimates the 
doubling time of a lesion by measuring the change in volume between subsequent volumetric CT 
scans. Proponents of volumetric measurement state this method more accurately measures growth 
of a lesion.145,146  This measurement has not been incorporated in any predictive models of lung 
lesions to date. Avidity measured by a PET scanner requires injection of a radiotracer and is not 
recommended until after a CT scan has been conducted. A combined PET-CT scan is considered 
among the most accurate, non-invasive diagnostic tests for lung cancer and is often conducted 
immediately prior to surgery.19,46,48 FDG-PET avidity is included in the SPN model in addition to 
growth, lesion size and edge characteristics.142  
 
  FDG-PETs role in diagnosing lung cancer  
Since the late 1990s, FDG-PET has become widely accepted for non-invasive clinical diagnosis 
and staging of lung cancer.46,147 FDG-PET scans use a fluorine radiotracer (F18) attached to a 
glucose receptor analogue (deoxyglucose). Hypermetabolism of lung tissue is measured by 
comparing tissue with higher concentrations of the radiotracer tagged glucose analogue (FDG) 
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which is above the background of surrounding lung tissue (Figure 8). When hypermetabolism is 
observed, the lesion is classified as being FDG avid or simply avid. Avidity is sometimes 
measured on a continuous scale called standard uptake value (SUV). SUV is estimated by 
measuring the average radionuclide activity concentration across the region of interest observed 
on the FDG-PET image at one time point and comparing that value with the background level 
measured in nearby lung tissue or by the injected radioactivity divided by body weight. An SUV 
above 2.5 is considered avid and suspicious for cancer by common convention among 
radiologists and thoracic clinicians.148-150   
 
Metabolically active tissues preferentially consume the FDG glucose analogue. Neoplastic cells, 
inflammatory lesions, wounds and active benign tumors have higher glucose metabolism. Slow 
growing cancers, especially neuroendrocrine tumors or lesions with little metabolic activity, will 
often not be distinguished on a FDG-PET scan and such cancerous nodules are known to generate 
false negative results. Inflammatory lesions, wounds and growing benign tumors are often 
metabolically active and known to cause false positive scan results.151,152 
 
A meta-analysis has shown FDG-PET to have high sensitivity (97%) and moderate specificity 
(78%) to identify lung cancer when the size of the lung nodule is greater than 1 cm.47 47 The 
estimated AUC of FDG-PET to diagnose lesions greater than 1cm across all the studies in the 
meta-analysis was 91% and the likelihood ratio for a positive test was 7.1.47 47 Based on the 
results of this study, FDG-PET was determined to be cost effective in the evaluation of patients 
with a solitary pulmonary nodule.153 153 Subsequently, FDG-PET was approved by Centers for 
Medicare and Medicaid Services for diagnosis of lung nodules suspicious of lung cancer in 2001, 
and current clinical guidelines recommend its use.46,154  In 2001, fusion FDG-PET/CT scanners 
became available. This scanning technology uses a computer program to adjust for breathing and 
other physiological factors to create a dynamic image of both the physical morphology of the 
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lung from the CT scan as well as the metabolic activity of the FDG-PET scan. Some studies have 
found the combination scanners to be more sensitive and specific in identifying lung cancer than 
PET scans alone.155-157 A recent review of published fusion FDG-PET and CT scan studies found 
slightly higher accuracy but not significantly different than the earlier meta-analysis by Gould 
and colleagues.48 The National Comprehensive Cancer Network guidelines advocate the use of 
combination FDG-PET/CT scans to diagnose solid or partially solid lung nodules whose 
maximum diameter is at least 8mm.   
 
However, the accuracy of FDG-PET is inconsistent, and false positive results are associated with 
infectious fungal lung disease and other inflammatory or infectious disease processes. The 
accuracy of FDG-PET drops significantly in areas with endemic granulomatous disease and up to 
30% of thoracic operations in these areas result in a benign diagnosis.158,159 Unfortunately, most 
of the studies included in Gould’s seminal 2001 meta-analysis were from medical centers in 
Europe, Japan and New England, areas that had low endemic granulomatous disease prevalence. 
The observed differences in the accuracy of FDG-PET to diagnose lung cancer may indicate an 
unintended selection bias in many of the earlier studies of FDG-PET accuracy used by the two 
meta-analyses. In some regions of the US where the prevalence of fungal lung disease is high or 
in Asia and Africa where tuberculosis is endemic 160-162, FDG-PET may not be effective in the 
diagnosis of lung cancer compared to CT alone.  
 
1.7 Infectious lung diseases as a spectrum bias of FDG-PET for diagnosis of 
lung cancer 
 
Infectious lung diseases that generate granulomas include fungal lung diseases from mycotic 
pathogens and mycobacteria, of which tuberculosis is the most common. Both classes of 
infectious pathogens have been shown to cause granulomas leading to false positive FDG-PET 
scans.158,163-168  The three major mycotic infections in order of North American prevalence are 
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histoplasmosis, coccidioidomycosis and blastomycosis.169,170 169,170 Chronic exposure to each 
individual pathogen is not known, as cross-reactivity between pathogens to the diagnostic skin 
test occurs.170  Prevalence of the three pathogens was 17.6% among naval recruits living in a 
single county screened between 1958 and 1969.170 Acute episodes of disease requiring 
hospitalization or outpatient therapy have been reported in elderly populations. The highest 
incidence rate was for histoplasmosis at 3.3 per 100,000 person years, followed by 
coccidioidomycosis (3.2 per 100,000 person years) and blastomycosis (0.7 cases per 100,000 
person years).169 Other less common fungal diseases include cryptococcosis, aspergillosis, 
actinomyocis, nocardiosis, candidiasis, and echinococcosis. Histoplasmosis is endemic across the 
Mississippi, Ohio, Missouri and Tennessee River valleys and an estimated 50 million individuals 
have been infected with histoplasmosis capsulatum.171  Coccidioidomycosis is endemic across the 
Southwest and San Joaquin valley in California.172  The highest incidence of coccidioidomycosis 
occurs in Arizona.173 Blastomycosis is the most broadly dispersed fungal disease of the three. 
Endemic areas occur across the southeastern US and up through the Great Lakes and as far west 
as Texas. Highest incidences are observed in the Ohio and Mississippi river valleys and lower 
Great Lakes area169 (Figure 9A). Mycotic fungal spores reside in soil as well as in bat and avian 
feces. Farmers, construction workers and those who engage in outdoor activity in rural areas have 
the highest risk of inhaling the spores. Acute and deadly single site outbreaks have been 
documented and were associated with nearby soils having a high concentration of avian fecal 
material and subsequently being disturbed by construction equipment.171,174 
 
Fungal lung disease is generally asymptomatic or causes flu-like symptoms. Immunocompetent 
individuals exposed to a fungal load that does not generate an acute response will create 
antibodies and typically eliminate the infection in less than 14 days. Reinfection is common in 
endemic areas. Current diagnosis of acute or disseminated pulmonary histoplasmosis is 
determined by serological or urine test.175,176 Only the skin antigen test is sensitive to exposures 
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that occurred more than two to three years prior. Similar to the tuberculosis skin test, the skin test 
for histoplasmosis is cross-reactive to coccidioidomycosis and blastomycosis. A skin reaction 
occurred if the individual was previously exposed to one of the fungi, but the test is no longer 
commercially produced and reagents for the skin test are no longer available.171   
 
An estimated 1 in 2,000 people infected by histoplasmosis will develop chronic pulmonary 
disease. Among individuals with symptomatic coccidioidomycosis disease who require antifungal 
treatment, 5% develop irreversible bronchiectasis, pulmonary nodules, or residual lung 
cavities.177 Granuloma formation in the lung is one possible result for any fungal infection. 
Granulomatous disease of the lung can look identical to cancerous tissue on a CT or PET scan 
(Figure 8) and can have all the hallmarks of a cancerous lesion including symptomatic 
hemoptysis, growth on repeated CT scans, spiculated edge characteristics and lack of 
calcification.178 While fungal lung diseases are the primary etiology of granulomas in the US and 
North America, tuberculosis is the more common cause of granulomas in Asia, Africa and 
developing countries.161,162,164,177,179-184 
 
 If infectious lung diseases like histoplasmosis in North America and tuberculosis in Southeast 
Asia and Africa generate granulomas and these granulomas reduce the specificity of FDG-PET 
scans to diagnose lung cancer, then the lack of published studies reflecting the impact of these 
infectious diseases on FDG-PET specificity may indicate a spectrum bias in the published 
literature and meta-analyses. Spectrum bias is a form of selection bias wherein the breadth or 
complexity of a disease is not well reflected in the population undergoing a diagnostic test185. 
Spectrum bias more commonly occurs when outliers in risk stratification are not included in the 
test population. For example, a cholesterol test is very accurate at classifying heart disease when 
the population with disease was recruited from a heart clinic and had moderate to high levels of 
cholesterol. An unbiased assessment of the test requires high and low levels of cholesterol in both 
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those with and without disease in order to reflect the possible population in which the test would 
be applied. Similarly, a diagnostic test may be highly accurate in moderately high or low risk 
strata but perform poorly in the tails of the risk distribution. With respect to FDG-PET scans, the 
prevalence of infectious lung disease and the granulomatous disease created by those infections 
may be causing the bias in published FDG-PET scan results.   
 
For infectious lung diseases the geographic variation in the prevalence of these diseases may have 
inadvertently created just such a bias for FDG-PET scans. This bias occurs in those with  
granulomas that, in turn, only influences or confounds diagnostic imaging and not the probability 
of lung cancer. This bias only becomes important in the context of diagnosing lung cancer with 
diagnostic imaging. No published reports have found granulomatous disease increasing or 
decreasing the likelihood someone develops lung cancer. Thus infectious lung diseases are not a 
confounder of lung cancer. Rather, granulomas from the disease generate false positive FDG-PET 
results which then influence the clinician’s estimate of the probability of lung cancer.   
 
1.8 Geographic variation in the diagnosis of lung cancer 
 
Evidence of geographic variation in the diagnosis of lung cancer after surgery or in the diagnostic 
accuracy of FDG-PET has implications for any models attempting to predict lung cancer in 
populations being evaluated by surgeons. Evidence of either implies that local variation in benign 
disease prevalence, patient work-up, fungal lung disease or other unknown factors occur and may 
influence a clinical prediction model.  
 
There is a fourfold geographic variation in lung cancer incidence across the US. Kentucky has the 
highest rate among both men (125.1 per 100,000) and women (80.3 per 100,000), and Utah has 
the lowest rates (29.2 for men and 19.0 per 100,000 for women).8 These incidence rates mirror 
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the historical smoking prevalence in those states and have remained fairly consistent over time. 
The variation in lung cancer rates follows smoking rates across the country. Fungal lung disease 
varies greatly by region of the country in the US. For example, the histoplasmosis prevalence in 
the central and western portions of Tennessee and Kentucky is between 80% and 97%, while in 
the Boston area and Pacific Northwest, it is a rare disease (Figure 9A and 9B).170  Variation in 
benign lung disease rates may occur across the US as well and reflect underlying infectious 
disease prevalence. The interaction between local smoking prevalence and infectious lung disease 
prevalence is unknown. The influence of local practice or referral patterns, clinical expertise and 
availability of specialists on the prevalence of benign disease after a lung operation for suspected 
lung cancer is also unknown.   
 
Whether geographic variation in the diagnosis of lung cancer after thoracoscopic surgery for 
suspected lung cancer occurs is unknown in the US. Answering this basic question is the first step 
in determining the scope of the variation in the surgical diagnosis of lung cancer. If such variation 
occurs and is clinically significant then examination of possible causes of that variation becomes 
important. One possible cause of variation in the US could be fungal lung diseases as a direct 
cause of benign lung diseases. Another indirect cause would be fungal lung diseases’ influence on 
FDG-PET scan accuracy to diagnose lung cancer.  
 
We can exploit the observed variation in the geographic distribution of fungal lung disease in 
North America to test the hypothesis that fungal lung disease confounds FDG-PET accuracy to 
diagnose lung cancer. If FDG-PET specificity varies inversely with endemic fungal lung disease, 
then we have both a possible measurement of the amount of bias in specificity caused by fungal 
lung disease and a strong argument supporting current clinical observation that fungal lung 
disease reduces FDG-PET accuracy to diagnose lung cancer. Secondly, if fungal lung disease is 
associated with benign disease after surgery for suspected lung cancer, then this is further 
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evidence of another factor that influences the surgical diagnosis of lung cancer.  Some 
measurement of fungal lung disease should be considered in predicting lung cancer. Finally, 
reports of granulomas of the lung and their underlying infectious diseases should appear in the 
literature as other researchers seek to improve the diagnosis of lung cancer.  A systematic review 
examining FDG-PET diagnostic accuracy could describe current knowledge as to the tests 
characteristics and factors that affect the diagnosis of lung cancer. 
 
1.9 Conclusion 
 
No clinical prediction model exists designed for surgeons evaluating a lung nodule prior 
to surgical biopsy. Existing models are either poorly calibrated to the higher prevalence 
of lung cancer in surgical populations or do not incorporate the breadth of information 
available to the surgeon at the point of decision to operate.  Because lung cancer is so 
deadly, patients and providers must aggressively pursue a diagnosis to rule out cancer. 
The high rates of benign disease after surgery observed in many of the lung cancer 
studies will be unchanged without an intervention for surgeons to aid their 
decision.50,56,59,62,186 The need for such a model will only increase as chest imaging 
technology progresses or a lung cancer screening regimen is implemented. 
 
A prediction model estimated with data from a single institution has limited clinical 
usefulness if local variation in cancer or benign disease after surgery occurs across the 
US.  Determining whether such variation is present and then exploring the possible 
causes of that variation are necessary prior to implementing a predictive model for lung 
cancer nationally.  Some evidence indicates radiographic imaging accuracy to diagnose 
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lung cancer varies across the US.  Since a predictive model for surgeons will rely heavily 
on such imaging, defining the extent of variation and possible causes of that variation 
will strengthen any prediction model for lung cancer applied nationwide. 
 
This dissertation begins the process of creating a clinical prediction model, the TREAT 
model, for surgeons evaluating individuals for lung cancer.  It explores whether variation 
in the diagnosis of lung cancer currently exists.  This research also begins to examine 
possible causes of variation that influence what is currently considered the most accurate 
radiographic imaging, FDG-PET scans.  These questions reflect current knowledge 
regarding predicting lung cancer and explore possible new information of import and for 
surgeons and patients struggling to answer the question, “Is it cancer?”       
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TABLES Chapter 1 
 
 
Table 1. Screening Criteria Risk Status – National Comprehensive Cancer Network 
High Risk Moderate Risk Low Risk 
Age 55 -74 
 
Age ≥ 50 Age < 50  
≥ 30 pack year history ≥ 20 pack year history OR 
second-hand smoke exposure 
< 20 pack year history  
Current smoker OR  
Smoking cessation ≤ 15 years 
No additional risk factors  
ORa    Age ≥ 50   
≥ 20 pack year history AND   
One additional risk factor (other 
than second-hand smoke)b 
  
a NCCN criteria category 2B level of evidence. 
b Risks include - Radon exposure, asbestos exposure, occupational exposure, cancer history, family history, other lung  
disease (COPD or pulmonary fibrosis). 
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Table 2: Comparison of existing predictive lung cancer models 
 Used for Screening Used for surgical referral after 
discovery of a lung lesion 
 Bach* Spitz Liverpool PLCO2012 Mayo VA SPN 
Age √ m m √ √ √ √ 
Race  m  √    
Sex √ m m     
Smoking Status  
     Ever/never 
     
√ 
 
√ 
 
     Years since quitting smoking √ √  √  √  
     Pack-Years  √ √    √ 
     Duration of smoking √   √    
     Cigarettes per day √   √    
Family History of lung cancer  √ √ √    
Education    √    
BMI    √    
Emphysema/COPD  √ √ √    
Environmental exposures** √ √ √     
Nodule Size (max diameter)     √ √ √ 
Nodule lung location     √  √ 
Nodule shape     √  √ 
Nodule growth       √ 
Previous cancer history (not lung)   √ √ √  √ 
Contrast CT scan positive       √ 
Hemoptysis       √ 
FDG-PET Avidity       √ 
Population Prevalence       √ 
ROC in validation and development  61-77 57-73 71 70-80 78-83 73-79 80 
m  = Variable matched in case-control study 
*   =  Predictive for smokers or ex-smokers only 
** = Asbestos (Bach, Spitz, Liverpool), Dust (Spitz), and Hayfever (Spitz) 
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FIGURES 
 
Figure 1. Annual Incidence and Mortality for the Most Common Cancers: 2012.  
Source: American Cancer Society, Cancer Statistics 2012 
 
 
 
Figure 2.Age Adjusted U.S.  Lung and Bronchus Cancer Incidence and Mortality Rates by 
Sex, 1975-2009.   Source: SEER 2012 
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Figure 3. Results of the National Lung Screening Trial.  Detection of lung  
Cancers by study arm (A) and Cumulative lung cancer related death by 
study arm (B).  Source: NLST, 2012. 
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  4A. Spiculated Lung nodule       4B. Spiculated Lung Mass         4C. Ground Glass Opacity 
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Figure 6. Diagnostic guidelines of lung nodules suspicious for lung cancer.  Adapted from 
Wahidi, Chest 2007 
 
 
Figure 7. Mechanistic framework for understanding how cigarette smoking causes lung 
cancer. Source: Hecht, Int J Cancer 2012. 
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Figure 8. Avid FDG-PET/CT scan of a granuloma 
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Figure 9A. Fungal lung disease prevalence, histoplasmin skin was cross reactive with 
coccidioidomycosis and blastomycosis (from Edwards et al, Am Rev Resp Dis 1969)  
 
 
Figure 9B.  Geographic distribution of histoplasmosis in persons >65 years of age, United 
States, 1999-2008. Values are number of cases/100,000 person years (from Baddley et al, 
Emerg Inf Dis 2011). 
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Chapter 2 
 
 
II. Development and validation of a clinical prediction model to estimate lung cancer 
risk for those being evaluated for surgery 
 
2.1  Introduction 
 
Lung cancer is the leading cause of cancer-related mortality in the U.S. among men and 
women.1,2 Poor prognosis for lung cancer remains common despite the steady decline in 
incidence of lung cancer likely due to , declining smoking rates, increased awareness in the 
general population, and the advent of new technologies to detect lung cancer in early stages of the 
disease. The average five-year survival rate for lung cancer is 16%, due to the late stage of the 
disease at the time of diagnosis.3 To decrease mortality from lung cancer beyond reducing 
smoking prevalence in the population, early detection and treatment are necessary. The National 
Lung Screening Trial (NLST) recently found a 20% reduction in deaths from lung cancer by 
screening a high risk population with low dose computed tomography (LDCT). However, 39% of 
patients screened with LDCT scans had at least one positive screening test (identification of 
suspicious nodule) requiring additional diagnostic evaluation.4 In addition, after nodule discovery 
and radiographic surveillance, 24% of procedures diagnosed benign disease. Other studies 
describing surgery for known or suspected lung cancer report benign disease between 20% and 
40%.5-8  
 
Unlike biopsy for other cancers with a screening regimen, the lung is difficult to access, and lung 
biopsy has significant risks associated with the procedure. Reviews of outcome after lung surgery 
have found 1% to 4% mortality rates within 30 days of surgery and rates as high as 7% at 90 
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days.9-12 The surgeon’s dilemma is balancing the likelihood that a lung nodule is cancerous with 
the possible harm caused by a surgical biopsy. A national screening program with LDCT would 
likely result in a reduction of lung cancer deaths but an increase in unnecessary deaths from 
invasive diagnostic procedures unless preoperative non-invasive evaluation for lung cancer 
becomes more accurate than it is in current practice. 
 
Diagnostic Evaluation of Patients with Lung Nodules 
The surgeon evaluating a patient with a lung nodule is in a unique clinical position. Surgeons 
have a relatively large body of diagnostic information often compiled from a variety of other 
specialists. Tests to determine whether the patient can survive an operation that may culminate in 
a lobectomy also influence the decision process. The American College of Chest Physicians and 
the National Cancer Comprehensive Network practice guidelines detail an evidence-based 
algorithm for the diagnosis of lung cancer.13,14 The guidelines require clinicians to estimate the 
likelihood of lung cancer using their clinical expertise or a validated prediction model. If the 
probability of lung cancer is greater than 60%, then patients are referred to a surgeon for further 
evaluation and diagnostic resection. If the patient’s probability of cancer is less than 5% then 
continued periodic surveillance with LDCT is suggested. If the patient has an intermediate 
probability of cancer, between 5% and 60%, then additional testing for lung cancer is 
recommended. Testing may include F18-fluorodeoxyglucose positron emission tomography 
(FDG-PET) or minimally invasive biopsy like bronchoscopy, endobronchial ultrasound, or fine 
needle aspiration.15,16  
 
The Mayo model17, the VA model18 and the Solitary Pulmonary Nodule (SPN) model19,20 have 
been externally validated for the prediction of lung cancer. Each of the three models uses 
epidemiological risk factors, such as age and smoking history, or symptomatic indications like 
hemoptysis, as well as imaging data including lesion size, growth, location and edge 
61 
 
characteristics (Table 1). These three models were developed in populations with lower 
prevalence of lung cancer than is observed by surgeons evaluating lung nodules suspicious for 
lung cancer. A clinical prediction model in a population whose prevalence of disease is 50% to 
80% and includes FDG-PET scans has not yet been published and current predictive models 
perform poorly in this population.20 Surgeons need a clinical model to help avoid the significant 
mortality and morbidity that accompanies thoracoscopic surgery for diagnosis of lung cancer 
without missing the lung cancer itself.21  
  
2.2 Methods 
   
  Study Population 
The Vanderbilt Lung Cancer Cohort was composed of two sources of individuals: 1) using 
Vanderbilt University Medical Center's Thoracic Surgery Quality Improvement database, 453 
patients were identified who underwent a surgical procedure for known or suspected non-small 
cell lung cancer (NSCLC) from January 2005 to October 2010. Demographic and clinical data for 
each surgery was abstracted using the Society of Thoracic Surgeons National Database for 
General Thoracic Surgery specifications and guidelines.22 Each lesion was confirmed by 
pathologic examination after thoracotomy, thoracoscopy, mediastinoscopy, or bronchoscopy with 
biopsy; and 2) a separate group of 39 individuals who had been evaluated by a thoracic surgeon 
for possible cancer but who underwent radiographic surveillance rather than surgery was included 
as well. Individuals with known metastatic disease, individuals without a definitive clinical 
diagnosis after surgery, or those who underwent re-operation on a known malignancy were 
excluded. Non-surgical patients with less than 18 months of radiographic surveillance or clinical 
follow-up were excluded. Patients with no physician or radiological report of maximum pre-
operative nodule size were also excluded. Vanderbilt University Institutional Review Board 
approved this study (IRB# 090781).  
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Radiographic data was abstracted by medical reviewers with experience from previous studies 
using radiologist reports of the most recent pre-operative CT scans for lesion growth, edge 
characteristics, and FDG-PET avidity.5,6,20,23 Lesion edge characteristics were defined by the 
terms smooth, lobulated, lobular, lobed, GGO, GGN, coronal, corona, spiky, or spiculated in the 
radiologists’ reports and designated by medical reviewers as either smooth, lobulated, ground 
glass opacity, spiculated or indeterminate. Growth on serial radiographs occurring at least 60 days 
apart is defined as an increase in mean diameter of 2mm for nodules initially less than 15mm in 
size and an increase of at least 15% compared to a baseline scan for nodules more than 15mm in 
size at baseline.13 For cases with one preoperative radiograph or whose subsequent radiograph 
was fewer than 60 days and deemed too short a time span to record lesion growth, the case was 
designated as “insufficient data.” FDG-PET scan results were categorized into four groups based 
on copies of the original physician reports or original scans. Categorization was determined by 
either physician report or by maximum standard uptake value (SUV). The categories of avidity 
and their corresponding SUVs are: Not avid/Not cancerous (SUV=0), Low avidity/Not likely 
cancerous (SUV 0.1 to 2.5), Avid/Likely cancerous (SUV 2.5 to 5) and Highly avid/Cancerous 
(SUV>5). Any radiological reports of insufficient quality to determine diagnosis, shape 
characteristics, or FDG-PET avidity by chart review were reviewed for determination by a 
thoracic surgeon. If no designation could be made, then original scans were reviewed by a 
thoracic radiologist blinded to clinical pretest data and pathological outcome. Pre-operative 
symptoms were defined as any documented evidence in the medical record of the following: 
shortness of breath, unplanned weight loss, pneumothorax, fatigue, pain, COPD, chronic 
bronchitis, pneumonia or bronchiolitis. Predicted forced exhaled volume in one second (FEV1) 
was a continuous variable based on the most recent pulmonary function test prior to surgery. 
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  Statistical analysis 
A multivariable logistic regression model, hereafter referred to as the TREATmodel, was 
developed to predict lung cancer, following the methodology of Harrell and Steyerberg.24,25 
Missing data was imputed using multiple imputation with chained equations. Multinomial logistic 
regression was used to impute categorical variables, and predictive mean matching was the 
method of imputation for all other variables. Missing data was analyzed by variable to determine 
the percentage missing of each variable, correlation between variables with missing data, and 
whether patterns of missing data suggest violation of the assumption that data are missing at 
random (MAR).26 A 10 imputed dataset burn-in was used and an additional 50 imputed datasets 
were then generated. These fifty datasets were used for all subsequent model estimation. After 
imputation, variable distributions were visually examined. Imputed data outside the range of 
observed data was limited to the maximum or minimum observed value. A sensitivity analysis 
was conducted comparing the estimated model using imputation results with chained equations to 
the same models using a multivariate normal imputation model that solely used predictive mean 
matching.  A separate sensitivity analysis compared the multiply imputed data with a model using 
complete data. 
 
Model development was guided by examination of published models predicting lung cancer in a 
population with lung nodules or lesions. Nonlinear associations between continuous variables and 
lung cancer were evaluated using restricted cubic splines of 3 and 5 knots, and linearity was 
tested using the Wald statistic. The model’s ability to discriminate between cancer and benign 
disease was evaluated by area under the receiver-operating-characteristic curve (AUC). Model 
calibration, the comparison of a model’s predicted probabilities to observed probabilities, was 
assessed with Brier score. Graphical interpretation of the model used partial effect plot and 
nomogram of the model (Appendix 1.3 and 1.4). 
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The developed model was internally validated using the .632 bootstrap method to estimate 
optimism corrected measures of AUC and Brier score.27 The .632 bootstrap method creates a new 
population by randomly sampling with replacement from the Vanderbilt Lung Cancer Cohort. 
The complete dataset was created with missing data being replaced by the mean value of imputed 
data across all 50 imputations. The model was then re-estimated for each bootstrap iteration and 
an iteration-specific AUC and Brier score created. This bootstrap process was repeated 500 times. 
Optimism corrected AUC and Brier score were estimated using the weighted equation from 
Efron.27,28 Large decreases in AUC or increases in Brier score indicate high optimism in model 
estimation and possible overfitting or lack of a stable, valid model. Due to the limited sample size 
and the limited power available to detect interactions between variables, no interactions were 
included in the model. A separate sensitivity analysis was conducted to estimate maximum 
possible AUC from the available variables by estimating a model with all clinically feasible 
interactions between variables included in a purposely overfitted model.    
 
AUC and Brier score for the Mayo model were estimated using published variable coefficients 
from the original article (MayoOriginal).17 The Mayo model probability of a malignant 
pulmonary nodule is of the form: 
 =  ex/(1+ex); 
where x = −6.8272 + (0.0391*age) + (0.7917*smoking history) + (1.3388*previous non-thoracic 
cancer) + (0.1274*lesion size) + (1.0407*spiculated lesion edge) + (0.7838*upper lobe location). 
Unlike the originally estimated and validated Mayo model, all cases with previous cancer were 
included in the comparative analysis. In their original study, Swensen and colleagues only 
included those with extra-thoracic cancer who were treated more than five years previous to the 
current evaluation.17  
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 Using the same variables as the original Mayo model cancer risk was predicted in the same 
population as the fitted TREAT model and variable coefficients re-estimated (MayoVUMC). A 
model with only non-imaging variables was estimated (EpiModel) and compared to a model 
composed of only imaging (ImageModel). Differences between model AUCs were measured 
using the binomial exact test.  Graphic comparisons of poor model fit used Bland-Altman plots 
for differences in predicted likelihood of cancer between the two models.   
 
Analysis of demographic variables and pre-specified predictors of lung cancer according to lung 
cancer status were conducted utilizing only observed data. The T-test was used to examine 
differences in continuous variables, the Wilcoxon signed-rank test for differences in medians, and 
the Fisher’s exact test for categorical variables. Analysis for imputation, model estimation and 
internal validation was performed in R v3.0.1 and Stata v12(College Station, TX). Code is found 
in Appendix 1.  
 
2.3  Results 
 
 
Lung cancer prevalence was 72%. Diagnosis was determined pathologically in 453 (92%) and by 
radiographic follow-up in 39 (8%) individuals. Complete data was available for 264 individuals. 
Those with a cancer diagnosis were more likely to have complete data (58%) than those with 
benign disease (43%). Missing data occurred with FDG-PET scan (22%), growth on serial CT 
scans (13%), predicted FEV1 (10%) and pre-operative disease symptoms (7%). The remaining 
variables of interest had less than 5% missing data. In univariate analysis, self-reported race, pre-
operative symptoms and previous history of cancer were not significantly different between those 
with or without lung cancer. Lung cancer was inversely related to body mass index (BMI) and 
predicted FEV1. Lung cancer was associated with sex, age, smoking, increasing lesion size, lesion 
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location in either upper lobe of the lung, lesion growth on serial radiographs, spiculated edge 
characteristics and FDG-PET avidity (Table 2).  
 
The imputation model consisted of the outcome (cancer or benign disease), height as a 
component of BMI, and any previous history of smoking as a dichotomous variable. Independent 
variables used as predictors of lung cancer risk in the fitted TREAT model were used in the 
imputation model and included: age, sex, pack years, lesion size, lesion location, lesion growth, 
spiculated lesion edge characteristic, predicted FEV1, BMI, previous history of cancer, any pre-
operative symptoms and FDG-PET avidity. FDG-PET avidity had the highest variance inflation 
due to imputation (1.37) on the estimated model followed by lesion growth for the insufficient 
data category (1.25) and then by any pre-operative symptoms (1.24).  
 
   Comparison of lung cancer risk models 
In the TREAT model lung cancer risk significantly increased with age, pre-operative lesion size, 
lesion growth, history of previous cancer and FDG-PET avidity (Table 3). Smoking intensity 
measured by pack years had a non-linear association with lung cancer in univariate analysis but 
not in multivariate analysis (p=0.1). The non-linear association between pack years and lung 
cancer risk was maintained in the TREAT model (Figure 2).   
 
The AUC for the TREAT model was 0.89 (95% CI: 86 - 92) and Brier score was 0.12. Internal 
validation with .632 bootstrap estimated an optimism adjusted AUC of 0.87 and Brier score of 
0.13. The MayoOriginal model, using published coefficients to estimate lung cancer risk, had an 
AUC of 0.80 (95% CI: 76 - 85) which was significantly less (P<0.001) than the AUC observed 
for the TREAT model. The Mayo model generally overestimated risk and its Brier score was 
0.17, showing poorer calibration than the new model. The MayoVUMC model used the original 
Mayo model variables, re-estimated coefficient values based on the Vanderbilt lung cancer 
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population, and had lower AUC 0.83 (95%CI: 79 - 87, p<0.001) than the TREAT model and 
similar Brier score (0.12) (Figure 3). The overfitted TREAT model had slightly higher AUC 
(0.90; 95%CI: 86 - 92) and slightly lower Brier score (0.11) than the TREAT model without 
interaction terms. 
 
In a separate analysis of classes of models, the lung cancer predictive model that included only 
epidemiologic data (age, smoking history, any pre-operative symptoms, predicted FEV1, previous 
history of cancer, BMI, race, and sex) had an AUC of 0.77 (95% CI: 72 – 82). The model relying 
on imaging data only (lesion location, size, FDG-PET avidity, lesion edge characteristics, growth 
on serial radiographs) had an AUC of 0.84 (95% CI: 80 – 88) and was significantly higher than 
the model with only epidemiologic variables (p=0.02) (Figure 4). 
 
Bland-Altman plots showed the Mayo model more frequently overestimated risk of lung cancer 
when compared to the TREAT model (Figure 5). No systematic differences in model risk 
estimation were observed between the TREAT and Mayo models for the covariates of age, 
smoking status, and pack years (Figure 6A, 6B and 6C). FDG-PET avidity and growth showed a 
systematic difference in predictive values between the two models. These two variables indicate 
metabolic activity of the lesion and were included only in the TREAT model. The Mayo model 
on average predicted a slightly higher risk of lung cancer compared to the TREAT model in 
individuals with no growth (Figure 6D) and a significantly higher risk among individuals with 
non-avid scans (Figure 6E). 
 
2.4 Discussion 
 
To date, to our knowledge, no clinical prediction model for lung cancer in a thoracic surgery 
population has been published. The TREAT lung cancer model found a high and consistent 
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predictive discrimination for lung cancer. The TREAT model used pre-specified variable 
selection based on covariates of lung cancer risk published in validated screening and lung lesion 
diagnostic models. Given the TREAT model’s high level of discrimination, it may be of value 
providing clinical guidance in estimating individual likelihood of lung cancer if externally 
validated.  
 
Although the TREAT model is relatively simple and includes no interaction terms and only one 
non-linear variable, a more complex over-fitted model found negligible improvement in AUC 
(0.90) compared to the apparent TREAT model AUC of 0.89. This small increase in 
discriminatory power indicates the TREAT model explains well the relationship between the 
variables in the model and the likelihood of lung cancer as currently specified. Little additional 
information is likely to be gleaned from the variables used in the TREAT model. 
   
Surgeons evaluating pulmonary nodules are faced with a basic question of equipoise. Is the risk 
for cancer such that the individual should undergo the possible harms arising from thoracoscopic 
surgery to determine diagnosis of the nodule? Diagnostic lung surgery has a 1-4% mortality rate 
associated with the procedure and 1.2% of those with benign disease in the NLST died within 60 
days of their procedure.9,29 Complications including prolonged air leak (5%) and atrial fibulation 
(11%) are also common from the procedure and recovery takes 4-6 weeks among non-
complicated patients.21,29,30 If the patient under evaluation has marginal lung function and other 
pre-operative comorbidities, then the likelihood of a poor outcome increases. This procedural risk 
is juxtaposed against the danger of missing a curable lung cancer. One suggested solution is for 
the clinician to delay biopsy and treatment until a more definitive non-invasive diagnosis is 
possible. The window of best prognosis from the time of lesion discovery to stage progression 
and metastasis is not well known; however, one study found that untreated clinical stage 1 lung 
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cancer had a median survival time of only 9 months.31 Thus clinical belief is that even among 
small and localized cancer, treatment should not be delayed if possible.  
 
The superior performance of the TREAT lung cancer model (AUC 0.89) compared to the Mayo 
model in its original published form (MayoOriginal AUC 0.80) or re-estimated within the 
Vanderbilt population (MayoVUMC AUC 0.83) arises from two factors. First, the population 
being evaluated by surgeons has a higher prevalence of lung cancer than other lung nodule 
evaluation populations. Current predictive models for lung nodules were established in 
populations being evaluated by pulmonologists (Mayo model) and radiologists (SPN model). A 
finding of risk from these models results in a referral to a proceduralist to establish tissue 
diagnosis and course of treatment. The performance of the Mayo model was similar to the AUC 
observed in the original study (0.83) and in the validation study in a population of veterans 
(0.80).17,18 The Mayo model performed well in the Vanderbilt population although the prevalence 
of disease was higher (72%) than that found in the original population in which the model was 
developed (23%) or validated (44%).17-19 However, the Mayo and SPN models underestimate risk 
for cancer in the lower quintiles of lung cancer risk.20 The higher prevalence of lung cancer is not 
uncommon in surgical populations being evaluated for lung cancer,6,32,33 which was one of the 
motivating factors for development of the TREAT model specifically for surgeons.  
 
The second factor contributing to the TREAT model’s superior discrimination is the addition of 
FDG-PET avidity and lesion growth as predictive variables. Each variable represents metabolic 
activity of the lesion which is information relatively independent from other imaging variables 
like lesion shape or size. The TREAT model takes advantage of the additional information 
available to clinicians at the time of decision to operate. The addition of FDG-PET, lesion 
growth, predicted FEV1 and presentation with any symptoms improved discrimination between 
benign disease and lung cancer. Each variable contributed to the variance explained, and FDG-
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PET avidity and lesion growth were the third and fourth strongest explanatory variables behind 
lesion size and age (Figure 7). 
 
The Bland-Altman plots reinforced the importance of FDG-PET avidity and lesion growth among 
the factors that discriminate a higher likelihood of lung cancer. When a lesion was not FDG-PET 
avid or did not have growth on serial radiographs, then the Mayo model had a consistently higher 
predicted probability of lung cancer and was associated with the largest differences in predicted 
risk between the Mayo and TREAT models. The distribution of this systematic bias was 
concentrated in the lower spectrum of risk (Figures 6D and 6E). Variables common to both 
models like age and smoking status did not show a systematic bias in predicted risk for lung 
cancer between the two models (Figures 6A-6C). Measurement of metabolic activity through 
FDG-PET and lesion growth appear to be an important biological factor missing from the Mayo 
model. 
 
As with most research this study has a number of weaknesses. The Vanderbilt Lung Cancer 
Cohort was a retrospective cohort which relied on chart review. Vanderbilt is a tertiary referral 
academic medical center and may not be representative of other surgical practices evaluating lung 
lesions. Other populations in other parts of the country may have differing prevalence of disease, 
differing referral patterns, radiologist expertise or other underlying factors, like fungal lung 
disease prevalence, that are relevant to a clinical prediction model but either not measured or not 
included in the TREAT model. 
 
Another weakness with this study is the high amount of missing data for variables of interest in 
the Vanderbilt Lung Cancer Cohort.  Missing FDG-PET scan results (22% missing) occurred 
most frequently overall.  Among the 39 who were managed by active surveillance, four had a 
FDG-PET scan. Of the 66 missing an FDG-PET scan in the entire cohort, 35 (53%) were in the 
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active surveillance group and did not undergo surgery. Conversely, among those with cancer, 
individuals with a high likelihood of lung cancer also were more likely to have missing FDG-PET 
scans. The lack of FDG-PET scan among those at the highest and lowest risk for lung cancer 
reflects clinical practice in which tests are not ordered that will not materially change the clinical 
decision to operate.  This pattern of work-up bias between individuals indicates that the data is 
not missing completely at random.  Similarly, predicted FEV1 is generally not performed unless 
surgery is likely and clinical guidelines suggest everyone receive a pulmonary function test, of 
which predicted FEV1 is a component, prior to surgery. The observed pattern and cause of the 
missing data may be a violation of the MAR assumption required for multiple imputation to be 
robust in its representation of the underlying true population. 
 
Patterns that suggest high correlation between seemingly unrelated variables like FEV1 and FDG-
PET scan may indicate an unknown underlying cause of missing data that is not captured in the 
observed data. Cluster analysis of the variables in the dataset showed moderate correlation 
(Appendix 1.1).  The multiple imputation methodology depends on missing data being missing at 
random (MAR) or the more restrictive missing completely at random mechanism. The MAR 
mechanism of missing data assumes that “missingness” depends upon or is explained by the 
observed variables and observations within the dataset and not on unobserved variables or 
unobserved individuals outside the dataset. Inclusion of the 39 non-surgical patients increased the 
amount of missing data for FDG-PET and predicted FEV1. However, their inclusion into the 
cohort captured a broader population of risk and better represented the entire population of lung 
nodules evaluated by surgeons. Logistic regression models were developed to predict the 
likelihood of a record’s variable being missing.  If the outcome (cancer) remained a significant 
variable after controlling for the other relevant variables, then the missing at random assumption 
is violated. For FDG-PET, lesion growth, and predicted FEV1 the cancer outcome was not 
significantly associated with predicting the cancer a record would have missing data.  Of the three 
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variables with missing data, cancer was most predictive of FEV1 (p=0.11) of having missing data. 
Therefore, the mechanism of missing data was likely MAR. If the likelihood an individual will 
have missing data had been associated with the outcome of cancer then non-ignorable missing 
data occurs and the assumptions behind valid imputation were violated. Such was not the case 
here. Furthermore, this dataset is retrospective, includes all persons evaluated by a thoracic 
surgeon and reflects the spectrum of risk likely to be encountered by a thoracic surgeon which 
removed the problem of non-ignorable missing data due to selection bias.34,35  
 
The FDG-PET scan and lesion growth results were primarily derived from the radiologist’s report 
and most individual patient FDG-PET scans were not reviewed by a radiologist or surgeon for 
this analysis. Reliance on radiologist’s report, while a limitation, also mirrors clinical practice 
where often the surgeon must rely on external expert interpretation if the original scans are not 
available or are of poor quality.  Individuals missing information on lesion growth were reviewed 
by a thoracic radiologist. After review a third category was created representing an individual 
with a single study or someone with serial studies who did not have a large enough interval 
between scans to determine growth. Approximately 40 of the 65 with lung cancer and missing 
data from this variable arose from the lack of stored scans in the radiology system. These missing 
scans were more likely to occur in individuals diagnosed between 2005 and 2007. 
 
Another limitation of this study was that family history of cancer was not collected in the 
Vanderbilt Lung Cancer Cohort. Screening models whose focus is on population-level lung 
cancer risk have included first degree family member history of cancer in their cancer risk 
predictions.36,37 Tammemagi et al. found that only among individuals with significant tobacco 
exposure was family history of cancer a risk factor.37 It is unknown whether family history adds 
new information to the existing cancer risk model, or to the TREAT model, since models that 
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include family history do not include radiographic predictive factors and the existing 
epidemiologic variables explain much of the observed variation with an AUC of 0.77. 
 
The Vanderbilt Lung Cancer Cohort is composed of individuals with known or suspected lung 
cancer. Ideally, a population composed of only suspected lung cancer would be used. Those with 
known lung cancer tend to have larger, growing, FDG-PET avid lesions. These cancers are more 
easily biopsied or diagnosed through sputum cytology. Inclusion of these individuals may bias 
our point estimates and standard errors for lesion size, FDG-PET avidity and growth. Another 
weakness of this analysis is the lack of an external validation dataset in which to compare the 
robustness of our results. Although little optimism was observed in the bootstrap adjusted AUC 
or Brier scores, the model must be validated in separate, external populations prior to use in the 
clinical setting.  
 
This study is unique in a number of ways which add strength and import to its results. This is the 
first study to predict lung cancer in a cohort with a lung nodule being evaluated by thoracic 
surgeons. The TREAT model includes a combination of strong predictors of lung cancer 
including FDG-PET avidity and lesion growth that have not been previously published. The high 
AUC and optimism adjusted AUC indicate a model that discriminates lung cancer better than 
other published models. If the TREAT model is externally validated then it can act as the base 
model of lung cancer risk when evaluating new biomarkers and diagnostic tests for lung cancer in 
surgical populations. Future work will validate this model in external datasets and prospectively 
evaluate the impact of the model in the clinical setting.  
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2.5 Conclusion  
 
In a population with a radiographically confirmed lung lesion being evaluated for possible 
surgery, the TREAT lung cancer model predicted the risk for lung cancer with high accuracy. The 
model was internally validated and showed little optimism in its estimate accuracy to discriminate 
between lung cancer and benign disease. The TREAT model incorporates the full spectrum of 
epidemiological and radiographic evidence and better predicts lung cancer with a higher AUC 
than existing published models. This model should be validated in external datasets and if valid 
applied in a prospective study to reduce unnecessary lung surgeries.   
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Table 1. Variables used in published, validated clinical lung 
cancer prediction models 
Variable Mayo Model VA Model SPN Model 
Age √ √ √ 
Smoking (Y/N) √ √  
Smoking - Pack Years   √ 
Years quit smoking  √  
Hemoptysis   √ 
Previous Cancer √   
Lesion Size √ √ √ 
Lesion Growth   √ 
Spiculation √  √ 
Lesion Location √  √ 
FDG-PET Avidity   √ 
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  Table 2. Univariate analysis of demographics and radiological data 
 Cancer 
N=352 
Benign 
N=140 
P-value 
Male (%) 192 (55)   60 (43) 0.02 
Caucasian (%) 
Missing  N=2 
324  (92) 
0 
128 (93) 
2 
0.79 
Age (SD)     65 (10.7)     55 (13.9) <0.001 
Smoking Status – Ever  (%) 297 (84)  81 (58) <0.001 
Median Pack – years among smokers 
(IQR) 
     Missing  N = 8 
        45 (30, 60) 
6 
       35 (20, 50) 
2 
0.001 
BMI, kg/m2 (SD) 
     Missing N=2 
   26.9 (5.5) 
0 
   29.6 (7.1) 
2 
<0.001 
Mean Predicted FEV1 (SD) 
     Missing N = 50 
    75.4 (18.8) 
17 
    84.5 (20.8) 
33 
<0.001 
Pre-operative symptoma (%) 
     Missing N = 33 
  82 (25.5) 
30 
36 (26.3) 
3 
0.85 
Previous history of cancer 136 (38.6) 45 (32.1) 0.18 
Upper lobe location 
     Missing N = 13 
214 (62.2) 
8 
69 (51.1) 
5 
0.03 
Lesion Size, Ave mm (SD)     31.6 (19.4)    18.8 (12.0) <0.001 
Growth 
     Missing N = 65 
160 (55.4) 
63 
 41 (29.7) 
2 
<0.001 
Spiculation 
     Missing N = 19 
176 (52.1) 
14 
38 (28.2) 
5 
<0.001 
FDG-PET Avidityb 
     Missing N = 109 
283 (86.2) 
43 
45 (60.1) 
66 
<0.001 
a – Symptoms include: hemoptysis, unplanned weight loss, shortness of breath, fatigue or chest 
pain 
b - Includes avidity categories “avid/likely cancerous – SUV 2.5-5” and “highly avid/cancerous 
     SUV >5” 
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Table 3. Multivariate logistic regression of lung cancer prediction model 
 Na Odds Ratio (95% CI) p-value 
Age (per year) 492 1.05 (1.03, 1.08) <0.001 
BMI 490 0.97 (0.93, 1.02) 0.24 
Gender - Male 492 0.94 (0.54, 1.64) 0.84 
Pack Yearsb 484 1.03 (1.01, 1.05) 0.02 
Pack Years’b 484 0.98 (0.95, 1.00) 0.09 
Lesion Size (per mm) 492 1.06 (1.04, 1.08) <0.001 
Spiculated lesion edge 473 1.42 (0.78, 2.59) 0.26 
Lesion location – upper lobe 479 1.00 (0.57, 1.75) 0.99 
Lesion Growth 
        No lesion growth 
427  
(ref) 
 
(ref) 
        Insufficient data on growth  1.25 (0.56, 2.79) 0.59 
        Growth observed  2.97 (1.45, 6.12) 0.003 
History of previous cancer 492 1.95 (1.07, 3.55) 0.03 
Predicted FEV1 442 0.99 (0.97, 1.00) 0.07 
Any pre-operative symptoms 459 0.63 (0.33, 1.19) 0.16 
FDG-PET Avid 382 6.81 (3.04, 15.3) <0.001 
a reported N is number of individuals with complete data in the dataset  
b Pack-years was modeled with a non-linear relationship with cancer.  Odds ratios are not directly 
interpretable and are included here for reporting purposes only.  See Figure 2 for graph of 
relationship.  
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Figure 1. Hosmer-Lemeshow test showing poor (p<0.001) calibration of SPN and Mayo 
models in a surgical population (from Isbell et al, Annals of Thoracic Surgery, 2011) 
 
Figure 2. Comparison of three relationships between pack years and lung cancer. 
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Figure 3. Comparison of AUC for two Mayo models and TREAT model  
 
Figure 4. Comparison of AUC for a model composed of only imaging data (ImageModel) 
and epidemiological data (EpiModel) (p=0.02) 
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Figure 5. Bland – Altman plot of log(odds) predicted risk for the TREAT and Mayo model.  
X axis is the log odds of lung cancer for TREAT model plus the log odds of lung cancer in 
the mayo model divided by 2.  Y axis is the log odds of lung cancer for TREAT model minus 
the log odds of lung cancer in the mayo model.  
 
Figure 6A. Bland – Altman plot of the difference in the log odds of the TREAT and Mayo 
models across participants age.  Red lines are the upper and lower confidence interval +/- 2 
standard deviations. 
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Figure 6B. Box plot of the difference in the log odds of the TREAT and Mayo models across 
by smoking history.  Red lines are the upper and lower confidence interval +/- 2 standard 
deviations. 
 
Figure 6C. Scatter plot of the difference in the log odds of the TREAT and Mayo models 
across pack-years.  Red lines are the upper and lower confidence interval +/- 2 standard 
deviations. 
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Figure 6D. Box plot of the difference in log odds of the TREAT and Mayo models across the 
three growth categories.  “Single” growth refers to participants with only one LDCTG scan 
or too short a per-operative period for serial scans to report growth.  Red lines are the 
upper and lower confidence interval +/- 2 standard deviations. 
 
Figure 6E. Box plot of the difference in the log odds of the TREAT and Mayo models across 
based upon FDG Avidity.  Red lines are the upper and lower confidence interval +/- 2 
standard deviations. 
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Figure 7. Chi-square plot of relative contribution to explaining variance by each dependent 
variable. 
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Chapter 3 
 
 
 
III.  Geographic variation in the diagnosis of lung cancer and implications for screening 
and diagnosis of lung cancer. 
 
3.1  Background 
 
Hundreds of thousands  of lung nodules are evaluated annually throughout the US.1  This number 
is likely to increase with the implementation of a national screening program for lung cancer. The 
National Lung Screening Trial (NLST) conducted a randomized control trial comparing annual 
screening with annual low dose computed tomography (LDCT) scans to chest x-rays in a 
population at high risk for lung cancer.  LDCT reduced lung cancer related mortality by 20% and 
all-cause mortality by 7.6% compared to screening with chest x-ray.2 A number of physician 
societies and patient advocate groups have since established guidelines recommending lung 
cancer screening using LDCT scans in populations similar to that enrolled in the NLST.3-5 The 
Affordable Care Act tasked the US Preventive Services Task Force with reviewing disease 
screening programs. If after their review the Task Force finds that a screening program provides 
significant benefit to those screened, then their recommendation for screening must be covered by 
insurers. The Task Force is currently reviewing the new evidence provided by the NLST and will 
publish their recommendations regarding lung cancer screening in 2013.6,7 Given the results of 
the NLST and the support for screening from both patient advocate groups and physician 
societies, a national lung cancer screening program for high risk populations using LDCT scans is 
likely in the near future. 
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Although there was a reduction in lung cancer related mortality in the NLST, 96% of lung 
abnormalities found by LDCT were false positive findings.2 Other studies have found similarly 
high false positive rates from CT scans.8 Furthermore, 24% of all lung procedures to diagnose 
lung cancer identified benign disease. Using the results of the NLST and the study’s definition of 
the appropriate population to screen, an estimated 7.4 to 8.7 million individuals per year could be 
eligible for screening.9,10 If 80% of the 8 million eligible were screened, then approximately 2.6 
million anomalies would be discovered requiring further diagnostic testing over the first three 
years of a screening program. These findings will generate over 1 million repeat CT scans, an 
additional 170,000 FDG-PET scans and 80,000 diagnostic operations, 20,000 of which would 
have a pathological finding of benign disease.  
 
Should a screening program be introduced in the US, then variation in the diagnosis and treatment 
of lung cancer may arise.  Geographic variation in screening efficacy and outcomes due to 
healthcare access, provider bias and carcinogenic exposures were observed in screening programs 
for breast, colon and prostate.11-14 Similar issues may occur with the implementation of screening 
for lung cancer.  Understanding variation in existing practice as well as identifying factors that 
induce variation and are unique to lung cancer screening, can inform clinicians and policy makers 
prior to its implementation.  Initiatives and policy can then be crafted, informed by epidemiology 
and health services research, to improve the administration of lung cancer screening.15  This 
research addresses two factors of possible importance to the implementation of a lung cancer 
screening program. 
 
First, the variation of benign disease prevalence in the US is unknown. If variation in benign 
disease occurs between states or regions of the country then this observed variation may be 
indicative of systemic underlying causes that should be determined, measured and where possible 
addressed as part of implementing a screening program. Should clinically significant variation in 
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benign disease prevalence exist, then a screening program may have geographically varying 
results. Measuring the amount of variation and possible patterns of variation in benign disease is 
the first step in determining whether a problem exists and the extent of the problem.   
 
Second, clinicians rely heavily on radiographic imaging for the non-invasive diagnosis of lung 
cancer. Diagnostic guidelines recommend using F18-fluorodeoxyglucose positron emission 
tomography (FDG-PET) for the diagnosis of lung cancer after lung lesion discovery.3  FDG-PET 
scans are considered among the most accurate and cost effective non-invasive tests available for 
the diagnosis of lung cancer.16-18 Some investigators have questioned the accuracy of FDG-PET 
in regions of the country were granulomatous disease is highly prevalent.19-21  They hypothesize 
that some populations would not benefit from a diagnostic FDG-PET scan and should only 
receive CT scans. The following analysis examines each issue in turn and the possible impact on 
screening for lung cancer. 
 
3.2 Geographic variation in benign disease prevalence after surgical lung 
resection in the US. 
 
  Introduction 
The NLST reported screening with LDCT led to the discovery and treatment of more early stage 
lung cancer.  This stage shift resulted in a 20% decrease in lung cancer related mortality 
compared to screening with chest x-ray.  The participants in the NLST were recruited and 
received most of their care at National Cancer Institute designated cancer centers by teams with 
extensive experience and specialization in lung cancer diagnosis and treatment.2,22 Yet even with 
this expertise, 24% of procedures performed to diagnosis lung cancer indicated benign disease 
and not lung cancer. A screening regimen for lung cancer with LDCT will likely lead to care 
being conducted by more clinical generalists and the efficacy of the screening intervention may 
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be reduced and the number of individuals needing to be screened to cure one lung cancer 
increase.23   
 
Geographic variability of benign lung disease prevalence has significant implications for a 
national lung cancer screening program. Geographic variation may indicate a mismatch of 
specialist availability or practice variation. Population risks for lung cancer, like smoking 
prevalence, or underlying risk factors for benign disease, like granuloma caused by endemic 
fungal lung disease, may not be evenly distributed over the landscape. The first step in identifying 
whether geographic variation exists and is clinically significant is to estimate the amount of 
variation across the US. Then possible causes of the observed variation can be explored. 
 
One possible cause of variation in the US could be fungal lung diseases which are the most 
common cause of benign granulomas. Granuloma formation is possible from any fungal lung 
disease.  The three most common fungal lung diseases occurring in the US are histoplasmosis, 
coccidioidomycosis, and blastomycosis.  Soils act as reservoirs for fungal spores that cause 
fungal lung disease.  Historically, fungal lung disease prevalence varied greatly by region of the 
country (Figure 1). If benign granulomas are causing variation in benign disease prevalence then 
regions with higher prevalence of fungal lung disease should be associated with high benign 
disease prevalence after lung surgery compared to regions with low fungal lung disease.  
 
We describe the benign disease point prevalence after surgical lung resection at the state level 
using the 2009 Medicare Provider Analysis and Review Hospital National Limited Data Set 
(MEDPAR).  This administrative billing dataset includes all 14.7 million inpatient discharges for 
calendar year 2009 covered by Medicare.  Medicare insurance covers hospital care for over 95% 
of all individuals over age 65 and is among the most comprehensive representation of hospital 
activity among the elderly.24  The median age for diagnosis of lung cancer is 71 years of age.25  
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Thus using Medicare hospital data will include the majority of the US population who had 
surgery for known or suspected lung cancer.  Fungal lung disease prevalence is examined as 
possibly being associated with geographic variation in benign disease point prevalence in the 
same surgical population. 
 
3.3 Methods: geographic variation in benign disease prevalence after surgical 
resection  
 
 
Study population 
We conducted a retrospective cohort study using the 2009 MEDPAR dataset.  The MEDPAR 
dataset contains claims data for services provided to beneficiaries admitted to Medicare certified 
inpatient hospitals and skilled nursing facilities during the 2009 calendar year.  The accumulation 
of claims occurs from the individual’s date of admission to date of discharge represents one 
hospital stay.  Records represent final action on the claims data submitted by the hospital after all 
adjustments have been resolved. This dataset was made available by the Center for Medicare 
Services (CMS) and included ICD-9CM codes for as many as 10 diagnoses. The primary 
diagnosis was determined by CMS as the diagnosis responsible for the majority of care delivered 
during that hospital stay.  Each record also included sex, county of residence at the time of 
admission and as many as 10 procedures that occurred during that stay. The primary procedure 
was determined by the procedure responsible for the majority of hospital days or healthcare 
services provided during that stay.26  
 
All individuals with a primary procedure ICD-9 code of lung resection or thoracoscopic biopsy 
(32.2, 32.9, 32.3, 32.40, 32.41, 32.49, 32.6, 32.9, 33.1, 33.2, or 33.28) were included in the study 
(N=33,655).  Those who had a second hospitalization with a primary procedure of lung resection 
or biopsy (N=538) were excluded from further analysis.  These procedures were likely re-
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operations from the initial hospitalization, treatment for later stage disease or palliative in nature.  
Outcome of the surgery was categorized by primary diagnosis. Diseases were classified into 
benign, cancerous or a disease not arising from a lung nodule. Benign diseases included: 
histoplasmosis, aspergillosis, blastomycosis, coccidiodomycosis, candida, other mycotic disease 
not otherwise specified, sarcoidosis, lung abscess, tuberculosis, other mycobacterial disease, 
pulmonary fibrosis, benign neoplasm, coin lesion, Wegeners granuloma, dermatophytosis, other 
non-neoplastic diseases of the bronchus, pulmonary diseases due to other mycobacteria and 
benign disease of the lung not otherwise specified.  Cancer diagnoses included all malignant lung 
neoplasms of the lung or bronchus, secondary neoplasms of the lung, malignant neoplasm of the 
pleura, carcinoma in situ of the lung or bronchus, neuroendrocrine neoplasms, and neoplasms of 
unspecified nature in the respiratory system.  
 
The diseases not arising from a lung nodule included: metastatic lung cancer, empyema, 
idiopathic pulmonary fibrosis, pneumonia, pneumonopathy, pneumothorax, emphysema, acute 
respiratory failure, septicemia and unspecified pleural effusion.  Each individual with a disease 
not arising from a lung nodule was excluded from further analysis. Total surgeries were grouped 
by state and point prevalence of benign disease was estimated by dividing the number of 
individuals with benign disease after lung surgery by the sum of lung surgeries for cancerous and 
benign disease.     
 
Fungal Lung Disease Exposure 
Over 1.2 million men age 17 to 21 received a histoplasmin skin test during physical examination 
upon entry into the Navy between 1959 and 1968. The histoplasmin skin test was similar to the 
modern tuberculosis skin test in that a solution with histoplasmosis capsulatum was injected 
subcutaneously and if a skin reaction occurred, the host had been exposed to histoplasmosis or 
coccidioidomycosis or blastomycosis with which the test was cross reactive.27 For purposes of the 
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national surveillance, a skin induration of at least 4mm was considered a positive reaction for 
fungal exposure. Among this population 488,010 white males reported residing in only one 
county during their lifetime prior to recruitment.28 Other races were not reported due to lack of 
sufficient numbers to allow county level public reporting of prevalence. Positive histoplasmin 
skin tests occurred in 16.5% of the white males from a single county of residence. Prevalence 
among the 488,010 participants was collated across years and reported in tabular form by county 
or groups of contiguous counties within a state.  
 
Fungal lung disease prevalence was assigned to 498 individual counties or state economic areas 
as reported in the 1969 National Surveillance Survey.28 This historical prevalence was used to 
assign to MEDPAR lung surgery patients their likely prevalence of fungal lung disease. State 
economic area lung disease prevalence estimates based on the 1969 survey were entered into a 
geographical information system (GIS) (ArcGIS v10, Redlands, CA).  The patient’s geographic 
residence was defined as their self-reported county of residence at the time of hospitalization and 
was added to the GIS.  New counties created since 1969 were assigned to state economic areas 
based upon the location of the county seat. All counties created since 1969 were within the 1969 
state economic areas and no population based weighting of exposure was necessary. Outcome of 
cancer or benign disease after surgery was input into this GIS for each individual. Estimated 
fungal lung disease exposure based upon participant’s county of residence at hospitalization, were 
examined for association with individual outcome of benign disease or lung cancer.  
 
Statistical Analysis 
Benign diagnosis point prevalence was estimated at the state level by dividing the total number of 
benign cases by the sum of the benign cases and malignant cases.  Benign disease point 
prevalence was compared between states using Pearson chi-square test.  Sensitivity analysis was 
conducted by removing the states with the highest and lowest benign disease prevalence and 
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benign disease point prevalence was estimated in this sample of 48 states.  Fungal lung disease 
prevalence based on county of residence at time of hospitalization and derived from 1969 national 
survey was compared between individuals with benign disease and those with cancer using 
univariate analysis with the Wilcoxon rank-sum test. All statistical analysis was conducted with 
Stata v12 (College Station, TX)  
 
3.4 Results 
 
 There were 25,378 Medicare beneficiaries that had a lung operation for known or suspected lung 
cancer in 2009.  Among these, 2,328 (9.2%) had a benign diagnosis and 23,050 had a diagnosis of 
lung cancer. Benign diagnosis was more frequent among women (9.8%) than men (8.5%) after 
surgery.  Crude in hospital mortality rate for all patients and among those with cancer was 2.3%. 
The mortality rate for patients with benign disease was 2.1%. A significant difference in crude 
mortality rate was not observed between those diagnosed with lung cancer and individuals 
diagnosed with benign disease (p=0.86).  Prevalence of benign disease varied significantly (chi-
square p<0.001) across states from a low of 1.3% in Vermont to a high of 25.0% in Hawaii 
(Figure 3).  Median benign disease by state was 8.9% (IQR: 7.8 – 10.9).  Other states with high 
prevalence included Wyoming (18.4%), New Mexico (16.7%) and Montana (14.5%).  States with 
low prevalence of benign disease were Idaho (5.2%), Maine (5.7%) and Rhode Island (5.7%). 
After excluding Vermont and Hawaii as possible outliers, significant differences in benign 
disease point prevalence between states remained (p=0.001). 
 
Median fungal lung disease prevalence mapped from the 1969 surveillance data was 5.5% (IQR: 
2.2%, 23.8%) among those with a diagnosis of lung cancer.  Median fungal lung disease 
prevalence was 5.2% (IQR: 2.2%, 23.9%) among those with a benign diagnosis.  Fungal lung 
disease prevalence was highly skewed with mean prevalence of 17.5% (standard deviation 
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24.0%) for those diagnosed with cancer. Fungal lung disease prevalence was estimated to 
be17.6% (standard deviation 24.3%) among individuals with a benign diagnosis. significant 
differences in fungal lung disease prevalence between those with cancer or a benign diagnosis 
was not observed (p=0.90).   
 
3.5 Discussion 
 
The benign disease point prevalence between states varied significantly in the 2009 Medicare 
population in univariate analysis.  The four Rocky Mountain States, Montana, Wyoming, 
Colorado, and New Mexico as well as Arizona, Nevada, Nebraska and Kansas had benign disease 
point prevalence between 10.8% (Kansas) and 18.4% (Wyoming). The three states of Maine 
(5.7%), New Hampshire (7.4%) and Vermont (1.3%) had low point prevalences.  These were the 
main observable clustering of benign disease by state.   
 
Screening for lung cancer in states with higher prevalence of benign disease will likely result in 
higher frequencies of benign diagnosis and exposing individuals to possible harm from surgery 
related mortality, given the variation in benign disease after lung surgery across the US.  Both 
outcomes act to decrease the efficacy of a screening program within high benign prevalence 
states.  Understanding the causes of the observed variation can inform clinical and policy 
interventions to decrease variation and improve the outcome of surgery for suspected lung cancer. 
 
Locally endemic fungal lung diseases were explored as a possible cause for higher benign disease 
prevalence. In univariate analysis, no statistically significant relationship was evident between 
individually estimated fungal lung disease exposure and benign disease after lung surgery. 
Estimated median exposures among those with cancer or benign disease (5.5% and 5.2% 
respectively) were one third the mean exposure and median exposure among those with benign 
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disease was actually lower than exposure among those with lung cancer. We estimated individual 
exposure based upon a national survey conducted from 1959 to 1968 of young, healthy men who 
lived in a single county. Using this survey of lung disease prevalence is problematic in a number 
of ways.  
 
First, the MEDPAR population is an elderly population compared to those surveyed in 1969 and 
may well have lived in multiple residences with a variety of occupations prior to surgery in 2009. 
Their exposure history is likely much more complex than the simple model used here to estimate 
individual exposure as being equal to the average likelihood of exposure based upon residence at 
time of diagnosis.  
 
Second, exposure prevalence from fungal lung diseases may be difference today, 44 years after 
the 1969 survey was completed. Fungal spores reside in soils and are preferential to floodplains 
and farmland in relatively humid climes.  Baddley and colleagues found higher prevalence of 
acute histoplasmosis in the elderly in the Nebraska and the Northern Great Lakes area than 
previously found.29 This may indicate a migration over time of fungal spores up the Missouri 
River valley and from the lower to the upper Great Lakes and New England or, in the case of the 
Northeastern US, increases seasonal mobility of New England populations to regions of higher 
fungal lung disease prevalence in the south.   
 
Finally, our individual exposure estimate based upon aggregate county level prevalence may 
suffer from the ecological fallacy. Ecological fallacy occurs when individual characteristics are 
assumed to be represented by an aggregated measure.  We used the average prevalence in each 
county or economic area from the Edward study to represent individual exposure. This assumed 
average, based upon a geographic area, may misclassify individual exposure. Increased 
urbanization and impermeable cover of soils may have greatly reduced possible exposure. The 
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reduction in rural population and farming occupations over this time period would act to reduced 
individual exposure as well. However, exposure is increased among those in agricultural 
industries or who frequent the outdoors. The lack of individual data on occupation also hampers 
estimation from another important vector of fungal lung disease exposure. 
 
Given the national demographic trends in the last 40 years of increased urbanization and 
increased mobility, one can conjecture that both trends cause misclassification of fungal lung 
disease exposure in such a way to attenuate any association toward the null. For example, 
increased urbanization concentrates populations in urban areas as well as spreads the extent of the 
urban geography into previously rural environments. The decrease in exposure to soils and 
transmission of fungal spores in urbanized areas would likely lead to overestimation prevalence 
of fungal lung disease in both those with and without cancer when using the 1969 study. On the 
other hand, greater population mobility would cause those currently residing in urban areas to be 
assigned a low prevalence when their historical exposure could be higher.  
 
While fungal lung disease acting through the mechanism of granulomas has biological 
plausibility as a cause of geographic variation of benign disease prevalence, the available 
geographically based estimates of fungal lung disease exposure are methodologically 
questionable. Independent verification of exposure through either direct measurement or a better 
estimate of fungal lung disease reservoirs in soils through land cover maps is necessary. Ideally, 
this land cover mapping would also be coupled with data on an individual’s occupational and 
residence history. 
 
Another possible cause of the observed variation in benign disease prevalence is the varying 
smoking rates by state. The prevalence of smoking in adults over age 18 who smoked more than 
100 cigarettes in 2009 ranged from a low of 9.8% in Utah to a high of 25.6% in West Virginia 
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and Kentucky.30 However, current smoking prevalence would not accurately represent smoking 
exposure since the latency period for the development of lung cancer is approximately 20 years. 
Jemal and colleagues found that the smoking prevalence between 1992 and 2007 decreased in all 
states except Wyoming.  Nationally, smoking among men decreased from 26.5% to 20.1% and 
among women decreased from 21.5% to 15.5%.  The largest decreases occurred in western states 
and the smallest decrease occurred in the Midwest.  Therefore, state level or ideally county level 
smoking prevalence from the early 1990’s would be necessary to control for smoking prevalence 
as a confounder. Higher prevalence of smoking results in more lung cancer in that state’s 
population.31,32  In our analysis we were unable to discriminate between those with known lung 
cancer and those with suspected lung cancer at the time of surgery.  This resulted in a  lower 
national mean prevalence of benign disease (9.2%) in this study when compared to the NLST 
(24%)2 or other surgical studies (20% to 40%).19,33,34  Therefore, higher rates of smoking and 
subsequent higher lung cancer prevalence in the state’s population will inflate the denominator in 
estimating prevalence and decrease the benign disease prevalence. States with higher smoking 
prevalence will tend to have lower benign prevalence compared to states with low smoking 
prevalence.  Not accounting for smoking prevalence likely biases the variance between states 
upward. Smoking prevalence from the 1992 Tobacco Use Supplement to the Current Population 
Survey was not available publically by state at the time of analysis.  However, a free source of 
this data has been located reporting smoking prevalence by sex by state.  Additional analysis 
using this resource will be future work.  
 
Surgical practice variation is well documented in outcomes literature related to diagnosis, hospital 
mortality, complications, and length of stay.35-39  In a recent study examining changing benign 
surgery rates at a single institution, the authors found that implementation of minimally invasive 
surgical technique reduced morbidity and mortality associated with the surgery, but they also 
observed that benign disease diagnosis rates increased after implementation of video assisted 
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thoracoscopic surgery.   The authors conjectured that due to a broader range of patients able to 
undergo surgery with the new and lower risk from the new surgical method, clinicians were 
willing to more aggressively pursue a diagnosis.  The risk threshold missing a cancer had 
effectively been reduced because the risk for undergoing surgery had decreased34.  Varying risk 
thresholds, training and specialist availability may all play a role in the observed benign disease 
prevalence variation.  The impact of new technology in the diagnosis and treatment of lung 
cancer should be explored to determine whether differential adoption by geography or across time 
influenced benign disease prevalence.  
 
Another clinical group pursuing best practices in lung cancer screening and treatment found that 
resection for benign disease could be minimized with adherence to a clinical diagnostic protocol 
even in an area with endemic histoplasmosis.40  The success of this clinical group in diagnosing 
lung cancer suggests that best practices do exist and that promulgation of such practices could 
reduce some of the observed variation in benign disease prevalence.  Much like the efforts to 
establish best practices in mammography screening,41,42 creation and promulgation of evidence 
based best clinical practices for diagnosis and treatment of lung cancer is critical to the success of 
a national lung cancer screening program.3,43 
 
One other weakness of this study is its analysis of one year of Medicare data to estimate benign 
disease variability.  Benign disease prevalence may not remain stable over time and individual 
states may jump between quartiles of disease prevalence.  Such variation over time by a state 
would weaken these results. Additional years of data should be pursued to estimate the relative 
stability of a state’s prevalence and their association with changes in practice described above.  A 
more complete model of benign disease prevalence variation that includes beneficiary 
demographics, smoking and fungal lung disease exposures, and practice changes that can vary 
over time and across the US would best be able to estimate benign disease prevalence.  
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In conclusion this exploratory study found significant variation by state in the point prevalence of 
benign disease after surgery for known or suspected lung cancer in the elderly.  The robustness of 
these results should be explored further by exploring variation in benign disease prevalence by 
state over time and associations with smoking and fungal lung disease prevalence. The high 
prevalence of benign disease in some states would decrease the efficacy of a screening program 
for early detection and treatment of lung cancer in those states.  
 
3.6  Geographic variation in the FDG-PET accuracy to diagnosis of early stage 
lung cancer in the ACOSOG Z4031 Trial 
 
  Background 
Once a lung lesion has been discovered, surgeons rely heavily on radiographic imaging for the 
non-invasive diagnosis of lung cancer.  According to national guidelines if a lung nodule is larger 
than 8mm in diameter and either the probability of cancer is between 5% and 60% or the nodule 
does not exhibit characteristics indicative of a benign etiology like calcification, then a F18-
fluorodeoxyglucose positron emission tomography (FDG-PET) combined with computed 
tomography scan is suggested for the non-invasive diagnosis of a lung nodule.3,43,44  Meta-
analyses of FDG-PET diagnostic accuracy reported a 96% sensitivity and 78% specificity.45,46 
FDG-PET scan is among the most accurate non-invasive tests available for the diagnosis of lung 
nodules.46  
 
FDG-PET scans were used as part of the diagnostic process in 8.3% of the individuals with a 
positive CT scan during the NLST. If a national lung screening program is implemented using the 
NLST criteria and proposed guidelines, then an estimated 170,000 FDG-PET scans at a cost of 
$2,000 to $3,000 per scan will be performed to diagnose the screening discovered lung 
lesions.2,47,48 However, some studies have questioned the efficacy of FDG-PET scans to diagnose 
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lung cancer where granuloma generating diseases of the lung are endemic.19,21 Granulomatous 
disease of the lung can look identical to cancerous tissue on CT or FDG-PET scan. It can have all 
the hallmarks of a cancerous lesion including symptomatic hemoptysis, growth on repeated CT 
scans, spiculated edge characteristics and the lack of calcification (Figure 2)49,50 Lung granulomas 
are often caused by fungal diseases in the US.34,51-54 Researchers in countries where tuberculosis 
is the etiological cause of most granuloma also question the use of FDG-PET to diagnose lung 
cancer.55,56 In these studies the specificity of FDG-PET was 25% to 50%, much lower than that 
reported in either meta-analysis. 
 
Granuloma is a common benign diagnosis of lung nodules in the US and accounts for 45% to 
65% of pathologically determined benign disease after FDG-PET imaging.16,19,52 Approximately 
15% to 40% of benign granulomas demonstrated an active fungal disease in these studies.  As 
described earlier, fungal lung disease prevalence varies widely across the US (Figure 1). What is 
not well understood is the interaction of endemic fungal lung disease, subsequent lung granuloma 
formation and its impact on FDG-PET imaging.  The studies by Croft and Deppen occurred in 
regions of the country were histoplasmosis prevalence was over 80% in the 1969 national survey.  
The relationship between endemic fungal lung disease and degradation of FDG-PET specificity 
may be localized to areas of extreme fungal disease prevalence or it may directly reflect local 
conditions and exposure patterns unique to a locale and the activities of the population or practice 
variation. If FDG-PET scan accuracy to diagnose lung cancer varies with endemic fungal lung 
disease, then populations may exist that would not benefit from this expensive diagnostic test.   
 
Furthermore, FDG-PET scans may not be as sensitive to detecting lesions below 2cm in 
maximum diameter.45 A screening population like that in the NLST has 50% pathologically 
determined stage 1 disease at time of diagnosis.  This compares to 15% stage 1 disease at 
diagnosis under current symptomatically and incidentally discovered lung cancer.  Clinical stage 
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1 disease is broken down further into stage 1A where the tumor is less than 3 cm in maximum 
diameter on radiograph (40% prevalence in the NLST) and stage 1B where the tumor is greater 
than 3 cm (10% prevalence in the NLST).  In clinical stage 1 disease, no lymph nodes are 
enlarged indicating possible local metastasis and no other tumors are evident in the lungs, bone or 
other organs.  The high prevalence of smaller lesions that typify the type of lesion discovered in 
LDCT screening may reduce the efficacy of FDG-PET to detect cancerous lesions and decrease 
the sensitivity of the test in a screening population. The NLST did not include FDG-PET 
outcomes in its study, but another national surgical trial found limited usefulness in FDG-PET for 
preventing unnecessary surgery of clinical stage 1 disease.33 The combination of reduced 
sensitivity due to the larger numbers of smaller lesions coupled with possibly poorer specificity 
among populations with endemic fungal lung disease may make FDG-PET scans a particularly 
ineffective test in screening populations in the US. A national study of participants with clinical 
stage 1 lung cancer who had a FDG-PET scan would emulate lesions arising from a screening 
program and presenting to surgeons for diagnosis.   
 
The recently concluded American College of Surgeons Oncology Group (ACOSOG) Z4031 trial 
evaluated participants with clinical stage 1 Non-small Cell Lung Cancer (NSCLC). The 
ACOSOG Z4031 trail obtained FDG-PET results in addition to bio-specimens associated with the 
studies primary research aim and provides the largest national sample to determine the accuracy 
of FDG-PET to diagnose early stage lung cancer to date. We conducted a secondary analysis of 
the ACOSOG trial to estimate the accuracy of FDG-PET to diagnose lung cancer in patients with 
known or suspected clinical stage 1 lung cancer. The possible exposure to fungal lung disease in 
this trial was likely to vary widely as this was a national trial with participants enrolling from a 
variety of cities and regions of the country. With this unique population we examined whether 
FDG-PET scan accuracy varied by the size of the lesion, by study site and whether false positive 
FDG-PET scans were associated with an estimated fungal lung disease exposure.  We 
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hypothesized that a population with smaller lesions and residing in a region of endemic fungal 
lung disease would likely not benefit from a FDG-PET scan for diagnosis prior to surgery. 
 
3.7 Methods 
 
Study Population 
The primary objective of the ACOSOG Z4031 study “Use of Proteomic Analysis of Serum 
Samples for Detection of Non-Small Cell Lung Cancer” (5U10CA076001-11) was to determine 
prospectively whether a serum proteomic profile can predict the presence of primary NSCLC in 
patients with suspicious lung lesions who are candidates for lung resection. The study design was 
a prospective study of 1000 patients undergoing lung resection for clinically known or suspicious 
clinical stage 1 lung lesions. The ACOSOG trial was a national study that occurred across 23 
states and Ontario, Canada in 51 hospitals in 39 cities (Figure 3). Patients were enrolled in the 
ACOSOG Z4031 trial from February 2004 to May 2006.  Inclusion criteria were: 1) 18 years or 
older, 2) clinically suspicious lung lesion that was possible stage 1 lung cancer, 3) CT scan < 60 
days prior to the lung resection and no evidence of metastatic disease, 4) no untreated 
malignancies, 5) no malignancy within the past 5 years except effectively treated basal cell or 
squamous cell skin cancer, surgically treated carcinoma in situ of the cervix, or surgically treated 
lobular carcinoma in situ of the ipsilateral or contralateral breast with low risk for recurrence, and 
6) able to provide informed consent.  Exclusion criteria included patients who had: 1) undergone 
previous lung resection within the preceding 30 days, 2) received prior chemotherapy or 
radiotherapy and 3) received a blood product transfusion of any kind within the past 60 days of 
the operative procedure.57  The ACOSOG Z4031 prospective clinical trial contains data on 969 
patients who met all the eligibility criteria.   
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Data Collection 
At time of enrollment age, sex, race, ethnicity, body mass index, date of operation, pre-operative 
clinical stage, CT radiologist reports, FDG-PET radiologist reports, enrolling site and zip or 
postal code of patient residence were collected. Follow up of the study participants was 5 years 
since time of enrollment.  Operative notes and pathological reports were collected along with 30 
day mortality status, status at last follow-up, date of last follow-up, and cause of death if dead at 
last follow-up.  All data were stored and maintained by the ACOSOG data center.   Additional 
data was extracted from ACOSOG case report forms and study analysis was conducted under a 
separate ACOSOG approved protocol (Z4095). Data abstracted from the study case report forms 
by two trained medical reviewers included: clinical maximum lesion diameter according to CT or 
PET/CT immediately prior to surgery, smoking status, smoking pack years, pre-operative FDG-
PET scan result and standard uptake value (SUV), pathological result for benign disease, and 
cancer histology.  FDG-PET scan results were categorized based on the radiologist descriptor of 
avidity or maximum SUV. Four categories of FDG-PET scan results were not avid/not cancerous 
(SUV=0), low avidity/not likely cancerous (SUV 0.1 to 2.5), avid/likely cancerous (SUV≥2.5 to 
5) and highly avid/cancerous (SUV≥5).  Categories were based on radiological guidelines and 
clinical convention.52,58 No original scans were reviewed. Pathological reports and operative notes 
were reviewed to determine etiology of benign disease and the specific cancer diagnosis. This 
secondary analysis of the ACOSOG Z4031 study was approved by the Vanderbilt IRB. 
 
Association with Fungal Lung Disease Exposure 
Fungal lung disease prevalence used the 1969 National Surveillance Survey and the details of this 
survey were described earlier in this chapter.28 Unlike the MEDPAR data, individually reported 
zip codes were available in the Z4031 trial.  The patient’s residence was defined as the 
geographic center of their self-reported residential zip code at the time of study enrollment and 
was entered into the GIS.  When a zip code crossed multiple state economic areas or counties and 
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possible differing fungal lung disease prevalence exposure, then fungal lung disease prevalence 
was weighted according to the proportion of the population in the zip code that was within a state 
economic area. Fungal lung disease exposure was the population weighted average disease 
prevalence for each county the zip code occurred. Population data were derived from 2000 census 
track data and mapped to each zip code occurring in 2000.59,60 Census data from 2010 was not 
available at the time of analysis and since the majority ACOSOG Z4031 study participant of 
enrollment occurred prior to 2006, the 2000 census was assumed to be more representative of the 
national distribution of adults than 2010 census data.  FDG-PET results, pathological diagnosis 
and estimated fungal lung disease exposure for each participant were added into the GIS. 
Estimated fungal lung disease exposure based upon participant zip code at study enrollment, were 
examined for association with individual pre-operative FDG-PET results. 
  
Statistical Analysis 
Differences in the demographics between the benign and malignant participants were compared 
using a t-test for continuous variables (age and lesion size) and binomial proportions test for 
differences in proportions (sex, race and FDG-PET avidity). Enrolling clinics in the same city or 
clinics in the same practice group were combined for geographic analysis of FDG-PET accuracy 
and outcome reported by city. Sensitivity, specificity, positive and negative predictive values 
were calculated for the ACOSOG study population who had FDG-PET scans available and 
among cities having at least 25 enrollees (N=8). The FDG-PET accuracy to diagnose lung cancer 
equals true positives plus true negatives divided by the total population tested and was calculated 
using the pathological diagnosis as the gold standard. Differences in the sensitivity and specificity 
between institutions were estimated using the chi-square statistic. The accuracy of FDG-PET by 
CT size group was compared with an analysis of variance. A logistic regression model was used 
to estimate the association of historical fungal lung disease prevalence of the patient’s residence 
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at time of enrollment with false positive FDG-PET scan results among all positive FDG-PET 
scans, adjusting for age at diagnosis and maximum lesion size reported on pre-operative CT. 
 
3.8  Results 
 
Our current analysis had 682 participants which met the ACOSOG Z4031 trial eligibility criteria 
and had a preoperative FDG-PET scan.  Benign disease was found in 116 patients (17%) and lung 
cancer in 566 patients (83%). Microbiology results were abstracted from pathological or 
operative reports and only 11% of benign cases have an unknown etiology. Of the 116 benign 
cases, 75 (65%) were documented in the pathology report as being granulomatous and 30 (26%) 
of the granulomas had documented histoplasmosis etiology in the pathology report. Smoking data 
was not collected at time of study enrollment but was abstracted for this analysis, resulting in 280 
(29%) patients with smoking exposure information. Patients with cancer were more likely to be 
older, non-Caucasian, and have larger lesions that were FDG-PET avid than patients with benign 
disease (Table 1).   
 
The overall accuracy of FDG-PET to diagnose lung cancer was 73% when compared to the 
pathologic diagnosis. The sensitivity and specificity were 82% and 31% and the positive and 
negative predictive values were 85% and 26%, respectively (Table 2). Table 3 shows the 
pathology of the enrollees with false positive and false negative FDG-PET scans.  The majority of 
patients with false positive FDG-PET scans had granulomas and the majority of false negative 
FDG-PET scan results had adenocarcinoma.  Of the 80 false positives, 69% of these were 
granulomas. Twenty-one of the 36 true positive lesions (58%) wee granulomas. Among the 101 
lung nodules with a false negative FDG-PET scan, 11 were less than or equal to 1 cm in 
maximum diameter measured by CT pre-operatively, and 62% of these lesions were 
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adenocarcinoma, 11% were squamous, 10% were broncho-alveolar cell and 9% had a 
neuroendocrine pathology.  
 
 
There were 8 cities with more than 25 participants (Table 4). The observed sensitivity by city 
varied from 68% to 91% (p=0.03) and the specificity ranged from 15% to 44% (p=0.72). FDG-
PET accuracy improved with lesion size (Figure 2) from 67% in lesions that were one to two cm 
(sensitivity 76% and specificity 35%) to 84% in lesions that were three to five cm (sensitivity 
90% and specificity 18%) (p<0.001).   
 
The median estimated prevalence of fungal lung disease in patients with FDG-PET avid lesions 
was 5.6% (IQR 2.7, 28.5). We evaluated the association of fungal lung disease prevalence and 
false positive FDG-PET scans among those with a positive FDG-PET scan using logistic 
regression, controlling for age and pre-operative CT size. Of 545 positive FDG-PET scans, 480 
had a valid residential zip code which could be assigned a 1969 fungal lung disease prevalence 
based on their residence at enrollment. Age (OR 1.04, 95% CI 1.01-1.07) and pre-operative CT 
size (OR 1.04, 95% CI 1.02-1.07) were strongly associated with a positive FDG-PET scan 
(p<0.01). The prevalence of fungal lung disease increased the likelihood of a false positive scan 
(OR 0.99, 95% CI 0.98-1.002), but the association was not statistically significant (p = 0.12). 
 
3.9 Discussion 
 
The poor results of FDG-PET to diagnose lung cancer in the ACOSOG Z4031 trial give insight 
into possible issues for this imaging modality when applied to lung nodules arising from a 
screening population. The ACOSOG Z4031 study had participants from 17 cities with enrolling 
centers that also participated in the NLST. Pathological stage 1A disease was observed in 45% of 
the ACOSOG trial and in 40% of the NLST. The NLST had more stage 3 and 4 lung cancer, and 
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the ACOSOG trial had more operable stage 2 disease. Individuals with CT evidence of possible 
metastatic disease would receive a FDG-PET scan for non-invasive staging and not for 
diagnosis.61,62 Thus, some number of participants in the NLST who received a FDG-PET scan did 
so for staging purposes and not for diagnosis.  Individuals with clinically determined stage 3 and 
stage 4 lung cancer are not candidates for surgery.  This analysis does not address the accuracy of 
FDG-PET for staging. The NLST did not collect data on FDG-PET scans, and direct comparison 
of FDG-PET accuracy between the Z4031 trial and the NLST is not possible. Even with these 
differences between the two populations, a number of conclusions can be drawn regarding the use 
of FDG-PET scans and extrapolated to the types of lesions likely to be found in a low dose CT 
screening environment.  
 
Currently available PET scanners have limited ability to detect metabolically active lesions 
smaller than 8 mm, and FDG-PET isn’t recommended for lesions smaller than 8 mm due to high 
false negative rates.3,63 For those lesions between one and three cm in diameter, a recent meta-
analysis found FDG-PET to be accurate (sensitivity 94% and specificity 83%).64 Stage 1A and 
stage 2A disease are characterized by T1 tumors that are smaller than three cm in diameter.65 The 
much lower sensitivity observed in the ACOSOG trial may be caused by this population having 
more lesions less than three cm compared to the studies used in the meta-analysis. The accuracy 
in the 448 lesions smaller than three cm was 68%. If smaller lesions can be expected to arise from 
a screening population than a clinical population, then the lower sensitivity of FDG-PET may be 
more similar to that observed in our study than previously reported in the literature. 
 
The specificity of FDG-PET to diagnose lung cancer in this trial is similar to two previously 
reported surgical series from Iowa City, Iowa and Nashville, Tennessee.19,21 Both of these regions 
have a high prevalence of fungal lung disease. Croft and colleagues reported a sensitivity and 
specificity of 93% and 40% respectively in their smaller (N=74), Midwest cohort, with all 
109 
 
imaging performed at a tertiary referral center.21 Deppen et al reported a sensitivity of 92% and 
specificity of 40% in a patient population (N=279) predominantly from the south central U.S., 
with imaging performed at a variety of regional imaging centers. Both studies noted elevated 
numbers of false positive scans and lowered specificity. The underlying populations from each 
study had a high prevalence of endemic fungal lung disease and granulomas were the most 
common benign results observed. The current study also had a preponderance of granulomas.    
   
The results from this study differ from prior meta-analyses by Gould et al which reported a 
sensitivity and specificity of 96% and 78%, respectively and by Cronin et al who report similar 
results for combined FDG-PET/CT scans (94% and 83%, respectively). 45,64 The differences in 
our current analysis compared to the two meta-analyses may arise from a number of factors. First, 
verification bias may be present in our current study due to the entire ACOSOG study population 
having a pathologic diagnosis after surgical resection. Not all results reported in either meta-
analysis relied solely on participants having a pathological diagnosis. Verification bias may 
explain the observed low specificity but does not explain the lower sensitivity in this study when 
compared to previous reports.66  
 
The population of patients in the Z 4031 trail may also be different from those collected from 
publications used by the meta-analyses. The inclusion criteria of the Z4031 trial required clinical 
stage 1 disease prior to surgery. Other single institution series include those with known or 
suspected lung cancer, as well as, all pre-diagnosis clinical stages. A large number of sites 
contributing patients in the ACOSOG study are in regions of the United States with a high 
prevalence of fungal lung disease; and consequently, a large number of granulomas were 
observed in this series. This was not true for the sites used in the meta-analyses. Granulomatous 
disease and the fungal lung disease and tuberculosis that cause them are rare in Europe and Japan.  
In Gould’s meta-analysis 727 of the 1474 (49%) lesions included were from either Japan or 
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European populations. At least another 15% of the lesions in the meta-analysis were from regions 
of the US where granulomatous disease is rare. Finally, the FDG-PET scans in the ACOSOG 
study were performed at many different institutions as well as from community imaging centers 
and were read by a variety of radiologists. This lack of uniformity in test administration and 
reporting likely introduced variability in scanning quality and interpretation by the radiologists. 
The studies included in both meta-analyses where conducted primarily at academic medical 
centers by thoracic radiologist specialists and not in the community setting.  Overall, our current 
study reports a reduced sensitivity and specificity and reduced accuracy of FDG-PET to diagnose 
lung cancer when compared to published meta-analysis. 
 
No association was observed between false positive FDG-PET scans and historical fungal lung 
disease after controlling for an individual’s age and lesion size.  The fungal lung disease 
increased the likelihood of a false positive FDG-PET scan but not significantly (p=0.12). The 
issues surrounding use of the 1969 survey were described in detail above.  In summary estimating 
fungal lung disease with the 1969 national survey may lead to exposure misclassification due to: 
1) ecological fallacy of assigning individual exposure from a population average, 2) historical 
data are being applied to an older population that has more varied exposure profile than that 
surveyed, 3) there is some evidence of migration of fungal spores over time, and 4) the 
distribution of both population to more urban settings and urbanization of the landscape over the 
last 44 years likely reduced exposure. Thus, it is not possible to know the direction of bias within 
the ACOSOG study population due to the counteracting effect of the various possible 
mechanisms of misclassification. Available estimates of exposure are methodologically 
questionable and require independent verification.  
 
Except for cytopathology or microbiology testing of the lung lesion after surgery, there is no 
method of directly measuring fungal exposure.  The skin test used in the 1969 survey is no longer 
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in production. There are three possibilities to solve the problem of determining whether an 
individual was exposed to fungal lung disease: reproduce the old skin test, better estimate fungal 
spore reservoirs in soils with land cover modeling or find another radiographic or biological 
biomarker that indicates the lesion is a granuloma. Land cover mapping of environments 
preferential to fungus spores coupled with an individual’s movement over time in the landscape 
could estimate individual fungal lung disease exposure.  Such an estimate should be a significant 
improvement over assigning a prevalence based upon representation of the population average 
within the arbitrary political boundary of a county.  
 
Our study is one of the largest series evaluating the accuracy of FDG-PET to diagnose lung 
cancer in clinical stage 1 disease and represents a national sample with over 650 patients from 39 
cities in the United States. Cancer or benign disease was determined pathologically as all patients 
had a surgical resection. Because it is a clinical study in a large national sample from multiple 
institutions with multiple surgeons and interpreting radiologists, the results from this analysis are 
generalizable to clinical practice for early stage patients being evaluated for surgical resection.  
However, as our study is a secondary analysis of a clinical trial designed and powered for other 
purposes, biases associated with retrospective reviews of the FDG-PET results are possible. To 
reduce these biases, reviewers were used who had experience with these types of chart reviews, 
were blinded to the final pathology and staging and did not conduct the statistical analyses. 
Because FDG-PET scans were performed at multiple academic and community centers, there 
were no standard FDG-PET scan administration or interpretation protocols. We believe this is 
both a strength and weakness of the study as it increases the generalizability of the study 
nationally but the results may not be applicable to high volume centers with expertise in FDG-
PET scans.  In addition, this study does not address the role of FDG-PET scan for clinical staging 
of lung cancer. 
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In conclusion, the accuracy of FDG-PET scan to diagnose lung cancer in a national sample of 
patients with known or suspected clinical stage 1 NSCLC is less than previously published meta-
analyses. Clinicians must assess the pre-test probability of disease and consider whether a 
positive or negative FDG-PET scan will material alter their treatment decisions. Smaller, stage 1 
lesions less than three cm in diameter may reduce the diagnostic yield of FDG-PET to such an 
extent that FDG-PET should not be used for diagnostic purposes. A positive scan is more likely 
to be cancer, because the prevalence of disease in a population being evaluated by surgeons is 
generally above 60%. False positive scan are common. Therefore, results of FDG-PET should be 
interpreted cautiously when diagnostic or treatment decisions are being made for patients with 
suspicious pulmonary lesions. Further research is needed to determine the impact of fungal lung 
disease on false positive FDG-PET results. In addition, additional diagnostic tests should be 
developed and used to minimize false negative results when adenocarcinoma, carcinoid or 
bronchoalveolar cell tumors are suspected.   
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Table 1. Characteristics of MEDPAR inpatient discharges with lung surgery,  
  United States 2009 
Characteristic Cancer 
N=23050 
Benign Disease 
N=2,328 
Male sex (% of diagnosis) 11,619 (49.6) 1,266 (45.6) 
White race (%) 20,734 (90.0) 2,063 (88.6) 
Age category 
         <65 
      65-69 
      70-74 
      75-79 
      80-84 
         >84 
 
  2,129   (9.4) 
  6,088 (26.4) 
  5,989 (26.0)  
  5,011 (21.7) 
  2,950 (12.8) 
     883   (3.8) 
 
423 (10.7) 
687 (26.7) 
591 (25.9) 
389 (21.3) 
177 (12.3) 
  61   (3.7) 
 
Table 2. Descriptive Characteristics of ACOSOG Z4031 patients with FDG-PET Scans 
Characteristic Cancer 
N=566 
Benign 
N=116 
p-valuea 
Male (%)  253 (45)    54 (47)     0.71 
Caucasian (%)  517 (91) 113 (97)    0.03 
Mean Age (SD)    67 (10)      61 (11) <0.001 
Lesion Size mm (SD) 26 (0.61) 20 (0.95)  <0.001 
FDG-PET Avidb (%)  465 (82)    80 (69) 0.002 
a Continuous variable statistics use t-test (Age and Lesion Size) and 
binomial proportions test for differences in proportions (Gender, 
Race and FDG-PET Avidity). 
b The categories of avidity and their corresponding SUV are: Not 
avid/Not cancerous (SUV=0), Low avidity/Not likely cancerous 
(SUV 0.1 to 2.5), Avid/Likely cancerous (SUV 2.5 to 5) and Highly 
avid/Cancerous (SUV>5).  PET avid was the sum of Avid/ likely 
cancerous and Highly avid/Cancerous (SUV≥2.5).   
120 
 
Table 3. Pathology of false negative and false positive lesions 
 
 
Malignant 
FDG-PET Non-Avid 
(False Negatives) * 
Adenocarcinoma 62 
Squamous Cell 11 
Bronchoalveolar Cell 11 
Carcinoid/Neuroendocrine 9 
Other NSCLC  4 
Other Cancer 1 
Small Cell 1 
Unknown 2 
 
Benign 
FDG-PET Avid 
 (False Positives) 
Granuloma** 55 
 Benign Tumor 8 
Active Infectious disease*** 9 
Fibrosis 4 
Other 4 
*11 of the false negatives were <1cm 
**Granuloma includes histoplasmosis, atypical mycobacteria, blastomycosis, cryptococcus, 
coccidiodomycosis, aspergillosis and nonspecific granulomas.   
***Infectious disease includes active Mycobacterium tuberculosis and active pneumonia 
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Table 4. Accuracy of FDG-PET to diagnose cancer among patients with clinical stage1 
NSCLC 
 
FDG-PET Cancera Benign   
Avidb 465 80 PPVc  85%  95%CI: (82, 88)  
Not-Avid 101 36 NPVd  26%  95%CI: (19, 35)  
 
Sensitivity  82%   95%CI: (79, 85) 
Specificity  31%   95%CI: (23, 40) 
Prevalence 83% 95%CI: (80, 86) 
 
 
aDiagnosis was based upon pathological result of the surgically resected specimen.  
bFDG-PET avidity was defined by an SUV > 2.5 or moderate or intense uptake.   
cPPV = positive predictive value 
dNPV = negative predictive value 
 
 
 
Table 5. FDG-PET sensitivity and specificity by enrolling city with at least 25 participants 
 
N 
462 
Sensitivity (%) Cancer 
N=378 
Specificity (%) Benign 
N=84 
Durham, NC 41 91 33 25 8 
Birmingham, AL 111 89 98 15 13 
Philadelphia, PA 78 85 66 46 12 
Pittsburg, PA 68 78 60 25 8 
Charlottesville, VA 52 76 34 33 18 
Cincinnati, OH 31 73 22 33 9 
St. Louis, MO 54 68 47 29 7 
Los Angeles, CA 27 67 18 44 9 
Chi-square test  p = 0.03  p = 0.72  
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Figure 1. Fungal lung disease prevalence, histoplasmin skin was cross reactive with 
coccidioidomycosis and blastomycosis (from Edwards et al, 1969) 
 
 
 
Figure 2. CT scan of a spiculated granuloma in a patient presenting with hemoptysis 
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Figure 3. Consort diagram of benign disease after surgery for known or suspected lung 
cancer, 2009 MEDPAR  
 
 
Figure 4. Point prevalence of benign disease after lung surgery by state in 2009 MEDPAR 
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Figure 5. Enrolling site location with size of circle corresponding to participation volume – 
51 sites in 39 cities.  Individual dots are study participants residence by zip code at time of 
enrollment.  Dots are overlapping for those with identical zip codes. 
 
 
 
Figure 6. Accuracy of FDG-PET to diagnose lung cancer by lesion size in millimeters. 
Accuracy = (True Positives + True Negatives) / Total Population in size group  
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Chapter 4 
 
 
IV. Variation in FDG-PET Accuracy to Diagnose Lung Cancer: a meta-analysis 
 
4.1 Introduction 
 
Clinicians rely heavily on radiographic imaging to discover and non-invasively diagnose lung nodules 
between 3 and 30mm in diameter. Lung nodules smaller than 30 mm are frequently asymptomatic and 
discovered incidentally from non-invasive imaging for other medical indications. One-third of these 
incidentally discovered nodules are malignant in persons over age 35.1 Guidelines for the management of 
lung nodules suggest relying on imaging to assess the risk that a lung nodule is cancerous and using 
increasingly intensive and invasive tests as the likelihood of cancer increases.2,3 As described in previous 
chapters, if the lesion is larger than 8 mm and the individual’s assessed risk for lung cancer is between 5% 
and 60%, then F18-Fluorodeoxyglucose positron emission tomography combined with helical CT (FDG-
PET/CT) is suggested for non-invasive imaging to characterize the lesion’s metabolic activity.   
 
FDG is a glucose analog (deoxyglucose) attached to an 18-Fluorine radionuclide. When injected into an 
individual, the glucose is consumed by metabolically active tissue and the radionuclide preferentially 
accumulates in the active tissue. Metabolically active organs like the heart, brain and gonads concentrate 
the radionuclide.4 Positron emissions from the radionuclide are detected by a positron emission 
tomographic scanner ring. In a modern combination PET/CT scanner, the PET image is combined with a 
CT image that adds anatomical structures to the PET image. Normal lung tissue is not metabolically 
active and thus does not accumulate the radionuclide. Neoplastic cells, pneumonia and other 
inflammatory diseases, wounds, and active benign tumors like hamartomas and granulomas have higher 
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glucose metabolism than the surrounding normal tissue and thus accumulate the 18F radionuclide 
attached to the glucose analog within the lung.5,6 This differential in normal, compared to abnormal, 
metabolism makes FDG-PET scans useful in the diagnosis of lung cancer.4 Less active tissue including 
slow-growing adenocarcinomas or carcinoid tumors do not concentrate the radionuclide. Lesions with 
low metabolic activity and lesions smaller than 8 mm commonly generate false negative scans.  
 
FDG-PET is 90% to 94% accurate in the characterization of cancer or benign disease in lung nodules, 
with a sensitivity of 96% to 99% and specificity of 78% to 82% according to previous meta-analyses.7,8 
FDG-PET has been demonstrated to reduce non-therapeutic resections (e.g. resection for benign lesions 
or metastatic disease) by 17% to 20%9-12. For these reasons, FDG-PET is widely accepted for the clinical 
diagnosis and staging of lung cancer in patients with suspicious lung nodules.13,14 
 
Since the publication of the meta-analysis in 2001, FDG-PET has been adopted worldwide for the clinical 
diagnosis and staging of lung cancer. When a test becomes widely adopted and is applied outside the 
controlled environment of clinical trials, the diagnostic accuracy of the test is usually diminished.15 The 
observed decrease in accuracy may be due to practice variation and poor quality control. Poorer accuracy 
may also arise in sub-populations within which some test-influencing factor is prevalent. If the 
confounding factor was not prevalent in the original studies measuring the diagnostic accuracy of the test, 
then a form of selection bias may have occurred in the original research. 
 
 
Recent studies observed reduced FDG-PET accuracy in diagnosing lung cancer in patients with lung 
lesions where histoplasmosis and other fungal lung diseases are endemic.16,17 Histoplasmosis, 
coccidioidomycosis and blastomycosis are the most prevalent fungal lung diseases in the US and are 
common etiologies of lung granulomas. Histoplasmosis and blastomycosis are endemic across much of 
the Mississippi, Ohio and Missouri River valleys through southern Ontario while coccidioidomycosis is 
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prevalent in the southwest US.18 Some international studies also found reduced FDG-PET accuracy in 
diagnosing lung cancer.19,20 These studies occurred in areas of endemic tuberculosis which is the primary 
cause of lung granulomas outside of North America.18,21 We undertook a systematic review and meta-
analysis of publications describing FDG-PET accuracy to diagnose lung cancer among patients being 
evaluated with lung nodules or masses and published since the earlier meta-analysis by Gould and 
colleagues.8 This meta-analysis investigated whether FDG-PET accuracy varies between studies 
according to characteristics associated with the tests, settings, participants or methodology. Our meta-
analysis also specifically investigated possible variation in diagnostic test accuracy caused by locally 
endemic infectious lung diseases in study participants.  
 
4.2  Methods 
  
  Study Selection 
Studies evaluating individuals for possible lung cancer using FDG-PET or combined FDG PET/CT scans 
were reviewed, including published and unpublished studies. We searched Medline using the Pubmed 
interface, Embase and the New York Academy of Medicine Grey Literature Report. The literature search 
in each database included any of the terms lung cancer, pulmonary nodule, lesion, non-small cell lung 
cancer, or NSCLC. From this set of publications additional descriptors were required that included any of 
the terms diagnostic, positron emission tomography, PET, fluorodeoxyglucose, FDG, or combinations of 
those terms (see Appendix 2). Unpublished abstracts were reviewed and extracted by a research librarian. 
Publication could be in any language, but the abstract had to appear in English in one of the above 
databases to be included. Bibliographies from meta-analyses and literature reviews were examined 
individually and papers of interest were included in the final list of abstracts for review. A search was 
conducted for published studies between October 2000 and March 2011. Complete citations including 
authors,  Pubmed identification number, abstract and year of publication were imported electronically into 
a dedicated REDCap database for abstract review and data extraction.  
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Exclusion Criteria 
All published abstracts were examined independently by two reviewers for inclusion. If either investigator 
deemed a study worthy of consideration after reviewing the abstract, then the publication received 
subsequent review and data extraction. Studies with 100% cancer prevalence or 100% benign disease 
prevalence were excluded. Studies reporting staging using FDG-PET and not reporting the results of lung 
nodule scans were excluded. Case reports were excluded. Studies with 10 or fewer participants were also 
excluded. Those studies not reporting enough information to determine the number of true positive, true 
negative, false positive and false negative results were excluded. Studies that preselected specific 
histologies, tumor characteristics in imaging including minimum standard uptake value, ground glass 
opacity observed in CT prior to FDG-PET scan, or lesion location in the lung were excluded. Studies 
using only gamma camera PET scanners were excluded. One study could be excluded for multiple 
reasons. Unpublished abstracts not excluded based on the above criteria but could be matched to a 
subsequent publication were excluded. Publications whose population, in part or in whole, was included 
in multiple studies were excluded so that the population under study contributed only once to the meta-
analysis. Authors were contacted to determine the uniqueness of a study population when multiple studies 
that possibly included the same population were observed and eligibility was uncertain.   
 
  Study quality 
Two reviewers independently assessed the quality of each study according to prospective criteria using a 
modified QUADAS set of 12 questions.22,23 The questions addressed the technical quality of the index 
test, the technical quality of the reference test, the independence and accuracy of the test interpretation, 
and the sample size and population representation. To evaluate agreement between the raters for 
assessments of study eligibility, we calculated the observed percentage of agreement and the kappa 
coefficient for inter-rater reliability. Study quality was graphically reviewed and subanalysis was 
conducted on prospective versus retrospective studies. Studies that used only pathological diagnosis were 
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compared to studies that used both pathological and radiographic determination of diagnosis, and studies 
that blinded reviewers to patient demographic and history were compared to those that did not. 
 
  Data Synthesis and Analysis  
After abstract review, articles designated for full text review and data extraction were independently 
coded into a database by two reviewers. All articles were reviewed and coded by one investigator (SD). 
Two other investigators (CK and AM) divided the articles into two groups and independently reviewed 
the full text and extracted relevant data. Each publication was reviewed independently twice. 
Discrepancies in coding were reviewed by the investigators and an independent clinician. Changes were 
agreed upon by consensus. Additional data extraction beyond citation, authors and year of publication 
included: type of population studied, method of determining final diagnosis, method of determining 
benign disease, scanner type, patient demographics, reported presence of infectious lung diseases, 
infectious lung disease prevalence, and country or region where the participant population was recruited 
(see Appendix 2 for database metadata). The methodology of designating the PET scan results included 
the metric of measuring FDG-PET avidity, which was either standard uptake value (SUV), modified 
SUV, radiologist’s assessment, or other. The number of levels of risk or avidity and the SUV threshold 
used to differentiate benign and cancerous diagnosis of disease were recorded.  For each study a 2x2 
contingency table of test and disease result was created. Sensitivity and specificity, diagnostic odds ratio, 
and positive and negative likelihood ratios for each article were estimated, and 95% confidence intervals 
were calculated based upon normal approximations to the binomial distribution.   
 
FDG-PET test performance was estimated in a pooled fashion using forest plots, and hierarchical 
summary receiver operator curves (SROC) were generated. Study heterogeneity was quantitatively 
measured by Cochrane Q and I2 statistics and assessed graphically by forest plot and SROC curve. 
Publication bias was graphically charted by funnel plot and quantitatively measured by Deek’s 
Asymmetry Test. Sub-group analysis was conducted by forest plots.  
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Considerable heterogeneity is expected in diagnostic studies and a meta-analysis model was created to 
summarize test performance by using a bivariate random-effects binomial regression model. This model 
was formulated so that the test results were conditioned on the probability of disease. This approach 
allowed fixed and random effects modeling of clinically relevant variables. For variables with missing 
data, multiple imputation with chained equations was performed. Predictive mean matching models 
estimated all missing data. An imputed dataset burn-in was used and an additional 10 imputed datasets 
were then generated. These 10 datasets were used for all subsequent model estimation.  
 
Study characteristics likely to generate heterogeneity were chosen for sub-group analysis and included in 
the meta-analysis model as linear effects within the random and fixed effect model. Those characteristics 
included: endemic infectious lung disease in the study population, mean or median lesion diameter less 
than 2 cm, the method of diagnosis, method of blinding scan readers, and scanner type as a categorical 
variable. Other study characteristics measuring relative quality were examined in sensitivity analysis to 
determine if they materially changed the results of the meta-analysis model.   
 
Variables measuring domains of study quality examined in sensitivity analysis included whether the study 
was prospective or retrospective, the method of final diagnosis and year of publication. Publication year 
was examined in both a linear and non-linear fashion. To determine whether the diagnostic accuracy of 
FDG-PET has changed over time, we ordered the studies chronologically, estimated each study’s 
diagnostic log odds ratio and performed a cumulative meta-analysis.24 The diagnostic odds ratio is defined 
as true positives divided by the false negative results; this fraction is then divided by the ratio of false 
positive to true negative results (TP/FN) / (FP/TN). Analysis of clinical relevance was conducted by 
estimating positive and negative likelihood ratios for the combined studies and plotting the estimated 
likelihoods with 95% confidence intervals graphically. All analysis was performed with STATA (v12, 
College Station, TX).  
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4.3 Results 
 
  Study identification 
1,218 articles and 33 meta-analyses or reviews were found. An additional 13 articles were added from the 
meta-analyses or reviews for a total of 1,231 articles that met the search criteria. Upon initial abstract 
review, 1013 articles were excluded. An article could be excluded for multiple reasons, but the most 
common reason for exclusion during either portion of the review was 100% cancer prevalence (637) 
(Figure 1).   
 
Five abstracts were included from foreign language journals and four of these were translated into 
English.25-28 The remaining abstract that was not translated had enough information in the English abstract 
to estimate sensitivity and specificity and test accuracy.29 One unpublished conference abstract was 
included in the initial review and its later publication was used in the secondary review.16 Two hundred 
and eighteen studies received full review and 158 were excluded upon this secondary review. The 
remaining 60 studies met all inclusion criteria and were used for final analysis. The total number of 
participants among the 60 studies was 6,347 and median study participant size was 75 (IRQ: 47, 127). 
Cancer prevalence among all 6,347 participants was 63.8%. Individual study cancer prevalence varied 
from 21% to 90% with a median prevalence of 62.6% across studies. Twenty-five of the 60 studies (42%) 
were conducted prospectively. Seven of 60 studies documented endemic infectious lung disease in the 
population scanned.16,17,20,30-33  
 
In a pooled analysis of all 60 studies using an unadjusted random effects model, sensitivity was 89% 
(95% CI: 87%, 91%) and specificity was 74% (95% CI: 70%, 78%) (Figure 2). Pooled diagnostic odds 
ratio was 24 (95%CI: 18, 33). The unadjusted area under the hierarchical summary receiver operator 
curve was 0.90 (95%CI: 0.87, 0.93) (Figure 3). Significant heterogeneity beyond that explained by 
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differences in thresholds chosen for diagnosis within studies was observed across studies for both 
sensitivity, with I2 of 81% (95%CI: 77%, 86%), and specificity, with an I2 of 76% (95%CI: 70%, 82%). 
Therefore, estimates of pooled sensitivity and specificity and the SROC should be interpreted with 
caution as they did not reflect differences in population and the assumptions for pooling data were 
violated. Heterogeneity of diagnostic odds ratio measured by I2 was 98 (95%CI; 95, 99) and an estimated 
5% of observed variability in sensitivity and specificity likely arose from variation in cutpoints across the 
60 studies. I2 values greater than 75% are indicative of strong heterogeneity between studies.34 Published 
studies of FDG-PET scan accuracy included small studies reporting low to moderate accuracy, and 
Deeks’ asymmetry test was not statistically significant for publication bias (p = 0.18) (Figure 4). 
 
Differences in FDG-PET accuracy over time were examined with a cumulative analysis of the diagnostic 
odds ratio accumulated over the years of publication (Appendix 2, Figure 1). Studies were grouped into 
four three-year populations of studies and their diagnostic odds ratios pooled. No statistically significant 
differences in accuracy measured by diagnostic odds ratio were observed between any two groups of 
studies. A bivariate boxplot was constructed to examine the interrelationship between sensitivity and 
specificity in the unadjusted random effects model (Appendix 2, Figure 2). The slight oblong distribution 
of the covariance region indicates a slight preference for sensitivity of FDG-PET scan over specificity and 
an asymmetric SROC. 
 
  Meta-analysis model 
A random-effects logistic regression model was created.  Heterogeneity between studies remained (rho 
=0.08 95%CI: 0.04, 0.12) after accounting for variability between studies caused by whether the study 
reported granulomas arising from endemic infectious lung disease or the scanner type, whether or not 
readers were blinded to patient information, and the average size of the lung lesion in the cohort being 
less than or equal to 20 mm (Table 2). Missing data occurred in 25 (42%) studies. Multiple imputation 
was performed with chained equations. Missing data occurred in a monotone pattern between the two (3% 
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of the 60 studies) reported neither blinding method nor a mean or median lesion size.35,36 The multiple 
imputation model was estimated using pathological diagnosis of cancer or benign disease, the year of the 
study, the method of diagnosis, scanner type, study specific cancer prevalence, whether the study was 
retrospective or prospective, and whether the study reported locally endemic infectious lung disease. The 
point estimates of the meta-analysis model variables using complete case data were generally higher than 
those from the imputed data, but the overall results were similar (Table 2).  
 
Odds ratios for the interaction terms with cancer that are greater than one increase sensitivity; odds ratios 
less than one decrease sensitivity. Odds ratios for variables without interaction with cancer influence 
specificity inversely. Therefore, odds ratios increased specificity when their values were less than one, 
and odds ratios decreased specificity when their odds ratios were greater than one. The variable’s overall 
effect on sensitivity was determined by the sum of coefficients for direct effect and for the interaction 
between the variable and a cancer diagnosis. For example, studies using combined PET/CT scanners had 
higher specificity (OR 0.63; 95%CI: 0.43, 0.94) and sensitivity (OR 1.47; 95%CI: 1.21, 2.31) when 
compared to studies that used PET only variables, the method of blinding scan readers (17%), and mean 
or median lesion size (23%). Two studies scanners. The pooled sensitivity from the meta-analysis model 
was 89% (95%CI: 82%, 94%). Estimated pooled specificity was 75% (95%CI: 46%, 86%). 
 
Sub-group analysis 
Seven studies reporting infectious lung disease endemic to the local population had significantly lower 
specificity, 59% (95%CI: 46%, 70%; p<0.001)16,17,20,30-33 compared to a specificity of 77% (95%CI: 70%, 
86%) in the remaining 53 studies (Figure 5). A sensitivity of 91% (95%CI: 90%, 93%) for the endemic 
disease studies were slightly higher compared to the other 53 studies, specificity 90% (95%CI 82%, 
93%). One study by Chundru and colleagues was an outlier in terms of cutpoint choice.30  The Bryant 
paper exerted significant influence due to its large size (N=585) compared to the remaining 6 studies that 
had a combined population of 60632. Excluding these two studies resulted in a sensitivity of 90% (95%CI 
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87%, 93%) that was the same as the 53 studies that did not report endemic infectious lung disease. The 
remaining 5 studies had a much lower specificity (39%; 95%CI: 29%, 51%) and excluding these two 
studies from the pool of studies that reported endemic infectious lung disease removed all heterogeneity 
for sensitivity and reduced heterogeneity for specificity measured by I2 by half to 43%. The SROC for 
these five studies was 0.88 (95%CI: 0.85, 0.91) (Figure 6). 
 
Among the 24 studies reporting average or median lesion diameter less than or equal to 20mm, the 
estimated sensitivity was 88% (95%CI: 82%, 91%).20,26,28,32,37-56 The 19 studies with average or median 
diameter greater than 20 mm had higher sensitivity, 91% (95%CI: 87%, 94%)16,17,27,31,57-71 compared to the 
studies with smaller mean lesion size (Figure 7). Specificity of FDG-PET to diagnose lung cancer was not 
significantly different between studies based upon mean lesion size. Specificity was 71% (95%CI: 42%, 
83%) among studies with mean lesion size above 20 mm and 75% (95%CI: 54%, 85%) specificity for 
studies reporting mean lesion size less than or equal to 20 mm.  
 
Combined PET/CT scanners were significantly more specific (p=0.02) and sensitive (p<0.001) when 
compared to PET only scanners (Figure 8). Twenty-five studies reported using PET only scanners in their 
diagnostic processes.17,27,29,31,33,36,39-41,46-48,56-59,61,72-79 Twelve of the 25 studies were published between 
2000 and 2002; combined PET/CT scanners became clinically available in 2001. The sensitivity for PET 
only scanners was 87.3% (95%CI: 82%, 91%). The sensitivity for the 28 studies using combined PET/CT 
scanners was 90.5% (95%CI: 87%, 94%).16,20,25,26,28,30,32,35,37,38,49-55,65,66,69-71,80-85 The sensitivity for the 
seven studies that used a PET or PET/CT scanner in combination with another type of scan was 91.2% 
(95%CI: 88, 93) which was significantly (p=0.03) higher than PET only scanners and similar to PET/CT 
scanner sensitivity.42,45,63,64,68,86,87 The specificity for PET only scanners was 70% (95%CI: 56%, 79%) 
which was significantly lower (p=0.02) than the observed specificity for combined PET/CT scanners, 
77.5% (95%CI: 57%, 86%). The specificity reported for scanners that used PET and some other 
radiographic modality was 76% (95%CI: 71%, 80%) and was not significantly different from PET only 
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scanners (p=0.65). Among the other imaging modalities reported, three studies used single-photon 
emission computerized tomography (SPECT) as the alternative secondary scanning modality.45,63,64 Two 
reported using F18-fluorothyminidine (FLT) in conjunction with FDG.68,87 One used a sodium iodide 
detector86 and one created an algorithm of staggered PET scans and a model in conjunction with standard 
uptake values.42 
 
  Study Quality 
Thirty-five (58%) of the included studies were retrospective and 25 (42%) were prospective studies 
(Table1). There was no statistically significant difference in sensitivity (90% and 89%) or specificity 
(76% and 74%) based upon study enrollment method. Method of diagnosis was either entirely based upon 
pathological diagnosis or a combination of pathological diagnosis and radiographic surveillance. There 
was no statistically significant difference in sensitivity between studies reporting using pathology only 
(90%; 95%CI: 82%, 94%) and those using a combination of methods for diagnosis (89%; 95%CI: 82%, 
93%). Studies using only pathological diagnosis had lower specificity (70%: 95%CI: 48%, 86%) than 
those reporting using a combination of methods (77%; 95%CI: 48%, 88%), but the differences were not 
statistically significant. 
 
 
Twelve studies blinded the scan reader to both patient history and outcomes of previous tests (Figure 
9).25,28-30,33,41,53,56,60,84,86 Scan readers were not blinded to patient history and outcome in 37 studies (60%). 
Another 12 studies did not report enough information to determine the method of reader 
blinding.31,35,36,40,42,46,48,51,55,57,58,70 The twelve studies that reported blinding of readers had slightly lower 
sensitivity (88%; 95%CI: 82%, 92%) and specificity (70%; 95%CI: 57%, 86%) when compared to the 37 
studies that did not (sensitivity 90%; 95%CI: 84%, 94% and specificity 74%; 95%CI: 46%, 80%). This 
was the only study quality variable used in the meta-analytic model and multiple imputation was used to 
estimate missing data for blinding in those 12 studies not reporting method of blinding. 
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The quality metric that most studies failed to meet was patients receiving the same reference standard 
regardless of index test result (58% No). Many studies examined the test accuracy in the clinical setting. 
Since FDG-PET scans are part of the diagnostic work up and considered standard of care for diagnosing 
lung cancer, this result is to be expected. Twenty-seven studies had fewer than 25 cancer or 25 benign 
cases. Most often studies lacked sufficient benign cases, and this was reflected in the higher variability of 
specificity across all studies. Most studies (83%) emulated the use of the test as it would be used in 
practice.  
 
Agreement between reviewers for the initial examination for eligibility of the 1,231 abstracts was 
examined quantitatively. The observed agreement for study eligibility between the three reviewers was 
94.1%, and Cohen’s Kappa was 0.85 showing strong agreement between reviewers. Consensus was used 
when reviewers disagreed for the remaining data abstracted and agreement was not reviewed 
quantitatively. 
 
4.4  Discussion 
 
For the last decade molecular imaging with FDG-PET has become part of the diagnostic process for lung 
nodules suspicious for non-small cell lung cancer. The limitation of FDG in smaller lesions or slower 
growing cancers has been well documented.3,4,88 Recently, significant research efforts have been 
undertaken by radiologists to find a complement or a replacement for FDG-PET scans.87,89-93 To date, no 
replacement for FDG has been suggested for the diagnosis of lung cancer.2,88 Previous meta-analyses 
found FDG-PET to be highly sensitive and fairly specific in the diagnosis of lung cancer.7,8 In our study, 
the sensitivity (89%; 95%CI: 82%, 94%) was less than the median sensitivity (94.2%; 95%CI: 89.1%, 
97.0%) reported by Gould.8 Specificity (75%; 95%CI: 46%, 86%) was also less than the specificity 
observed (83.3%) in the earlier meta-analysis.8 The unadjusted model estimated summary receiver 
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operating curve (SROC) was 0.90 (95%CI: 0.87, 0.93) and this estimated SROC was similar to that 
reported by Gould and colleagues (SROC 0.91; 95%CI: 0.89, 0.93). However, under conditions of a 
correctly pooled meta-analysis, differences between studies should be illustrated by a choice of different 
combinations of sensitivity and specificity and movement along the curve. Thus, studies should cluster 
along the SROC curve and within the 95% prediction contour. The large dispersion of studies and large 
prediction area illustrates the wide variance or heterogeneity between studies (Figure 3). This dispersion 
of study points suggests multiple SROC curves for the different populations observed across the studies 
being evaluated. Thus, the plotted SROC curve does not comply with the assumptions for a single pooled 
SROC. Both the SROC curve in this study and in the Gould meta-analysis showed significant 
heterogeneity across studies.   
 
This meta-analysis had slightly greater variance in both sensitivity and specificity when compared to 
either earlier meta-analysis. Yet our meta-analysis had a pooled population that was four times larger than 
that reported in Gould and five times that reported in Cronin’s meta-analysis. The more sensitive nature 
of the systematic review that included studies comparing FDG-PET to other imaging modalities and 
seeking  the causes of the observed heterogeneity results in recently published articles are likely the 
causes of the greater variance in this study’s FDG-PET accuracy. Significant heterogeneity arose from 
three sources not related to the quality of study in this meta-analysis. They were the type of scanner used, 
the mean or median size of the lesion examined, and endemic infectious lung disease in the study 
population.  
 
The newer technology of combination PET/CT scanners has generally replaced the stand-alone PET 
scanner since their introduction into clinical practice in 2001.94,95 This analysis found significant 
improvement in sensitivity and specificity among the studies of combination PET/CT scanners when 
compared to studies using stand-alone PET scanners. Others have found the newer combined scanners to 
also improve non-invasive staging of lung cancer.96,97   
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Among the 24 studies that reported average or median lesion diameters of 20mm or less, pooled 
sensitivity was 88% which was significantly less (p=0.001) than the sensitivity (91%) in those studies 
whose mean or median diameter was greater than 20 mm. The populations undergoing FDG-PET scans in 
the studies reviewed had high prevalences of lung cancer; the median prevalence was 63% across all 
studies. The high prevalence of disease coupled with the low survival rate for lung cancer resulted in 
clinicians preferring sensitivity over specificity. The observed 3% difference in sensitivity appears 
clinically insignificant on its face; however, this seemingly small difference arising from studies with 
lesions less than 20mm in diameter and with 63% lung cancer prevalence translated into missing two 
cancers per 100 individuals scanned. High dose CT scans with less than 5 mm thin slices have a high 
sensitivity (95%), but the specificity of such scans is only 50%.98-100 The high specificity of FDG-PET 
scans is one of the primary reasons they have been recommended for the diagnosis of lung cancer. 
 
 
Seven studies reported confounding of FDG-PET specificity due to false positive granulomas generated 
by endemic infectious lung disease.16,17,20,30-33 The pooled specificity among the seven studies was 59%. 
Granuloma prevalence in the population with benign diagnoses within these studies ranged from 45%32 to 
over 75%.20 Studies reporting endemic infectious lung disease included the largest two individual studies 
(N=585 and 211) in the systematic review.16,32 Mean lung cancer prevalence in these seven studies was 
76.7% compared to the 60.7% prevalence observed in the remaining 53 studies. Two of the seven studies 
were retrospective16,31 and five studies determined diagnosis with pathology only.16,17,20,32,33  
 
Of the seven studies, Bryant et al. and Chundru et al. were identified as possible outliers. The article by 
Bryant and colleagues is of interest in that it was both the largest study in the analysis (9% of the total); it 
reported benign granulomas as a common diagnosis from false positive FDG-PET scans; and the reported 
sensitivity (93%) and specificity (75%) were the most accurate among the seven studies. The study by 
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Chundru and colleagues may not have been from consecutive patients and may have selected an enriched 
population with benign disease, which would cause it to be excluded from all analysis.  The novel method 
of assessing the likelihood of cancer in the Chundru was unique among all studies.30 For the five 
homogeneous studies SROC was 0.88 with a sensitivity of 90% and a specificity of 39%, which is a 
striking difference from the specificity of 59% when the Bryant and Chundru studies are included in the 
pooled estimates. One possible explanation for the difference in specificity results from the Bryant et al. 
paper can be found by comparing it to the study by Deppen et al. Bryant and colleagues derived their 
population from central and southern Alabama, and Deppen and colleagues reported on FDG-PET scans 
of the population immediately to the north. Both studies are from large tertiary academic medical centers 
and report results from a thoracic surgery population. But the prevalence of fungal lung disease in middle 
Tennessee, northern Alabama and southern Kentucky is twice that found in central and southern 
Alabama. Therefore, the prevalence of benign granulomas among those being evaluated was less in 
Bryant’s study. The lower specificity of FDG-PET scans in populations with endemic infectious lung 
disease puts into question the cost effectiveness of FDG-PET in the diagnosis of lung cancer when 
compared to thin slice, high dose CT scans with contrast in such populations. FDG-PET scans are over 
five times more expensive than high dose CT scans. High dose CT scans cost between $350 and $500 
compared to the $2000-$3000 for a FDG-PET scan.96,101 The strikingly low specificity in the seven 
studies and in the five more homogeneous studies raises the question of how such a sub-population could 
have been missed in prior meta-analyses. 
 
In the meta-analysis by Gould and colleagues, 727 of the 1,474 (49%) lesions included were from studies 
that reported on either Japanese or European populations. Fungal lung disease and tuberculosis that 
causes granulomas are rare in Europe and Japan. At least another 15% of the lesions in the meta-analysis 
were from regions of the US where granulomatous disease is rare. Similarly, in the meta-analysis by 
Cronin, 860 of the 1,190 lesions (72%) reported in the 22 studies reviewed were from populations where 
infectious lung disease was rare. One of the studies from Germany included in both meta-analyses 
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concluded that the prevalence of histoplasmosis and coccidioidomycosis was far lower in Europe and that 
their results may not translate to North America.102 These imaging centers that dominated the early 
reporting of FDG-PET results may have introduced a spectrum bias into the evaluation of FDG-PET 
scans to diagnose lung nodules. The lack of infectious lung disease in the populations being evaluated for 
lung cancer resulted in optimistic estimates of the test’s specificity. In regions where infectious lung 
disease is highly prevalent, the specificity of FDG-PET scans to diagnose lung nodules suspicious for 
lung cancer appears to be near 40%.   
 
These two conclusions have significant implications for clinicians. In individuals who are being evaluated 
for lung cancer and reside in a region of the US or in other countries with significant endemic infectious 
lung disease with lesions less than 20 mm, a FDG-PET/CT scan will not likely differentiate the lesion as 
cancer or benign disease. The false positive rate is high, which reduces the positive likelihood ratio and 
the false negative rate is also too high to elicit a differential diagnosis. The lower positive and negative 
likelihood ratios observed in this meta-analysis in populations with small nodules from areas with 
endemic infectious lung disease greatly limit the usefulness of FDG-PET. This limitation is illustrated in 
likelihood quadrant plots.   
 
A likelihood quadrant graph plots the positive and negative likelihood ratio of a test. The plot is divided 
into four quadrants based upon a designation of a “discriminating” test. A highly discriminating 
diagnostic test will have a positive likelihood ratio above 10 and a negative likelihood ratio less than 0.1 
(Upper Left Quadrant). Such a test, if negative, will definitively rule out disease due to its low negative 
likelihood ratio, and if positive will rule in disease due to its high positive likelihood ratio. The 2001 
meta-analysis reported a positive likelihood ratio of 7.1 and a negative likelihood ratio of 0.06. Tests with 
high positive likelihood ratios (>10) and high negative likelihood ratios (>0.1) are best at confirming 
presence of disease (Upper Right Quadrant) while tests with low positive likelihood ratios (<10) and low 
negative likelihood ratios (<0.1) best discriminate those without disease (Lower Left Quadrant). Studies 
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that have low positive likelihood ratios (<10) and high negative likelihood ratios (>0.1) are relatively poor 
tests for discriminating either those with or without disease (Lower Right Quadrant).   
 
For each of the plots (Figures 11 to 13) the pre-test probability of disease was the pooled lung cancer 
prevalence (63.8%) and each study is plotted according to its individually estimated positive and negative 
likelihood ratio. Figure 11 displays all the studies in this meta-analysis. As we can see, a majority of 
studies lie in the Lower Right Quadrant. The pooled likelihood ratios and their respective 95% confidence 
intervals (positive LR 3.56, 95%CI: 1.51, 6.71 and negative LR 0.15, 95%CI: 0.07-0.39) are the brown 
diamond and crosshairs bisecting the diamond. The high sensitivity of most studies placed them in the 
lower left quadrant. Only one study is in the preferred upper left quadrant.86 Figure 12 displays only the 7 
studies that reported endemic infectious lung disease. Except for the Bryant study (point 3) with its high 
sensitivity (93%)30 and low negative likelihood ratio (0.09) and the study by Chundru et al. (point 5) with 
its high specificity and high positive likelihood ratio (7.5)30, none of the other six studies were near either 
discriminating quadrant. The pooled positive likelihood ratio was 2.21 (95%CI: 1.67-3.10) and the 
negative likelihood ratio was 0.15 (95%CI: 0.10-0.22). For the clinician deciding whether to order a 
FDG-PET scan for a patient from an area with high prevalence of endemic infectious lung disease, there 
is little likelihood that the test will discriminate whether the individual has or does not have the disease.   
 
Lesions under 15 mm are known to reduce the sensitivity of FDG-PET in lung cancer diagnosis.8 The test 
is not recommended in nodules smaller than 8 mm3. In Figure 13, the 24 studies reporting a mean or 
median lesion diameter less than or equal to 20 mm had a pooled positive likelihood ratio of 3.75 
(95%CI: 2.07, 6.35) and a negative likelihood ratio of 0.16 (95% CI: 0.11, 0.30). Sixteen of the twenty-
four studies lie within the non-discriminating lower right quadrant and the combined likelihood ratios and 
their confidence intervals lie entirely within this quadrant as well. These two aspects of poor 
discrimination for FDG-PET scan, endemic infectious lung disease, and smaller lesion size should cause 
the clinician to question the need to order a FDG-PET scan when they occur in patients. In these 
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instances, when no indication of metastatic disease is evident in prior imaging, the additional expense of a 
FDG-PET scan may not be warranted as the results will not likely change the diagnostic plan to obtain a 
biopsy or watch for further indications of cancer or benignity.  
 
 
The limitations of this analysis are those common to any meta-analysis and include publication bias, 
selection bias, and heterogeneity of those studies included. While no significant publication bias was 
observed according to Deek’s funnel plot and test, this is not proof that no bias exists. Since FDG-PET 
has been well established for the diagnosis of lung cancer, there may be a bias for reporting poor results 
of FDG-PET accuracy in more recent years. Among those studies testing a novel radiopharmaceutical 
there may have been reporting or other study biases not well captured in this review which was more 
general in its nature. An argument can be made that studies reporting results from PET only scanners no 
longer reflect clinical practice and should not be included in this analysis.  However, we attempted to 
control for the shortcomings of PET only scanners in the random effects model so that the impact on 
FDG-PET accuracy in studies reporting results from smaller lesions and from regions with endemic 
infectious lung disease could be explored. To avoid selection bias, this meta-analysis reviewed 
unpublished studies and attempted to broadly review studies reporting use of FDG-PET to characterize 
lung nodules and evaluate them for lung cancer.   
 
Heterogeneity across studies reporting diagnostic test accuracy is to be expected. We attempted to control 
for such heterogeneity through a bivariate random-effects binomial regression model with a number of 
clinically important covariates. Significant differences between studies remained after including those 
covariates and as such, the pooled analysis is only an approximation. Another weakness of this meta-
analysis was the use of multiple imputations for two variables, the blinding of readers and lesion size. The 
missing data pattern was monotonic which allows most imputation methods to be statistically robust103, 
and there did not appear to be systematic bias in the mechanism of why either variable was missing. 
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4.5 Conclusion 
 
This meta-analysis found a reduction in FDG-PET specificity in certain localized populations that 
reported endemic infectious lung disease. FDG-PET may not offer differential diagnosis for lung cancer 
in individuals with lesions smaller than 20 mm or who have had significant exposure to granuloma 
causing lung infections. Therefore, it is likely that some populations exist that would not benefit from a 
FDG-PET scan for the diagnosis of a lung nodule suspicious for lung cancer. The effectiveness of FDG-
PET/CT scans compared to high dose CT scans in these populations may be much lower than previously 
reported.101      
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Table 1: Participant and Study Characteristics for Diagnosis of Pulmonary Nodules. 
Citation Study Method Scanner Type 
Number 
of scans 
Mean or 
Median Age 
% CA 
Prevalence 
Study 
Population 
Diagnosis 
Method Blinding 
Halter G, 2000 57 Prospective PET 67 44 63% Surgical Pathology Only NR 
Higashi K, 200140 Prospective PET 66 65 82% Radiological Pathology Only NR 
Hung G, 200158 Prospective PET 26 53 77% Undetermined Pathology Only NR 
Imdahl A, 200159 Prospective PET 87 61 79% Surgical Pathology Only Yes 
Menda Y, 200160 Retrospective PET 127 64 68% Radiological Pathology Only No 
Roman M, 200179 Prospective PET 61 67 90% Oncological 
Pathology & 
Observation No 
Sasaki M, 200136 Retrospective PET 94 NR 80% Radiological 
Pathology & 
Observation NR 
Skehan S, 200176 Retrospective PET 77 64 74% Radiological 
Pathology & 
Observation Yes 
Uppot R, 200177 Prospective PET 25 63.5 44% Radiological 
Pathology & 
Observation Yes 
Yang S, 200161 Not reported PET 56 65 63% Undetermined 
Pathology & 
Observation Yes 
Croft, D 200217 Retrospective PET 85 63.2 82% Pulmonary Pathology Only Yes 
Keith C, 200286 Retrospective  89 66.7 54% Pulmonary 
Pathology & 
Observation No 
Lee J, 2001 41 Prospective PET 71 NR 61% Radiological 
Pathology & 
Observation No 
Demura Y, 200363  Prospective 
PET/CT-
SPECT 80 65 63% Radiological Pathology Only Yes 
Pastorino U, 200378 Prospective PET 42 58 48% Radiological Observation* Yes 
Buck A, 200587 Prospective PET 43 61.9 40% Radiological Pathology Only Yes 
Kahn D, 200464 Prospective 
PET/CT-
Other 157 68 78% Radiological 
Pathology & 
Observation Yes 
Bastarrika G, 200538 Prospective PET/CT 25 54.7 52% Oncological Pathology & Observation Yes 
Chhajed P, 200572 Retrospective PET 74 64 69% Pulmonary Pathology & Observation Yes 
Ding Q, 2005 28 Prospective PET/CT 60 56 50% Radiological Pathology Only No 
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Citation Study Method Scanner Type 
Number 
of scans 
Mean or 
Median Age 
% CA 
Prevalence 
Study 
Population 
Diagnosis 
Method Blinding 
Halley A, 2005 45 Multi-arm 
Trial 
PET/CT-
SPECT 
 
28 59 64% Radiological Pathology & 
Observation 
Yes 
Herder GJ, 200573 Prospective PET 106 64 58% Oncological Pathology & Observation Yes 
Mamede, M 200533 Prospective PET 60 65 77% Surgical Pathology Only No 
Nomori H, 200544 Prospective PET 139 59 66% Surgical 
Pathology & 
Observation Yes 
Sachs S, 200583 Retrospective PET/CT 161 62.4 44% Pulmonary 
Pathology & 
Observation Yes 
Bryant A ,200632 Prospective PET/CT 585 66 85% Surgical Pathology Only Yes 
Christensen J, 
200639 Retrospective PET 42 66 60% Pulmonary 
Pathology & 
Observation Yes 
Ferran N, 200665 Prospective PET/CT 29 52 69% Radiological Pathology Only Yes 
Naalsund A, 200647 Prospective PET 29 62 69% Radiological 
Pathology & 
Observation Yes 
Yi  C, 200646 Prospective PET/CT 119 55 66% Radiological 
Pathology & 
Observation NR 
Kim SK, 200749 Retrospective PET/CT 42 67 69% Pulmonary Pathology Only Yes 
Núñez R, 200727 Prospective PET 83 69 86% Radiological Pathology Only Yes 
Orlacchio A, 200726 Prospective PET/CT 56 63 46% Undetermined Pathology Only Yes 
Tsunezuka Y, 
200748 Prospective PET 150 65 55% Surgical Pathology Only NR 
Veronesi G, 200784  
Retrospective 
- screening PET/CT 157 57 37% Radiological 
Pathology & 
Observation No 
Wang F, 200766 Prospective PET/CT 44 62 71% Radiological 
Pathology & 
Observation Yes 
Alkhawaldeh K, 
200842 Retrospective 
PET/CT 
Dual 265 67 27% Radiological 
Pathology & 
Observation NR 
Baram D, 200870 Retrospective PET/CT 313 62 69% Surgical 
Pathology & 
Observation NR 
Chundru S, 2008 30 Prospective PET/CT 62 68 21% Radiological 
Pathology & 
Observation Yes 
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Citation Study Method Scanner Type 
Number 
of scans 
Mean or 
Median Age 
% CA 
Prevalence 
Study 
Population 
Diagnosis 
Method Blinding 
Degirmenci B, 
200852 
Retrospective PET/CT 49 69 53% Radiological Pathology & 
Observation 
Yes 
Jeong S, 200850 Retrospective PET/CT 100 58 40% Radiological 
Pathology & 
Observation Yes 
Kim SC, 200831 Retrospective PET 158 70.3 65% Radiological 
Pathology & 
Observation NR 
Lan X, 200835 Prospective PET/CT 45 53 62% Radiological 
Pathology & 
Observation NR 
Ohno Y, 200851 Prospective PET/CT 202 72 75% Radiological 
Pathology & 
Observation NR 
Pauls S, 200869 Prospective PET/CT 261 64.3 83% Radiological 
Pathology & 
Observation Yes 
Tian  J, 200868 Prospective 
PET/CT 
Other 55 55 29% Radiological 
Pathology & 
Observation Yes 
Yamamoto Y, 
200885 Retrospective PET/CT 54 70 67% Radiological 
Pathology & 
Observation Yes 
Aukema T, 200980 Prospective PET/CT 114 63 84% Pulmonary Pathology Only Yes 
Kagna O, 2009 53 Retrospective PET/CT 93 67 40% Surgical 
Pathology & 
Observation No 
Ning X, 200929 Prospective PET 101 53.6 65% Undetermined 
Pathology & 
Observation No 
Ohba Y, 200954 Prospective PET/CT 130 NR 78% Pulmonary Pathology Only Yes 
Schillaci O, 200925 Prospective PET/CT 30 59.3 60% Radiological 
Pathology & 
Observation No 
Barnett P, 201037 Prospective PET/CT 375 66 54% Pulmonary 
Pathology & 
Observation Yes 
Chang C, 201081 Retrospective PET/CT 117 62 37% Radiological 
Pathology & 
Observation Yes 
Grgic A, 201082 Retrospective PET/CT 140 62 57% Radiological 
Pathology & 
Observation Yes 
Huang Y, 201071  Retrospective PET/CT 56 59 61% Undetermined 
Pathology & 
Observation Yes 
Sathekge M, 2010 20 Prospective PET/CT 30 60 47% Radiological Pathology Only Yes 
Deppen S, 201116 Retrospective PET/CT 211 64 80% Surgical Pathology Only Yes 
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Citation Study Method Scanner Type 
Number 
of scans 
Mean or 
Median Age 
% CA 
Prevalence 
Study 
Population 
Diagnosis 
Method Blinding 
Macdonald K, 
201156 Retrospective PET 54 65.2 48% Radiological 
Pathology & 
Observation No 
Ohno Y, 201155 Prospective PET/CT 76 73 57% Radiological 
Pathology & 
Observation NR 
NR= Not reported 
 
Table 1. Participant and Study Characteristics for Diagnosis of Pulmonary Nodules. (Continued) 
 
Citation Mean or Median Size 
Lesion Size Range Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
Endemic Infectious Disease (Type, 
Country or Region) 
Halter G, 2000 57 NR 14-73 84  81 No 
Higashi K, 200140 20 8 to 63 81 (69-91) 42 No 
Hung G, 200158 26 12  45 95 50 No 
Imdahl A, 200159 30 NR 90 72 No 
Menda Y, 200160 33 5-100 94 76 No 
Roman M, 200179 NR NR 96 83 No 
Sasaki M, 200136 NR NR 81 79 No 
Skehan S, 200176 NR NR 95 85 No 
Uppot R, 200177 NR NR 91 71 No 
Yang S, 200161 NR 18-72 94 71 No 
Croft, D 200217 
 
44 7-170 93 40 
Yes 
(Histoplasmosis, Iowa, USA) 
Keith C, 200286 NR NR 92 95 No 
Lee J, 2001 41 18.5 7-30 88 75 No 
Demura Y, 200363  NR 11 to 60 76 56 No 
Pastorino U, 200378 NR NR 90 82 No 
Buck A, 200587 NR NR 94 73 No 
Kahn D, 200464 22 5 - 105 96 71 No 
Bastarrika G, 200538 13 8-20 69 91 No 
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Citation Mean or Median Size 
Lesion Size Range Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
Endemic Infectious Disease (Type, 
Country or Region) 
Chhajed P, 200572 NR ≤ 30 94 70 No 
Ding Q, 2005 28 18 5-30 90 93 No 
Halley A, 2005 45 20 5-30 94 70 No 
Herder GJ, 200573 NR NR 97 71 No 
Mamede, M 200533 
 
NR NR 87 21 
Yes 
(Tuberculosis, Japan) 
Nomori H, 200544 20 10 to 30 58 77 No 
Sachs S, 200583 NR NR 90 83 No 
Bryant A ,200632 
NR 
<25 93 75 
Yes  
(Granuloma, Alabama, USA) 
Christensen J, 200639 15 7-25 88 76 No 
Ferran N, 200665 26 10-60 100 88 No 
Naalsund A, 200647 17 5-30 90 67 No 
Yi  C, 200646 20 6.2-30 96 88 No 
Kim SK, 200749 15 7-30 97 85 No 
Núñez R, 200727 25 10-120 85 41 No 
Orlacchio A, 200726 18 ≤ 30 77 100 No 
Tsunezuka Y, 200748 NR ≤ 20 76 64 No 
Veronesi G, 200784  20.5 NR 88 93 No 
Wang F, 200766 48 12-110 100 46 No 
Alkhawaldeh K, 200842 17.5 5-30 90 80 No 
Baram D, 200870 28.8 11-180 82 78 No 
Chundru S, 2008 30 
 
20 5-30 65 92 
Yes 
(Granuloma, Michigan, USA) 
Degirmenci B, 200852 16.5 NR 62 80 No 
Jeong S, 200850 21 9 to 30 88 77 No 
Kim SC, 200831 
 
 
29 2-110 87 53 
Yes 
(Inflammation and Granuloma, 
New York, USA) 
Lan X, 200835 NR NR 86 65 No 
Ohno Y, 200851 15.7 5-30 93 54 No 
Pauls S, 200869 41 7-140 96 87 No 
Tian  J, 200868 28.2 6-110 88 59 No 
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Citation Mean or Median Size 
Lesion Size Range Sensitivity 
(95%CI) 
Specificity 
(95%CI) 
Endemic Infectious Disease (Type, 
Country or Region) 
Yamamoto Y, 200885 NR NR 97 50 No 
Aukema T, 200980 NR NR 97 56 No 
Kagna O, 2009 53 16 3-30 77 83 No 
Ning X, 200929 NR NR 79 77 No 
Ohba Y, 200954 20 10-30 74 79 No 
Schillaci O, 200925 19 3.5-30 83 91 No 
Barnett P, 201037 17 NR 95 87 No 
Chang C, 201081 NR NR 88 89 No 
Grgic A, 201082 NR NR 94 63 No 
Huang Y, 201071  24 5-100 79 77 No 
Sathekge M, 2010 20 
 
19 NR 86 25  
Yes 
(Tuberculosis, South Africa) 
Deppen S, 201116 
 
29 5-140 92 40 (25-56) 
Yes 
(Histoplasmosis, Tennessee, USA) 
Macdonald K, 201156 16.5 4-30 58 89 (72-98) No 
Ohno Y, 201155 15.8 8-30 91(78-97) 52 (34-69) No 
 
NR= Not reported 
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Table 2. Meta-analysis bivariate random effects modela 
 
 Complete Case Analysis N=35 Multiple Imputation N=60 
 Odds 
Ratio 
95% CI p-value Odds 
Ratio 
95% CI p-value 
Cancer 24.30 14.4 - 40.9 <0.001 23.6 16.1 - 34.5 <0.001 
 Endemic Disease   3.51    1.96 - 6.27 <0.001 2.57 1.53 - 4.31 <0.001 
   Endemic Disease w/CA b   0.41     0.25 - 0.67 <0.001 0.50 0.34 - 0.75   0.001 
 PET only scanner   Ref  Ref Ref Ref Ref Ref 
    PET/CT scanner   0.49    0.29 - 0.84 0.01  .63 0.43 - 0.94 0.02 
    PET/CT scanner w/CA b      3.04    1.87 - 4.93 <0.001 2.31 1.64 - 3.25 <0.001 
    PET+Other scanner    1.28   0.59 - 2.78 0.53 .88 0.50 - 1.53 0.64 
    PET+Other w/CA   0.82   0.39 - 1.77 0.63 1.77 1.05 - 3.00 0.03 
 Lesion size ≤ 20mm   0.66   0.40 - 1.07 0.09 0.89 0.60 - 1.30 0.53 
  Lesion size ≤ 20mm w/CAb   0.63  0.41 - 0.99 0.04 0.73 0.53 - 1.00 0.05 
 Blinding of readers   1.73  1.01 - 2.96 0.05 1.53 0.98 - 2.38 0.06 
  Blinding w/CA   0.86  0.51 - 1.43 0.55 0.76 0.51 - 1.12 0.16 
 Rho for random effects   0.07  0.03 - 0.13 <0.001 0.08 0.04 - 0.12 <0.001 
a Odds ratios for interaction terms with cancer which are greater than one increase sensitivity and odds ratios less than one decrease 
sensitivity. Odds ratios for variables without interaction with cancer influence specificity inversely.  Odds ratios with values less than one 
increased specificity. Odds ratios with values greater than one decreased specificity.  The variable’s overall effect on sensitivity is 
determined by the sum of coefficients for direct and interaction term. 
b Interaction term for variable interacting with those diagnosed with cancer. 
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Figure 1. Consort diagram of systematic review of eligible studies. 
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Figure 2: Forest plot of individual study estimates using simple pooled sensitivity and specificity and study heterogeneity, (I2) 
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Figure 3.Summary ROC curve from the unadjusted random effects model and  
estimated 95% prediction contour within which the curve and summary operating  
point may be located. 
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Figure 4. Deeks’ Funnel Plot and Asymmetry Test for publication bias. No significant slope coefficient (p=0.18)  
was observed and generally random study diagnostic odds ration distribution is illustrative of likely lack of  
publication bias. When the regression line has a significant slope (p<0.05 or <0.10), then a relationship is observed  
between diagnostic odds ratio and the size of the study and indicated likely publication bias. 
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Figure 5. Sub-group analysis of 7 studies reporting endemic infectious lung disease, Forest plot.  Sensitivity, 
specificity and their confidence intervals are estimated using meta-analysis model with multiple imputation for covariates 
of reader blinding and mean lesion size. 
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Figure 6. SROC with random effects model for 5 studies reporting endemic infectious lung disease. 
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Figure 7. Sub-group analysis of studies with mean or median lesion size less than or equal to 20mm in diameter, Forest plot.  Combined 
sensitivity, specificity and their confidence intervals are estimated using meta-analysis model with multiple imputation for covariates 
of reader blinding and mean lesion size. 
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Figure 8. Sub-group analysis of studies reporting use of PET only scanners, Forest plot.  Combined sensitivity, specificity and their 
confidence intervals are estimated using meta-analysis model with multiple imputation for covariates of reader blinding and mean lesion 
size. Reported studies are only those without missing data. 
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Figure 9. Sub-group analysis of studies reporting blinding of readers to patient history, Forest plot.  Combined sensitivity, 
specificity and their confidence intervals are estimated using meta-analysis model with multiple imputation for covariates of 
reader blinding and mean lesion size. Reported studies are only those without missing data. 
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Figure 10. QUADAS quality metrics reported for each study by 2 reviewers. 
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Figure 11. Likelihood ratio graph for all studies. Diamond and crosshatch is the estimated positive (3.56) and negative (0.147) likelihood 
ratio from the random effects meta-analysis model with covariates and the 95% confidence interval for positive (1.52, 6.71) and negative 
(0.07, 0.39) likelihood ratio. The gray diamond represents the results from the Gould 2001 meta-analysis. 
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Figure 12. Likelihood ratio graph for seven studies reporting endemic infectious lung disease. Diamond and crosshatch is the estimated 
positive (2.21) and negative (0.15) likelihood ratio from the random effects meta-analysis model with covariates and the 95% confidence 
interval for positive (1.67, 3.1) and negative (0.10, 0.22) likelihood ratio. 
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Figure 13. Likelihood ratio graph for seven studies reporting mean or median lesion size less than or equal to 20 mm. Diamond and 
crosshatch is the estimated positive (3.75) and negative (0.16) likelihood ratio from the random effects meta-analysis model with 
covariates and the 95% confidence interval for positive (2.01, 6.35) and negative (0.11, 0.30) likelihood ratio.
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Chapter 5 
 
 
V.  Summary and Future Directions 
This dissertation sought to help surgeons diagnose individuals with lung lesions suspicious for lung 
cancer.  Increasingly, clinicians rely on radiographic imaging for the identification and diagnosis of 
possible lung cancer, and they use the same imaging to determine the lesions’ characteristics non-
invasively. Discriminating lung cancer from other benign etiologies is complicated by benign 
granulomatous disease of the lung that can physically and metabolically appear similar to common lung 
neoplasms upon imaging. Using a retrospectively collected cohort of individuals being evaluated by 
thoracic surgeons for possible lung cancer, I estimated and internally validated a clinical predictive model 
using data available to surgeons at the time of operative evaluation. This highly enriched dataset contains 
multiple diagnostic tests, some of which were not available prior to this point in the diagnostic work-up of 
the patient.  
 
Variation in benign disease prevalence after lung surgery by state was also estimated in a separate 
analysis of Medicare administrative data. If a screening program using low dose CT scans to detect lung 
cancer is implemented nationally, then variation in the prevalence of benign disease after lung surgery 
may cloud the efficacy of screening and indicate possible local or systemic factors that gave rise to the 
observed variation. Given the importance of FDG-PET scans in the diagnostic process, factors that 
influence the accuracy of FDG-PET scans were explored through a systematic review and meta-analysis 
of the published literature and through secondary analysis of the nationally conducted ACOSOG Z4031 
trial in clinical stage 1 lung cancer. The association between observed benign disease and fungal lung 
disease exposure in the Medicare population and in a separate analysis of false positive FDG-PET scans 
 
 
174 
 
in the ACOSOG trial was conducted using historic surveillance information with fungal lung disease 
prevalence by county.  A summary of the results is outlined below: 
1. Currently available models for estimating lung cancer risk after the discovery of a lung nodule or 
lesion were calibrated to populations with far lower prevalence of disease than what was found 
among individuals being evaluated for surgical biopsy. The more extensive diagnostic data 
available to surgeons allowed for the estimation of a predictive model, the TREAT model, that 
better discriminated cancer from benign disease (AUC 0.89 95%CI: 0.86, 0.92) when compared 
to the Mayo model, using the Mayo model’s published point estimates (AUC 0.80: 95%CI: 0.76, 
0.85) as well as the Mayo model’s variables and re-estimating the coefficients of those variables 
within the Vanderbilt Lung Cancer Cohort (AUC 0.83; 95%CI: 0.79, 0.87). The TREAT model 
was better calibrated within the Vanderbilt Lung Cancer Cohort (Brier score 0.12) when 
compared to the Mayo model which estimated cancer likelihood using published point estimates 
(Brier score 0.17) and was the same for the Mayo model re-estimated within the Vanderbilt 
cohort (Brier score 0.12). Little optimism was observed after internal validation of the TREAT 
model using a bootstrap method with an AUC of 0.87 and Brier score of 0.13 (Chapter 2). 
 
2. Benign disease prevalence after lung surgery varied widely by state in the 2009 Medicare 
population. The mean prevalence across the US was 9.1% and the median state point prevalence 
was 8.9% (IRQ 7.8%, 10.9%). The lowest prevalence was observed in Vermont (1.2%) and the 
highest in Hawaii (25%). After excluding these two states as possible outliers, significant 
differences in benign disease prevalence after surgery remained (p=0.001) in the 48 states 
examined.  An in-hospital mortality rate of 2.1%  was observed among those patients with benign 
disease. No differences in estimated fungal disease exposure between patients with cancer and 
patients with benign disease were observed (p=0.90), although the measurement of infectious 
disease exposure using historical exposure in young white men was likely flawed. The cause of 
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observed differences in benign disease prevalence between states is not known but may be due to 
practice variation, work-up bias or locally endemic lung diseases. (Chapter 3). 
 
3. The accuracy of FDG-PET scans in diagnosing lung cancer was examined in the completed 
ACOSOG Z4031 trial. The trial included only those individuals with clinical stage 1 lung cancer. 
All participants underwent surgery and pathological diagnosis of their lung lesion. The clinical 
characteristics of the lesions evaluated in the ACOSOG trial were similar to those found in the 
recently completed National Lung Screening Trial, thus giving possible insight into the accuracy 
of FDG-PET scans in diagnosing lung cancer in screening populations. Among the 692 
individuals with usable FDG-PET scans, lung cancer prevalence was 83%. The sensitivity (82%; 
95%CI: 79%, 85%) and specificity (31%; 95%CI: 23%, 40%) of FDG-PET to diagnose lung 
cancer were much lower than that published in previous meta-analyses. Significant variation in 
sensitivity (p=0.03) was found between eight enrolling cities that recruited at least 25 
participants. The sensitivity varied from a low of 67% to a high of 91%. FDG-PET scan accuracy 
increased with increasing lung lesion size. A separate analysis found no association between false 
positive scan results and exposure to fungal lung diseases (histoplasmosis, blastomycosis and 
coccidiomycosis) using the historical prevalence of fungal disease during the 1960s to estimate 
fungal lung disease exposure. No association was observed between false positive scans and 
fungal lung disease after adjusting for age and lung lesion size on pre-operative CT scans. 
(Chapter 3).    
 
4. A systematic review of published and unpublished literature found 1,231 abstracts that 
investigated FDG-PET scan accuracy to diagnose lung cancer. After initial review, data 
abstraction was performed on 218 published articles. Articles that reported staging and not 
diagnosis, or included only lung cancer cases and not benign disease cases, were the most 
commonly excluded from the review. Sixty of the 218 abstracted articles were included for meta-
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analysis. Overall pooled sensitivity among the 60 reports was 89% (95%CI: 87%, 91%) and 
specificity was 74% (95%CI: 70%,78%); however, significant heterogeneity was observed across 
studies beyond what was expected from differences in threshold sensitivity and specificity choice 
between studies. A binomial random effects model was estimated that included covariates of 
clinical significance. Those covariates were: lesion size, scanner type, method of blinding 
radiograph readers and presence of endemic infectious lung disease. Heterogeneity between 
studies remained after inclusion of these covariates. The estimated sensitivity was 89% (95%CI: 
82%, 92%) and specificity was 75% (95%CI: 46%, 86%). Sub-group analysis found differences 
in FDG-PET accuracy by scanner type. PET only scanners (n=25 studies) had significantly lower 
sensitivity (88%) (p<0.001) and specificity (69%) (p=0.02) when compared to combined PET/CT 
scans (sensitivity 90% and specificity 78%, n=29 studies). In 24 studies with lung lesions less 
than or equal to 20 mm in diameter, sensitivity was 88% compared to 91% in the 19 studies 
whose mean or median lesion size was greater than 20 mm (p=0.05). The specificity was similar 
between the two groups. Seven studies from populations with high endemic infectious lung 
disease reported lower specificity (59%) and similar sensitivity (90%) to the 53 studies that did 
not report infectious lung disease in the studied population. The diagnostic accuracy of FDG-PET 
varied little across the 11 years reviewed, and no evidence of publication bias was observed 
across the 60 studies (Chapter 4). 
 
A clinically viable predictive model designed for surgeons evaluating lung nodules suspicious for lung 
cancer was successfully estimated and internally validated. Collectively this analysis also found that 
FDG-PET’s performance in diagnosing lung cancer was much poorer than previously published. These 
results call into question the use of this expensive, non-invasive test for diagnosis of smaller lung nodules 
or in populations where endemic infectious disease is high. This sensitive test remains an important 
predictor for lung cancer, and the use of FDG-PET for staging of lung cancer was not addressed in any of 
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the research conducted in this dissertation. The prevalence of benign disease after surgery was found to 
vary widely across the US, but the reasons for the observed variation are not well known. Practice 
variation and work-up bias, infectious lung disease induced granuloma, and other unknown factors are all 
possible causes. No association between fungal lung disease and false positive FDG-PET scans was 
observed. Understanding the factors that influence benign disease prevalence and patient selection prior to 
surgery are necessary steps in exploring relevant predictors of local variation to be added to a nationally 
applicable model to predict lung cancer for surgeons. This research raised a number of questions to be 
addressed in future work.  They include: 
1. The proposed TREAT model for lung cancer appears promising and should be externally 
validated. External validation would ideally be conducted in a variety of datasets that vary across 
the spectrum of fungal lung disease prevalence. This is an indirect method of determining 
whether a variable is missing from the model. One would expect that as the prevalence of fungal 
lung disease decreases, the accuracy of radiographic imaging to diagnose lung cancer increases. 
Thus the amount of variance explained by those variables collectively should increase. More 
complex time–to-event models or a linear model with interactions between variables and non-
linear relationships should be explored as more data becomes available. Finally, local factors like 
cancer prevalence at the practice level, availability of specialists, and diagnostic practice variation 
should be explored to make the model more robust in a national setting.    
 
2. The estimates for fungal lung disease exposure used in these analyses were indirect and likely 
flawed. The estimates used county and regional level prevalence measured in naval recruits from 
the 1960s. This young, healthy population who lived in one location for their entire lives was not 
representative of the much older and more mobile population being evaluated for lung cancer.  
Misclassification in the current analysis was likely. Current demographics and land use have 
changed greatly over the past 50 years and some evidence shows migration of fungal lung disease 
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to the upper Midwest. Since histoplasmosis and other fungal lung diseases reside primarily in 
soils, a land cover analysis using geographical information systems and available satellite 
imaging of land use could be conducted to estimate exposure based upon soil conditions, land 
cover impermeability and areas of possible exposure.  
 
3. Measurement of fungal lung disease exposure using land maps and historical prevalences are both 
indirect measurements of exposure and are subject to misclassification and ecological bias. Using 
serum and lung tissue samples on hand in the Vanderbilt Lung Spore repository, researchers can 
directly measure the presence of fungal lung disease in these biological samples and link those 
results to available imaging results. Such data would allow the estimation of the prevalence of 
fungal lung disease in false positive imaging. Subsequently, investigation into radiographic or 
biomarker evidence indicating presence of fungal lung disease or granuloma should be pursued, 
as currently available biomarkers for lung cancer diagnosis have achieved mixed results.
1
   
 
 
4. If fungal lung disease complicates the diagnosis of lung cancer and leads to higher rates of benign 
disease, then a natural experiment should be possible where clinicians trained in areas with low 
prevalence of infectious lung disease and who subsequently moved to areas with high prevalence 
of disease would exhibit a change in their patients’ benign disease prevalence over time. This 
change in practice would occur as clinicians learn how to incorporate fungal lung disease into 
their diagnostic process. Essentially, one would expect clinicians to learn how to recognize fungal 
lung disease over time, and their prevalence of benign disease after  procedures should decrease. 
Using contacts through clinical societies and training programs, we would contact individual 
surgeons and pulmonologists who were trained in areas where fungal lung disease is rare and 
currently practice in areas of high prevalence and measure their prevalence of benign disease over 
time. A similar experiment could be conducted for radiologists.  
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5. The causes of the observed variation in benign disease prevalence by state in the Medicare 
population are unknown at this time. The implementation of technological innovations like video 
assisted thoracotomy and robotic assisted surgery has increased the population who can receive 
surgical biopsy for the diagnosis of lung cancer. One center found their benign disease prevalence 
after surgery doubled with the implementation of the newer video assisted thoracotomy when 
compared to the older surgical technique.
2
 These and other factors that represent practice 
variation or work-up bias may influence the benign disease prevalence across states and over 
time. Prevalence variation between states and across years should be explored in national 
datasets. Understanding how broad changes to clinical practice and local factors influence benign 
disease prevalence in populations being evaluated for lung cancer can inform policy makers 
evaluating the efficacy of a national screening program for lung cancer. 
 
6. The systematic review and meta-analysis for FDG-PET diagnostic accuracy was conducted 
through 2001 and should be updated to include research published since 2011 and the results 
should be disseminated. Using the results of the meta-analysis, we will conduct a cost-
effectiveness study to determine whether populations exist that would not likely benefit from a 
FDG-PET scan to diagnose lung cancer. 
 
 
Given the results of the National Lung Screening Trial (NLST) and the support for screening healthy, 
high risk individuals with low dose computed tomography by clinical and patient advocacy groups, we 
will likely see screening for lung cancer in the near future. The implementation of a national screening 
program for lung cancer will increase the volume of CT-discovered lung anomalies requiring diagnosis by 
approximately 2.6 million, extrapolating from the results of the NLST.
3
 An estimated 80,000 diagnostic 
operations will be conducted as part of the diagnostic process. Surgeons evaluating lung nodules and 
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weighing the decision to undertake a diagnostic operation need a clinically useful model to help in that 
decision process. This research is the first step toward developing such a model. The initial results of the 
TREAT model are promising and should be externally validated. The impact of fungal lung disease on 
diagnostic imaging remains unclear. Whether the observed variances in FDG-PET scans arose from local 
practice variation or from endemic infectious lung disease was not established in this research. However, 
a growing body of evidence has shown that FDG-PET scans perform poorly in the diagnosis of smaller 
lesions or in regions where the patient population has been exposed to infectious lung disease. As the US 
moves toward screening for lung cancer with low dose CT scans, researchers should examine why the 
prevalence of benign disease varies in order to inform health policy and clinical guidelines as we seek to 
better diagnose and treat this deadly disease. 
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Appendix 1 
 
 
 
Appendix 1.1  Cluster analysis – missing data and missing data patterns 
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Appendix 1.2  Results of imputation for the 1st observation across 50 imputed datasets. 
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Appendix 1.2 Results of imputation for the 1st observation across 50 imputed datasets. 
(Continued) 
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Appendix 1.2 Results of imputation for the 1st observation across 50 imputed datasets. 
(Continued)
 
Appendix 1.3 Odds Ratios and confidence bars, using dichotomous differences or quartiles of 
continuous variables for assessing the effects on the odds of lung cancer. 
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Appendix 1.4 Nomogram for TREAT lung cancer model 
 
R code 
library("Hmisc") 
library("rms") 
library("boot") 
library("rpart") 
 
## get data from shared directory 496 observations and 30 variables 
predict.out.09062012 <- read.delim("F:/Thoracic Surgery Research/Common folder/Lung Cancer 
Cohort/Nodule study/predictive model/predict out 10162012.txt") 
 
describe (na.detail.response=TRUE, predict.out.09062012) 
s<-summary(cancer~ age + gender + bmi + smokeyn + pack_years + ct_size + spicul + upperlobe 
+ prev_cancer +  fev1_pred + anysympt + growthcat + petpos34, data=predict.out.09062012) 
s 
w<-latex(s) 
plot(s) 
par(mfrow=c(1,1)) 
nimp <- 50   ### number of imputation 
set.seed (5690) 
nx<-naclus(predict.out.09062012) 
plot(nx); naplot(nx) #Show patterns of NAs - missing data 
 
f  <- aregImpute(~cancer + age + wandw+ bmi + gender + growthcat+ smokeyn + pack_years + 
ct_size + spicul + upperlobe + prev_cancer +  fev1_pred + anysympt  + weight + petpos34, 
n.impute=nimp, x=TRUE, nk=3, tlinear=F, data=predict.out.09062012) 
par(mfrow=c(2,2)) 
print (f, digits=3) 
plot (f, nclass=NULL, type=c('ecdf','hist'),datadensity=c("hist", "none", "rug", "density"), 
diagnostics=T, maxn=1) 
 
187 
 
m<-lrm(is.na(petpos34) ~ cancer + age + wandw+ bmi + gender + growthcat+ smokeyn + 
pack_years + ct_size + spicul + upperlobe + prev_cancer +  fev1_pred + anysympt, 
data=predict.out.09062012 ) 
m 
 
#fit the logistic regression model assuming additive variables and non-linear pack years 
lungCA <- fit.mult.impute(cancer~ age + bmi + gender+rcs(pack_years,3) + ct_size + spicul + 
growthcat + upperlobe +  prev_cancer +  fev1_pred + anysympt + petpos34, lrm, f, 
data=predict.out.09062012) 
 
varcov0<-vcov(lungCA) 
serror0<-sqrt(diag(vcov(lungCA))) 
 
options(digits=3) 
post.anova<-anova(lungCA) 
par(mfrow=c(1,1)) 
plot(post.anova) 
print(post.anova) 
print(lungCA) 
exp(cbind(OR=coef(lungCA), confint.default(lungCA)))##OR and confidence interval using 
reported std errors 
 
 
lungCA.test<-lungCA[[3]] 
Ctrain<-lungCA.test [6]## Apparent C index 
Btrain<-lungCA.test [11]## Apparent Brier Score 
Btrain 
Ctrain 
 
##Heidi's OR and 95% CI code 
lrm_OR <- function(lrmin) { 
   
  temp <- data.frame("coef"=lrmin$coefficients) 
  temp$se <- NA 
  for ( i in 1:nrow(temp)) { 
    temp$se[i] <- sqrt(lrmin$var[i,i]) 
  } 
   
  temp$OR <- round(exp(temp$coef),3) 
  temp$LCI <- round(exp(temp$coef-1.96*temp$se),3) 
  temp$UCI <- round(exp(temp$coef+1.96*temp$se),3) 
  temp$CI <- paste(temp$LCI,temp$UCI,sep=" to ") 
  temp$p <- round(1-pchisq((temp$coef/temp$se)^2,1) ,4) 
  colnames(temp) <- c("Coef", "se", "Odds Ratio","LCI", "UCI", "CI","p-value") 
  print(temp[,c("Coef", "se", "Odds Ratio","CI","p-value" )]) 
   
} 
lrm_OR(lungCA) 
 
#complete case analysis 
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lungCA.complete <- lrm(cancer~ age + bmi + gender+rcs(pack_years,3) + ct_size + spicul + 
growthcat + upperlobe +  prev_cancer +  fev1_pred + anysympt + petpos34, 
data=predict.out.09062012) 
varcov0<-vcov(lungCA.complete) 
serror0<-sqrt(diag(vcov(lungCA.complete))) 
 
options(digits=3) 
post.anova.complete<-anova(lungCA.complete) 
par(mfrow=c(1,1)) 
plot(post.anova.complete) 
print(post.anova.complete) 
lungCA.test<-lungCA.complete[[3]] 
Ctrain.c<-lungCA.test [6]## Apparent C index 
Btrain.c<-lungCA.test [11]## Apparent Brier Score 
Btrain.c 
Ctrain.c 
 
#overfitted model 
overfit.lungCA <- fit.mult.impute(cancer~ age + bmi + gender+rcs(pack_years,4) + rcs(ct_size,4) 
+ spicul + growthcat + upperlobe +  prev_cancer +  rcs(fev1_pred,4) + anysympt + petpos34 + 
petpos34%ia%rcs(ct_size,4) + anysympt%ia%rcs(fev1_pred,4) + petpos34*growthcat + 
growthcat%ia%rcs(ct_size,4), lrm, f, data=predict.out.09062012) 
##Heidi's OR and 95% CI code 
lrm_OR <- function(lrmin) { 
   
  temp <- data.frame("coef"=lrmin$coefficients) 
  temp$se <- NA 
  for ( i in 1:nrow(temp)) { 
    temp$se[i] <- sqrt(lrmin$var[i,i]) 
  } 
   
  temp$OR <- round(exp(temp$coef),3) 
  temp$LCI <- round(exp(temp$coef-1.96*temp$se),3) 
  temp$UCI <- round(exp(temp$coef+1.96*temp$se),3) 
  temp$CI <- paste(temp$LCI,temp$UCI,sep=" to ") 
  temp$p <- round(1-pchisq((temp$coef/temp$se)^2,1) ,4) 
  colnames(temp) <- c("Coef", "se", "Odds Ratio","LCI", "UCI", "CI","p-value") 
  print(temp[,c("Coef", "se", "Odds Ratio","CI","p-value" )]) 
   
} 
lrm_OR(overfit.lungCA) 
overfit.lungCA.test<-overfit.lungCA[[3]] 
over.Ctrain<-overfit.lungCA.test [6]## Apparent C index 
over.Btrain<-overfit.lungCA.test [11]## Apparent Brier Score 
over.Btrain 
over.Ctrain 
 
#fit Mayo model in VUMC population for comparison of AUC and brier 
mayoCA<-fit.mult.impute (cancer~age + ct_size + smokeyn + spicul +  prev_cancer + upperlobe, 
lrm, f, data=predict.out.09062012) 
varcov.m<-vcov(mayoCA) 
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serror.m<-sqrt(diag(vcov(mayoCA))) 
 
options(digits=3) 
postm.anova<-anova(mayoCA) 
plot(postm.anova) 
print(postm.anova) 
exp(cbind(OR=coef(mayoCA), confint.default(mayoCA)))##OR and confidence interval using 
reported std errors 
print (mayoCA) 
 
mayoCA.test<-mayoCA[[3]] 
Cmayotrain<-mayoCA.test [6]## Apparent C index 
Bmayotrain<-mayoCA.test [11]## Apparent Brier Score 
Bmayotrain 
Cmayotrain 
 
#fit SPN model in VUMC population for comparison 
SPN.CA<-fit.mult.impute (cancer~age + ct_size + spicul + pack_years + prev_cancer + 
upperlobe + growthcat +petpos34 + hemotypsis, lrm, f, data=predict.out.09062012) 
varcov.m<-vcov(SPN.CA) 
serror.m<-sqrt(diag(vcov(SPN.CA))) 
 
options(digits=3) 
postSPN.anova<-anova(SPN.CA) 
plot(postSPN.anova) 
print(postSPN.anova) 
exp(cbind(OR=coef(SPN.CA), confint.default(SPN.CA)))##OR and confidence interval using 
reported std errors 
print (SPN.CA) 
 
 
SPN.CA.test<-SPN.CA[[3]] 
CSPN.train<-SPN.CA.test [6]## Apparent C index 
BSPN.train<-SPN.CA.test [11]## Apparent Brier Score 
BSPN.train 
CSPN.train 
 
###getting predicted probabilities for ROC analysis and bootstrap optimism 
 
phat.data<-data.frame(predict.out.09062012$study_id) 
   
for (j in 1:nimp) { 
compl<-predict.out.09062012 
  train.impute<-impute.transcan(f, imputation=j, data=predict.out.09062012, list.out=TRUE, 
pr=F, check=F) ##get imputed values using f model above and imputed dataset j 
  compl[names(train.impute)]<-train.impute  ###put imputed values and names into new dataset 
   
  imagefit<-predict(overfit.lungCA, compl, type="fitted") ##get prediction coefficients from 
lungCA model and estimated predicted cancer using withheld data in test that has become a 
complete cases dataset using imputation 
 phat.data<-cbind(phat.data,imagefit) 
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   } 
xhead<-c("study_id","phat1", "phat2","phat3", "phat4","phat5", "phat6","phat7", "phat8","phat9", 
"phat10","phat11", "phat12","phat13", "phat14","phat15", "phat16","phat17", "phat18","phat19", 
"phat20", "phat21", "phat22","phat23", "phat24","phat25", "phat26","phat27", "phat28","phat29", 
"phat30","phat31", "phat32","phat33", "phat34","phat35", "phat36","phat37", "phat38","phat39", 
"phat40", "phat41", "phat42","phat43", "phat44","phat45", "phat46","phat47", "phat48","phat49", 
"phat50") 
names(phat.data)<-xhead 
phat.data<-cbind(phat.data, phatbar=rowMeans(phat.data[,-1])) 
 
d<-datadist(compl) 
options(datadist="d") 
nomogram(overfit.lungCA) 
fsum<-summary(overfit.lungCA) 
fsum 
plot(fsum) 
plot (overfit.lungCA, xlim=c(0,1), ylim=c(0,1)) 
 
###getting predicted probabilities MAYO model for ROC analysis 
phatmayo.data<-data.frame(predict.out.09062012$study_id) 
 
for (j in 1:nimp) { 
  compl.mayo<-predict.out.09062012 
  trainmayo.impute<-impute.transcan(f, imputation=j, data=predict.out.09062012, list.out=TRUE, 
pr=F, check=F) ##get imputed values using f model above and imputed dataset j 
  compl.mayo[names(trainmayo.impute)]<-trainmayo.impute  ###put imputed values and names 
into new dataset 
   
  phatfit.mayo<-predict(overfit.lungCA, compl.mayo, type="fitted") ##get prediction coefficients 
from lungCA model and estimated predicted cancer  
   
  phatmayo.data<-cbind(phatmayo.data,phatfit.mayo) 
   
} 
 
names(phatmayo.data)<-xhead 
phatmayo.data<-cbind(phatmayo.data, pmayobar=rowMeans(phatmayo.data[,-1])) 
phatmayo.data 
 
pbar.out<-merge (phat.data, phatmayo.data,by="study_id") 
write.table(pbar.out, file="F:/Thoracic Surgery Research/Common folder/Lung Cancer 
Cohort/Nodule study/predictive model/imputed mayo treatover.ROC.csv", sep=",") 
 
plot (phatbar, pmayohat) 
 
##epidemiology only predictive model 
epi.ca<-fit.mult.impute (cancer~age +gender + rcs(pack_years, 4) + prev_cancer  + anysympt + 
hemotypsis + bmi, lrm, f, data=predict.out.09062012) 
varcov.m<-vcov(epi.ca) 
serror.m<-sqrt(diag(vcov(epi.ca))) 
 
191 
 
options(digits=3) 
postSPN.anova<-anova(epi.ca) 
plot(postSPN.anova) 
print(postSPN.anova) 
exp(cbind(OR=coef(epi.ca), confint.default(epi.ca)))##OR and confidence interval using reported 
std errors 
print (epi.ca) 
##imaging only model 
image.ca <- fit.mult.impute(cancer~  rcs(ct_size, 4) + spicul + growthcat + upperlobe +  
petpos34, lrm, f, data=predict.out.09062012) 
varcov.m<-vcov(image.ca) 
serror.m<-sqrt(diag(vcov(image.ca))) 
 
options(digits=3) 
postimage.anova<-anova(image.ca) 
plot(postimage.anova) 
print(postimage.anova) 
exp(cbind(OR=coef(image.ca), confint.default(image.ca)))##OR and confidence interval using 
reported std errors 
print (image.ca) 
 
#END TRAINING MODEL ESTIMATION 
nboot <- 500  ### number bootstrap resampling 
sum_c<-0 
sum_b<-0 
n<-nrow(predict.out.09062012) 
   
for (i in 1:nboot){ 
  x1<-sample(n,n,replace=T) #bootstrap with replacement from the original 
  x_train<-compl[x1,]  #training dataset 
  x_test<-compl[-x1,]   #test dataset from original dataset and not in training 
  
  ##estimated model with bootstrap training set 
  lungCA.train <- fit.mult.impute(cancer~ age +  gender+ bmi + rcs(pack_years,3) + ct_size + 
spicul + growthcat + upperlobe +  prev_cancer +  fev1_pred + anysympt + petpos34, lrm, f, 
data=x_train, pr=F) 
   
  ########### calculated C-index and Brier from bootstrap test set by each imputed dataset 
iteration 
  Ctest<-0 
  Briertest<-0 
     for (j in 1:nimp){ 
   
   
  pfit<-predict(lungCA.train, x_test, type="fitted") ##get prediction coefficients from 
lungCA.train model and estimated predicted cancer using withheld data in test that has become a 
complete cases dataset using imputation 
   
  ##get C-index from likelihood ratio test and get brier score within this imputation iteration 
  lrm_test <- lrm(x_test$cancer ~ pfit)  #c-index using current test     
  cindex.test<-lrm_test[[3]] 
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  if (lrm_test$coefficient[2]>0) Ctest_temp<-cindex.test[6]else 
  Ctest_temp<-1-cindex.test[6]  ##occasionally if predictive relationship is inverted, then c-index 
<0.5, adjusting for this possibility   
  Btest_temp<-cindex.test[11] 
  Ctest<-Ctest+Ctest_temp 
  Briertest<-Briertest+Btest_temp 
  
  }  
  sum_b<-sum_b+(Briertest/nimp) 
  sum_c<-sum_c+(Ctest/nimp) 
  
} 
 boot632.c<-(0.368*Ctrain)+(0.632*(sum_c/nboot)) 
 boot632.brier<-(0.368*Btrain)+(0.632*(sum_b/nboot)) 
boot632.c 
boot632.brier 
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Appendix 2 
 
 
 
/*********************************************************************/ 
/* Diagnosis for lung cancer *****************************************/ 
/*********************************************************************/ 
 
data nis.biopsy nis.no_biopsy; 
 set 'F:\PATH NAME HERE; 
 
array out1 PR1; 
 
 do over out1; 
 
  if out1 in: ('3220','3229') then lung_excision=1; 
 if out1 in: ('3230') then segmental_resection=1; 
 if out1 in: ('3240','3241','3249') then lobectomy=1; 
 if out1 in: ('3260') then disection_lung=1; 
 if out1 in: ('3290') then other_lung_excision=1; 
 if out1 in: ('3310') then lung_incision=1; 
 if out1 in: ('3320') then thora_lung_biopsy=1; 
 if out1 in: ('3328') then open_lung_biopsy=1; 
 
 
end; 
 
 if lung_excision=1 or segmental_resection=1 or lobectomy=1 or 
disection_lung=1 or other_lung_excision=1 or 
    lung_incision=1 or thora_lung_biopsy=1 then output nis.biopsy; 
    else output nis.no_biopsy; 
run; 
 
proc freq data=nis.biopsy; 
tables lung_excision segmental_resection lobectomy disection_lung 
other_lung_excision 
    lung_incision thora_lung_biopsy; 
run; 
 
data nis.lung; 
 set nis.biopsy; 
 
array out3 DX1; 
 
 do over out3; 
 
 if out3 in: ('1150','1151','1159') then histoplasmosis=1; 
 if out3 in: ('1160','1161','1162') then blastomycotic_inf=1; 
 if out3 in: 
('0110','0111','0112','0113','0114','0115','0116','0117','0118','0119') 
then tuberculosis=1; 
 if out3 in: ('1140','1143','1144','1145','1149') then coccidio=1; 
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 if out3 in: 
('1170','1171','1172','1173','1174','1175','1176','1177','1178','1179') 
then other_mycoses=1; 
 if out3 in: ('5130','5131') then lung_abscess=1; 
 if out3 in: ('135') then sarcoidosis=1; 
 if out3 in: ('51889') then other_lung_dis=1; 
 if out3 in: ('2123') then benign_neoplasm=1; 
 if out3 in: ('5198','51919') then other_dis_bronchus=1; 
 if out3 in: ('1124') then candida=1; 
 if out3 in: ('1620','1622','1623','1624','1625','1628','1629') 
then malignant_lung=1; 
 if out3 in: ('1630','1631','1638','1639') then 
malignant_pleura=1; 
 if out3 in: ('1970') then sec_malig_resp=1; 
 if out3 in: ('2312') then brunchus_insitu=1; 
 if out3 in: ('2357') then bronchus_uncertain=1; 
 if out3 in: ('2391') then bronchus_unsp=1; 
 if out3 in: ('7931') then coin_lesion_nodule=1; 
 if out3 in: ('4464') then wegeners=1; 
 if out3 in: ('0310','20961','7866') then other_benign=1; 
 if out3 in: ('20921') then other_malig=1; 
  
 end; 
 
array out4 DX1; 
 
do over out4; 
  
 if out4 in: ('5120','5121','5128') then pneumothorax=1; 
 if out4 in: ('5100','5109') then empyema=1; 
 if out4 in: 
('1980','1981','1982','1983','1984','1985','1986','1987','1988') then 
sec_malig_nos=1; 
 if out4 in: ('5163') then ipf=1; 
 if out4 in: ('515') then chronic_ipf=1; 
 if out4 in: ('1961') then intrathoracic_lymph_node=1; 
 if out4 in: 
('1971','1972','1973','1974','1975','1976','1977','1978') then 
sec_malig_resp_ex=1; 
 end; 
 
 
run; 
 
data nis.lung; 
 set nis.lung; 
 
/**********************************/ 
/*dichotomize age for calculations*/ 
/**********************************/ 
 
if age<18 and age ne "." then agec=0; 
if age>=18 and age ne "." then agec=1; 
if age=". " then agec="."; 
 
run; 
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Appendix 3 
 
 
 
Appendix 3.1 FDG-PET imaging in the diagnosis of lung cancer 
Last updated March 30, 2011 
Search terms Search resultS 
#1   lung neoplasms[mh] OR lung cancer[tiab] OR lung nodule[tiab] OR lung 
nodules[tiab] OR pulmonary nodule[tiab] OR pulmonary nodules[tiab] 
OR lung lesion[tiab] OR lung lesions[tiab] OR pulmonary lesion[tiab] 
OR pulmonary lesions[tiab] 
166,206 
#2  Positron-Emission Tomography[mh] OR fluorodeoxyglucose F18[mh] 
OR fluorodeoxyglucose F18[nm] OR FDG-PET[tiab] OR FDG-
PET/CT[tiab] OR positron emission tomography[tiab] 
39401 
#3 #1 AND #2 AND eng[la] AND humans[mh] AND 2000:2011[dp] 2244 
#4    #3 AND case reports[pt]  542 
#5 #3 AND letter[pt] 77 
#6   #3 AND review[pt] 370 
#7   #3 AND editorial[pt]  32 
#9   #3 AND comment[pt] 97 
#9 #3 AND practice guideline[pt] 9 
#10 #3 AND historical article[pt] 4 
#11 #3 AND news[pt] 4 
#12 #3 AND meta-analysis[pt] 11 
#13 #4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 
OR #14 OR #15 
1026 
#14 #3 NOT #13 1218 
Key:  [la] language; [mh] medical subject heading; [nm] substance name; [pt] 
publication type; [dp] publication date; [tiab] keyword in title or abstract Science Citation 
Index Search, Web of Science Interface 
TS=(fdg) AND TS=(pet) AND TS=(lung) AND TS=((screen OR screening OR diagnosis 
OR diagnose OR diagnostic)) 
Refined by: Document Type=( PROCEEDINGS PAPER OR MEETING ABSTRACT ) 
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Appendix 3.1. Cumulative meta-analysis of diagnostic odds ratio. 
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Appendix 3. 2. Bivariate boxplot of log odds sensitivity and log odds specificity for all studies. 
Oblong shape of boxplot indicates threshold preference for higher sensitivity and an asymmetric 
SROC curve. 
 
 
